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Abstract
Current treatment strategies for Type 2 Diabetes Mellitus (T2DM) include a range
of anti-diabetic drugs, supplemented by lifestyle modifications to reduce dietary fat
intake and body fat. However, for their anti-diabetic action, most drugs recruit insulin
signaling pathways, which are already impaired in T2DM. Also, compliance and success
in achieving sustained improvements in diet or obesity over the long term is marginal.
Therefore, an agent that improves diabetes independent of insulin signaling or lifestyle
changes may be highly useful. Human adenovirus Ad36 offers such a model. Ad36
improves glycemic control in chow-fed mice or rats and attenuates diabetes and hepatic
steatosis in high fat(HF)-fed mice, despite the HF intake and without reducing adiposity.
In human adults, natural Ad36 infection predicts better glycemic control and lower
hepatic lipid stores. Ex-vivo cell signaling studies suggest that in mice, Ad36 activates
Ras-mediated phosphatidyl- inositol 3-kinase (PI3K) pathway (Ras/PI3K) to up-regulate
glucose uptake in skeletal muscle and adipose, and suppresses glucose output from the
liver. This study determined if the anti-diabetic properties of Ad36 could be creatively
harnessed. Objective 1 determined that Ad36 seropositivity was associated with
improved glycemic control and lower hepatic lipids in Caucasian, Hispanic, and African
American children and adolescents. Objective 2 determined which of the conventional
contributors of insulin sensitivity are modulated by Ad36. In vitro, Ad36 increased
preadipocyte differentiation, de-novo lipogenesis, and fat oxidation. Ad36 increased the
proportion of small adipocytes in mice on a chow diet, whereas in HF-fed mice, Ad36
increased the proportion of large adipocytes. Adipose tissue macrophage infiltration and
angiogenesis were not affected by Ad36. Objective 3 determined the E4orf1 protein of

x

Ad36 mediates its anti-hyperglycemic property. E4orf1 is sufficient and necessary to
improve glucose uptake. Mirroring the actions of Ad36, in vitro, E4orf1 also upregulates the Ras/PI3K pathway, and adiponectin –an insulin sensitizing adipokine, and
down-regulates inflammatory cytokine expression. E4orf1 increases glucose uptake in,
preadipocytes and adipocytes. In hepatocytes, E4orf1 reduces glucose output and the
metabolic studies indicate it favors less hepatic lipid storage. Overall, this study offers a
broad foundation to further determine the potential of E4orf1 as an anti-diabetic agent.

xi

Chapter 1. Introduction
1.1 Obesity Prevalence, Treatment, Causes
Obesity prevalence has risen to epidemic proportions across the globe and has spread to
almost every demographic(1), while the driving causes remain unclear(2). Obesity is
characterized by excess body fat, and is clinically defined by Body Mass Index (BMI). BMI is
body mass in kilograms divided by the square of height in meters, and represents weight adjusted
for height. BMI between 25.0-29.9 is overweight, and over 30.0 is obese. Several classes of
obesity were more recently defined by the World Health Organization, with 30.0-34.9 defined as
class I, 35.0-39.9 as class II, and above 40 as class III obesity.
Obesity was first recognized as a health threat by health insurance companies in the
1950’s (3). Tracking of obesity prevalence in the United States began in the 1960’s, and
prevalence was fairly stable between 1960-1980 (4; 5). Following 1980, however, prevalence
climbed 8% in one decade, from 14.5% to 22.5% (4). Prevalence continued to increase through
the 1990’s, to 30.5% by 2000(6), but prevalence remained somewhat stable through the last
decade, with rates only increasing slightly to 33.8% (7). Increasing obesity prevalence trends
were only statistically significant for men, not women over the last decade (7). Currently, 68%
of adults are overweight or obese in the United States. Childhood and adolescent obesity
prevalence is also on the rise. Prevalence of BMI above the 95thpercentile has increased threefold since 1980 in children and adolescents, and prevalence has remained stable but high at
approximately 17% (8; 9).
Obesity is associated with increased risk for Type 2 Diabetes Mellitus (T2DM), certain
cancers, coronary heart disease, hypertension, sleep apnea, osteoarthritis, liver and gallbladder
disease, and stroke (10), and its effective prevention and treatment is crucial. The most common
1

treatment for overweight or moderately obese individuals consists of behavioral, diet, and
exercise modifications for weight loss. Obesity is considered a result of positive energy balance,
therefore reducing caloric intake and increasing energy expenditure to induce negative energy
balance is the objective of these modifications. Commercially available programs for the general
public, such as Weight Watchers, produce only modest weight loss and have high drop-out rates
and high weight regain post intervention (11). In addition, most individuals do not achieve their
weight loss goals, and 50% are not able to achieve even what they themselves would consider a
“disappointing” amount of weight loss (12). Both weight loss interventions and public
awareness regarding weight loss as treatment for obesity and its co-morbidities have failed to
slow the obesity epidemic or improve obesity rates at a community level (1; 13-16).
Furthermore, scientific weight loss interventions with trained dieticians and consistent
counseling are only marginally effective at an individual level. Studies that carefully control
caloric intake and physical activity are initially successful, but most participants regain the
weight lost one year post intervention (17; 18). Even follow up interventions with the purpose of
helping participants maintain weight loss are often unsuccessful (19) except for few effective
techniques such as consistent self-weighing (20) and very high continued physical activity levels
(21), which have a very limited acceptance and applicability. As a result, behavioral weight loss
treatment has had little impact on the obesity epidemic.
Pharmacological agents provide support for weight loss, but serious side effects, marginal
efficiency of the available drugs, or low enthusiasm in approval of new drugs by the Food and
Drug Administration (FDA) have limited their use (22; 23). Currently, only one drug (Orlistat) is
approved for long term use in obesity treatment. Bariatric surgery is very effective in inducing
large weight losses in severely obese subjects and improves their health risks and reduces
mortality (24). However, there are many limitations about bariatric surgery. At present, it is
2

offered mainly to severely obese subjects, in whom the risk due to comorbidities of obesity
outweighs that of a surgical procedure. Bariatric surgery patients may even regain a large
portion of the weight initially lost 5-10 years post operative (25). Importantly, considering the
resource-intense nature of this approach, surgery is unlikely to be a treatment for 67% of the
adults suffering from overweight or obesity in the US or millions other globally. Thus, although
conventional weight loss approaches may succeed in improving health risks at individual levels,
achieving and maintaining weight loss is highly challenging at a community level. Alternative
therapies are urgently needed to alleviate obesity related comorbidities, either by effectively
reducing obesity, or by improving metabolic health independent of weight loss.
Obesity is a complex, multifactorial disorder, which may explain the difficulty of
reducing weight simply by increasing energy expenditure and decreasing energy intake. Per
capita energy availability, food intake (26-28), and eating patterns such as eating away from
home and snacking have increased since the 1980’s (29). The built environment has changed as
well, which may be associated with obesity and less physical activity (28; 30). The environment
in developed countries has changed drastically and has been recently termed “obesogenic”,
however, the response of a given individual to this environment varies greatly. Evidence
suggests a biological predisposition determines our response to an obesogenic environment (31).
A complex system controlling energy balance exists between the hypothalamus, adipose
tissue and the gastro-intestinal system, all of which integrate nutrient and environmental cues
(32; 33). When this system is functional, body adiposity remains fairly stable. Healthy
individuals recover from long-term overfeeding lasting 100 days, and return to normal weight 4
months after resuming a normal diet(34). Perturbations in body weight can be effectively
countered by the body’s physiological responses in an attempt to return to its stable state (35).
The ability of individuals to adapt to positive energy balance is, however, variable. Humans
3

have high variation in energy expenditure, with approximately 10% variation in total energy
expenditure in healthy men (36; 37). Weight gained over time is associated with 24 hr energy
expenditure at baseline, and this association is familial (38). When exposed to long term
overfeeding, a large range of weight gain occurs, and variation in weight gain is three times more
between identical twin pairs than within pairs (39). A similar phenomenon was reported for
weight loss, induced in identical twin pairs exposed to long term high levels of exercise (40).
Evidence thus suggests a strong genetic component may predict an individual’s response to an
obesogenic environment.
Many genes have been associated with obesity; as of 2005, 176 cases of monogenic
obesity from mutations in 11 different genes, 50 loci involved in Mendelian disorders related to
obesity, and 127 more candidate genes with 22 having 5 or more supportive studies have been
identified(41). A leptin receptor mutation, for example, causes leptin resistance due to absence
of weight-controlling feedback of leptin from adipose tissue (42). Variations in FTO gene, as
another example, are strongly related to energy intake and obesity (43).
In addition, several alternative contributors to the obesity epidemic unrelated to physical
activity and caloric consumption have been recently identified, such as infections, epigenetics,
intrauterine environment, maternal age at birth, assortative mating, endocrine disruptors,
pharmaceutical iatrogenesis, reduction in variability of ambient temperatures, greater fecundity
in more obese individuals, and sleep debt (44). These factors may alter weight-regulating
mechanisms, or interact with a genetic predisposition to obesity- and combined with an
obesogenic environment, lead to obesity.
1.2 Obesity and Metabolic Syndrome
Obesity is highly associated with the development of Metabolic Syndrome. As defined
by the National Heart, Lung, and Blood Institute (NHLBI) and American Heart Association
4

(AHA), Metabolic Syndrome is characterized by three or more of the following: large waist
circumference (> 40 in for men, 35 in for women), high blood pressure (> 130/85 mmHg), high
fasting blood sugar (> 100 mg/dL), low HDL cholesterol (men < 40 mg/dL, women < 50
mg/dL), and high triglycerides (> 150 mg/dL). Metabolic Syndrome increases the risk of
cardiovascular disease and T2DM, kidney disease, nonalcoholic fatty liver disease (NAFLD),
peripheral artery disease, and stroke. It is considered one of the top causes of mortality in
developed countries (45-47). In the United States, the overall prevalence of Metabolic
Syndrome is approximately 22%. The prevalence of metabolic syndrome is 4.6%, 22.5%, and
59.6% for normal weight, overweight, and obese men, with similar trends in women (48). In
children, the prevalence also increases with the severity of obesity, and 50% of severely obese
(BMI z score above 2.5) children have metabolic syndrome (49). Therefore, excess body fat is
highly associated with development of metabolic syndrome.

1.3 Metabolism in Type 2 Diabetes Mellitus
The United States alone has 26 million diabetics and 79 million prediabetic persons
(http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf). T2DM is defined as having fasting blood

glucose ≥ 126 g/dL. T2DM is characterized by a chronic state of insulin resistance, and is often
accompanied by symptoms of Metabolic Syndrome. Insulin action is impaired at the signaling
level in these individuals. Normally, after Insulin binds to the Insulin Receptor (IR), Insulin
Receptor Substrate 1 and 2 (IRS1/IRS2) are activated via tyrosine phosphorylation, which in turn
activates Phosphatidyl inositol 3-kinase (PI3K) (50) – this is considered proximal insulin
signaling. PI3K phosphorylates and activates AKT (PKB), which leads to translocation of
glucose transporter Glut4 to the cell membrane, resulting in cellular glucose uptake (50) – this
signaling is conventionally considered as distal insulin signaling. In addition, in the liver, PI3K
5

activation also suppresses gluconeogenesis, and increases glycogen and protein synthesis.
Activation of SREPB-1c via hepatic insulin signaling increases lipid synthesis (50). In T2DM ,
however, proximal insulin signaling is impaired at the level of IR, IRS1/2, and PI3K (50-53).
Because insulin signaling is defective, blood glucose remains elevated, and as a result, the
pancreas receives constant stimulation to secrete more insulin to improve glucose disposal.
Pancreatic beta cells therefore become necrotic, and over time are unable to secrete insulin in
quantities sufficient for maintenance of normoglycemia (54; 55). Other pathologies of
pancreatic beta cells have also been suggested, which could contribute to impaired insulin
signaling (56).
Impaired insulin signaling has several metabolic outcomes. Glucose is not cleared by
adipose tissue and muscle, two of the main tissues involved in glucose clearance. Due to hepatic
insulin resistance, gluconeogenesis is not suppressed in postprandial state, so hepatic glucose
output is uncontrolled. Also, due to insulin resistance, hepatic de novo lipogenesis (DNL) is not
stimulated, which impairs clearance of cellular glucose. These are some of the key contributions
of the liver to hyperglycemia in insulin resistant state. In adipose tissue, lipid uptake is not
stimulated by insulin, and lipolysis in adipocytes is not suppressed by insulin in an insulin
resistant state. Therefore, systemic levels of free fatty acids increase, which could promote the
deposition of these lipids ectopically in tissues such as the liver, skeletal muscle or heart, which
further impairs glucose disposal by these tissues.
1.4 Metabolically Healthy Obesity- Adipose Tissue and Liver in the Regulation of Glycemic
Control
Many factors influence the metabolic profile of an obese individual; those who smoke
less, exercise more, have smaller waist circumferences, and who are non-Hispanic or nonAfrican American are metabolically healthier (57; 58). Although approximately 60% of obese
6

persons have metabolic syndrome, 40% of obese adults do not have metabolic syndrome, and are
apparently “metabolically healthy” for many disease markers. This population, referred to as
metabolically healthy obese (MHO), has better insulin sensitivity, high density lipoprotein levels,
triglyceride levels, (59) and inflammatory profiles (60) than the obese metabolically abnormal
population. It has even been suggested that obesity in these individuals may be protective
against co-morbidities (61). Furthermore, normal weight persons can also demonstrate the
unhealthy metabolic profile typical of an obese person (62; 63). Nearly one quarter of the
normal weight American population is metabolically abnormal, and those with higher waist
circumference, greater age, and lower physical activity fall into this category (58). Another
example is the normal weight Asian Indian population which has particularly high percent body
fat in addition to hyperlipidemia, insulin resistance, high ectopic lipid deposition in skeletal
muscle, and a high level of inflammatory markers (64-66). Thus, many factors besides adiposity
seem to determine the metabolic health of an individual.
The exact mechanisms for obesity leading to Metabolic Syndrome and its related comorbidities are not well understood, and comparing metabolically healthy obese to metabolically
abnormal obese is one approach to better understand this complex relationship. Recent research
suggests many adipose tissue and liver characteristics distinguish obesity with metabolic
abnormalities and insulin resistance from metabolically healthy obesity.

1.4.1 Adipose Tissue and Glycemic Control
While adipose tissue was once considered simply a storage organ, it is now considered an
endocrine organ that influences metabolic health and insulin sensitivity (67). Several factors,
termed adipokines, are secreted from adipose tissue and regulate insulin action, lipid metabolism,
and energy expenditure. For example, adiponectin is secreted from adipocytes and is an insulin
7

sensitizing, anti-inflammatory adipokine (68). Resistin on the other hand, another adpokine
secreted from adipose tissue, is pro-inflammatory and associated with insulin resistance in
rodents (69). In addition, adipose tissue is vital for efficient storage of fatty acids, which are
otherwise metabolically toxic as in the case of lipodystrophy. A relative lack of adipose tissue in
lipodystrophy causes marked insulin resistance, which can be reversed by restoration of adipose
tissue (70; 71). Appropriately functioning adipose tissue is therefore imperative for metabolic
health. Several other characteristics of adipose tissue such as adipose tissue distribution,
inflammation, macrophage infiltration, hypoxia, adipose tissue expandability and remodeling,
adipocyte size, and adipokine seceratory profile have been associated with insulin resistance.
1.4.1a Adipose Tissue Distribution
Distribution pattern of adipose tissue throughout the body is associated with insulin
resistance. Although BMI is related to development of metabolic abnormalities, visceral fat,
estimated by waist circumference or wait-to-hip ratio, is often a better predictor of health risk
(72-74). Gluteal and femoral adipose depots, on the other hand, may be more protective against
the development of metabolic abnormalities (75). In response to a high fat diet, visceral fat upregulates lipoprotein lipase and hormone sensitive lipase more so than subcutaneous fat, which
may release more free fatty acids and contribute to increased systemic free fatty acids, and
ectopic lipid deposition in liver and skeletal muscle (76). Visceral fat secretes more
inflammatory cytokines that may contribute to insulin resistance. Particularly, Interleukin-6 (IL6) expression is up-regulated in visceral adipose tissue, which in turn may increase C-reactive
protein secretion from the liver (77; 78). Alternatively, reduction of visceral obesity reverses
hepatic insulin resistance (79).
Inflammation may also be a factor in the relationship between visceral fat and insulin
resistance, as macrophage infiltration is greater in visceral adipose tissue of insulin resistant
8

subjects (80; 81). These macrophages may be a source of adipokines visfatin and resistin (80),
both of which may be associated with insulin resistance. In addition, insulin-sensitizing
adipokine adiponectin is negatively associated with visceral fat (82).

Therefore, increased

visceral fat lipolysis, inflammation, and changes in adipokine secretion may contribute to the
association between visceral obesity and insulin resistance.
1.4.1b Adipose Tissue Inflammation
Inflammation is a potential contributor to Metabolic Syndrome and insulin resistance in
obesity(83). C-reactive protein (CRP), a marker of inflammation, is markedly up-regulated in
obese individuals with Metabolic Syndrome (84). Expression of pro-inflammatory cytokines and
chemokines such as Tumor Necrosis Factor alpha (TNF-α)(85; 86), Interleukin 6 (IL-6)(87),
Interleukin 1-beta (IL-1β) (88), Interleukin-18 (IL-18)(89), and Monocyte chemotactic protein-1
(MCP-1)(90) in adipose tissue inhibits insulin signaling and/or is associated with insulin
resistance. Cytokine expression is elevated in adipose tissue of obese persons, especially in
insulin resistant obese more so than insulin sensitive obese (91). Activity of inflammatory
pathway transcription factors, such as Jun-terminal kinase (JNK) and nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB), is also up-regulated in adipose tissue of obese,
insulin resistant persons, which down-regulates insulin signaling, leading to insulin resistance
(91-93). Interestingly, inflammatory cytokine expression decreases with weight loss and
resembles that of a lean individual in response to very low calorie diet (94).
Macrophage populations in adipose tissue may play a major role in mediating
inflammation and insulin resistance, although the role of macrophages is not completely
understood. Macrophage infiltration into adipose tissue is associated with obesity and adipocyte
hypertrophy (95-97), likely through increased MCP-1 secretion from adipocytes (90; 98),
Macrophages in obese adipose tissue tend to aggregate in crown-like structures (CLS) (97),
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which aggregate around necrotic adipocytes(97; 99), and weight loss reduces macrophage
infiltration (97). On the other hand, macrophages also aid with development of new blood
vessels in response to inflammation (100) and ischemia (101), possibly through platelet derived
growth factor (PDGF) (102), and therefore may be involved in adipose tissue growth and
remodeling (102; 103).
In addition, inflammation may contribute to insulin resistance through increasing
systemic free fatty acids. Inflammatory cytokines such as TNF-α, which increase lipolysis in
adipocytes, are increased with insulin resistance (104). Uncontrolled lipolysis contributes to
increased systemic levels of free fatty acids, which may contribute to insulin resistance through
several mechanisms. First, free fatty acids enhance pancreatic response to glucose and may lead
to hyperinsulinemia (105; 106), and hyperinsulinemia is enough to induce insulin resistance due
to an innate feedback loop downstream of insulin signaling that inhibits IRS-1 (107). In skeletal
muscle, impaired fatty acid oxidation may lead to buildup of diacylglycoerol (108), which
mediates insulin resistance (107).
1.4.1c Adipose Tissue Hypoxia
Adipose tissue hypoxia is another factor associated with insulin resistance and
inflammation (109; 110). As adipocytes undergo hypertrophy and adipose tissue expands in
response to positive energy balance, increased vascularization must occur to allow expansion,
and prevent hypoxia and inflammation (111). Obesity and insulin resistance are associated with
adipose tissue hypoxia. Hypoxia-inducible factor alpha (HIF-1α), the key hypoxia induced
transcription factor, is elevated in diet induced and ob/ob obese models (112). Exposing human
and rodent adipocytes or macrophages to hypoxia induces expression of inflammatory cytokines,
and exposing preadipocytes to hypoxia inhibits differentiation (112). In mice, adipose tissue of
obese animals (ob/ob mice) demonstrates a marked 70% reduction in O2 partial pressure and a
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marked reduction in adiponectin compared to control lean mice (113). In humans, obesity is also
linked to increased adipose tissue HIF-1α expression, which is improved after bariatric surgery
induced weight loss (97; 114). Thus, obesity is associated with hypoxia in adipose tissue.
Hypoxia in adipose tissue may also contribute to insulin resistance through several
mechanisms (109). Hypoxia and related inflammation increases adipocyte death (99; 110; 115),
which may in turn contribute to increased systemic free fatty acids. In addition, hypoxia
suppresses insulin induced glucose uptake in 3T3-L1 adipocytes, and therefore may cause insulin
resistance locally in adipose tissue (110). Adipokine secretion is also altered by hypoxia; it may
induce leptin expression (116) and suppresses anti-inflammatory adiponectin expression (117;
118).
1.4.1d Adipose Tissue Expandability
Adipose tissue expandability also influences insulin sensitivity (119). If the expansion
threshold is limited during positive energy balance, new adipocytes may not get recruited.
Instead, the existing adipocytes may undergo hypertrophy, but eventually become insulin
resistant and necrotic. Adipocyte death may in turn cause systemic free fatty acid “spill over”
and ectopic lipid deposition (119). If adipose tissue is able to recruit new adipocytes and
respond with hyperplastic expansion, however, and effectively “remodel” in response to positive
energy balance, it retains its function in maintaining insulin sensitivity. T2DM drug class
Thiazolidinedione (TZD) is a well known example of an agent which remodels adipose tissue.
TZDs are agonists of PPARγ, the predominant regulator of adipogenesis (120), and increase
insulin sensitivity (121). TZDs reverse glucose intolerance in obese Zucker rats not by changing
adipose tissue mass, but rather by decreasing mean adipocyte size (122). Treatment with TZDs
specifically expands subcutaneous adipose tissue (123; 124), increasing the ratio of subcutaneous
/ visceral adipose tissue mass (125). A shift from hypertrophic to hyperplastic subcutaneous
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adipose tissue occurs, as indicated by greater number of smaller adipocytes (125-127). This shift
to hyperplastic expansion of adipose tissue is thought to be the mechanism by which TZDs
increase insulin sensitivity (128). This hypothesis is also supported by the association of
impaired adipogenesis with insulin resistance (129). Thus, expansion of adipose tissue appears
to accommodate incoming lipid in adipose tissue, thereby, preventing its ectopic storage and the
consequential deterioration in glycemic control.
Several animal models of excessive adipose tissue expansion have demonstrated
improved insulin sensitivity (68; 130). Collagen VI is one of the predominant components in the
extracellular matrix (ECM) that surrounds adipose tissue, which must be rearranged upon
adipose tissue expansion (130). On a high fat diet or ob/ob genetic background, Collagen VI
knock-out mice have uninhibited adipose tissue expansion, yet improved insulin sensitivity
(130). Collagen VI KO ob/ob mice are characterized by larger adipocytes, improved lipid
clearance, lower inflammation and improved insulin sensitivity in adipose tissue, less pancreatic
hyperplasia, and less adipocyte death compared to ob/ob controls (130). Alternatively, excessive
Collagen VI gene expression is also related to impaired insulin sensitivity, as db/db mice have
greater collagen expression compared to wild type mice, and collagen expression decreases
following TZD treatment of wild type mice (130).
The involvement of fibrosis in adipose tissue dysfunction in humans is evident in Asian
Indians, who are insulin resistant at a lower BMI compared to Caucasians (45-47) and have
greater expression of Collagen VI (130). In human obesity, expression of extra-cellular matrix
components is up-regulated and may be mediated by the response of preadipocytes to high levels
of inflammation (131; 132). Therefore, expandability of adipose tissue may be directly affected
by the extra-cellular matrix, and may influence insulin sensitivity.
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Collectively, it is postulated that increased lipid storage demands result in expansion of
adipose tissue mass. Expanding adipose tissue increases oxygen demands, resulting in hypoxia.
This hypoxia stimulates angiogenesis for supplying oxygen through increased blood supply,
allowing the formation of new adipose tissue. Thus, hypoxia, angiogenesis and adipose tissue
expansion together offer increased capacity to store lipid, thereby preventing systemic free fatty
acid increase and ectopic fat deposition.
1.4.1e Adipose Tissue Adiponectin
Adiponectin may be one of the most important insulin sensitizing adipokines. Adipose
tissue specific overexpression of adiponectin in ob/ob mice improves insulin sensitivity despite
marked obesity (68). These mice have lower ectopic lipid deposition in liver and skeletal
muscle, greater adipogenesis, smaller adipocyte size, lower triglycerides, less macrophage
adipose tissue infiltration, less systemic inflammation, less pancreatic hyperplasia, and lower
fasting glucose and insulin levels compared to ob/ob control mice (68). On the other hand,
hypoadiponectinemia is associated with insulin resistance in rodents, non-human primates, adults
and children (82; 133-137), and adiponectin receptor ApidoR1 and AdipoR2 expression is
reduced in insulin resistance (138; 139).
Adiponectin may influence insulin resistance in several ways. First, adiponectin has
systemic effects on glucose and lipid metabolism. Through its receptors, adiponectin robustly
up-regulates AMP-activated protein kinase (AMPK) activation in the liver, thereby increasing
fatty acid oxidation and decreasing hepatic glucose production and output (140-142). Certain
isoforms of adiponectin may have a similar effect on AMPK in skeletal muscle, increasing
glucose uptake and fatty acid oxidation (143). The systemic action of adiponectin is dependent
on expression levels of adiponectin receptors AdipoR1 and AdipoR2 (144). AdipoR1 is
abundantly expressed in skeletal muscle, whereas AdipoR2 is expressed in liver (144). During
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fasting, adiponectin receptors are up-regulated, likely for stimulation of fat oxidation and hepatic
glucose output, and they are down-regulated postprandially (138). This mechanism is regulated
by insulin mediated activation of PI3K, which phosphorylates and inactivates transcriptional
forkhead transactivator FOXO1 (138). Adiponectin therefore improves systemic glucose
clearance by suppressing glucose output from the liver, decreasing steatosis of the liver by upregulating fatty acid oxidation, and increasing glucose uptake in skeletal muscle.
The autocrine-paracrine action of adiponectin in adipose tissue may improve
inflammation, increase glucose uptake and improve insulin resistance. Chronic inflammation
and hypoxia normally present in obesity suppresses adiponectin secretion (113). Adiponectin
suppresses TNF-α expression, suggesting it has anti-inflammatory properties (145). Adiponectin
receptors are expressed in adipose tissue macrophages, and adiponectin has anti-inflammatory
action on these cell types (146). In fact, adiponectin desensitizes macrophages to proinflammatory stimuli (146), and switches macrophages to anti-inflammatory phenotype (147).
Adiponectin also activates AMPK in adipocytes and increases glucose uptake, and reverses
TNF-α induced insulin resistance in adipocytes (148) . Lastly, adiponectin up-regulates
angiogenesis, and therefore may prevent hypoxia in adipose tissue (149; 150).
1.4.1f Adipocyte Size
Adipocyte size is also a marker of insulin sensitivity and adipose tissue metabolic
health. Several reports have found an association between insulin resistance and large
subcutaneous adipocyte size (151-153). This is apparent in Pima Indians, a population with
marked obesity and insulin resistance, with a 20% increase in fat cell size in T2DM subjects
compared to those with normal glucose tolerance (153). Mean adipocyte size is negatively
correlated with insulin sensitivity after adjusting for body fatness (153).
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Several mechanisms may link large adipocyte size and insulin resistance. Large
adipocyte size may be a result of decreased capacity for adipogenesis (129), whereby mature
adipocytes become hypertrophic because new cells are not being recruited in response to positive
energy balance. Also, adipocyte size is positively correlated to expression of pro-inflammatory
cytokines and chemokines (154), suggesting dysfunctional hypertrophic adipocytes may be proinflammatory. In addition, large adipocytes have higher rates of basal lipolysis than small
adipocytes and may therefore increase systemic free fatty acids (155). Lastly, large adipocytes in
both omental and subcutaneous adipose tissue are associated with hepatic lipid accumulation and
fibrosis (156).
Conversely, small adipocyte size is associated with improved insulin sensitivity, as
demonstrated with TZD treatment (126-128) and adipose tissue specific adiponectin over
expressing mice (68). Metabolically healthy obesity is associated with smaller omental
adipocyte size, but not smaller subcutaneous adipocyte size, compared to metabolically abnormal
obesity (156; 157). Small adipocytes secrete more adiponectin (122; 158), which may contribute
to improved insulin sensitivity. It should be noted, however, that Collagen VI knock-out mice
demonstrate larger adipocyte size and better insulin sensitivity compared to controls. This
contradictory finding suggests adipocyte size is a function of adipose tissue remodeling capacity.
In the absence of the extra cellular matrix, with uninhibited adipose tissue expansion, perhaps
large adipocytes have “room to grow” and are therefore less problematic. Also, large fat cell
size was negatively correlated with insulin resistance in non-diabetic subjects, suggesting other
factors may play a more important role after progression to T2DM(151).
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1.4.2 Hepatic Regulation of Insulin Sensitivity
Hepatic functioning is also vital for maintenance of normoglycemica. Prevalence of fatty
liver due to excessive lipid accumulation is 15% in normal weight individuals, but rises to 65%
and 80% in obese and morbidly obese subjects, respectively (159-163). Many changes can lead
to hepatic triglyceride accumulation; however, excess de novo lipogenesis (164; 165) and lower
lipid export from liver (166; 167) are major contributors of NAFLD. NAFLD prevalence is
extremely high in T2DM (69.5%) (168). NAFLD can be present without T2DM, however, those
patients are generally younger with a less advanced stage of the problem, whereas those with
T2DM have a more severe form including cirrhosis (169) or Non Alcoholic Steatohepatitis
(NASH) (170). NASH is a more advanced stage of NAFLD, which includes inflammation and
fibrosis in addition to lipid accumulation. Fatty liver is associated with insulin resistance
independent of BMI, percent body fat, and visceral fat (159; 171-175). In addition, hepatic
triglyceride content is the best predictor of impaired insulin action in liver, skeletal muscle, and
adipose tissue, independent of body fat and BMI (172). NAFLD improves after bariatric
surgery, and gene expression of inflammation and fibrosis are lower 1 year post surgery (176).
Several associations have been reported between hepatic steatosis and other contributors
to insulin resistance(159). Many adipose tissue factors are highly correlated with steatosis.
Adipose tissue macrophage infiltration and inflammation are closely linked to severity of
NAFLD and fibrosis independent of body fatness (81; 177). Specifically, omental macrophage
content and adiponectin levels are the best predictors of hepatic fibroinflammatory lesions (81).
IL-1β secretion from adipocytes in response to activated macrophages and TNF-α may mediate
the effect of adipose tissue inflammation on hepatic insulin resistance (178). Adiponectin
secretion from adipocytes is also likely to play a large role in steatosis, as adiponectin induces
fatty acid oxidation (141), is inversely associated with hepatic steatosis (179; 180), and
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adiponectin therapy corrects steatosis in mice (159; 180). Local hepatic inflammation may also
play a role in insulin resistance. Liver-specific activation of NF-κB is sufficient to induce
hepatic insulin resistance and moderate systemic insulin resistance and has similar effects to high
fat diet (181). Lastly, hepatic lipid accumulation may result in build-up of fatty acid compounds
such as diacylglycerol that have negative feedback on insulin signaling (182). Thus, hepatic
lipid is a strong contributor to insulin resistance.
Many characteristics of adipose tissue and liver therefore contribute to insulin resistance
and distinguish metabolically healthy from metabolically unhealthy obesity. Reducing obesity
leads to improvements in obesity-associated metabolic comorbidities (183-185), however,
compliance with lifestyle modifications for weight loss is highly challenging for the general
population. As a result, drug therapies are a promising alternative for improvement of
hyperglycemia. Specifically, drug therapies that improve hyperglycemia without weight loss and
despite continued consumption of a high fat diet would be of practical benefit.
Current drug therapies improve insulin secretion, insulin action at the receptor level, or
enhance the insulin signaling pathway. Insulin signaling is impaired in the T2DM condition (5053; 186; 187), however, diminishing the effectiveness of treatments that target these weakened
pathways.

For these reasons, an agent that improves glycemic control despite continued

consumption of a high fat diet, without weight loss, which bypasses insulin and insulin signaling
through an alternative pathway, may be more effective than treatments available currently.
Interestingly, human Adenovirus type 36 (Ad36) infection increases glucose disposal despite
impaired proximal insulin signaling (188; 189), improves glycemic control in mice on a high fat
diet without weight loss (190), and offers an excellent template for the study of such alternative
pathways.
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1.5 Ad-36 and its E4orf1 Protein for Improvement of T2DM
Human adenovirus Ad36 infection is a model to study metabolically healthier obesity for
the prevention of metabolic complications in obesity. Ad36 is a serologically unique human
adenovirus, compared to 50 other serotypes of human adenoviruses, and belongs to subgroup D
(191). It was first isolated in 1978 in Germany, from a fecal sample obtained from a girl who
was suffering from diarrhea (191). Human adenoviruses cause a range of symptoms depending
on the serotype, including conjunctivitis, gastroenteritis, and upper respiratory distress. Ad36
causes obesity in animal models (192-194) and is associated with human obesity (195; 196), yet
its infection is associated with better lipid, cholesterol (195), and insulin sensitivity profiles (188;
197). Ad36 infection increases glucose uptake in diabetic and non-diabetic skeletal muscle and
adipose tissue explants (188; 189) and attenuates high fat diet-induced hyperglycemia in mice
(190). Studying the favorable effect of Ad36 on metabolic consequences of obesity may provide
insight to novel treatments that improve glycemic control despite adiposity. Using infection as
treatment for metabolic syndrome is not practical; however, identifying the viral protein that is
responsible for influencing glucose disposal may help in developing a novel anti-diabetic
therapeutic agent. A background for this approach is provided below.
1.5.1 Animal Models of Ad36-Induced Obesity
Several animal experiments clearly demonstrate the effect of Ad36 on increasing
adiposity. Chickens, mice, rats and marmosets (non-human primates) all have greater adiposity
in response to Ad36 infection at various ages and infection routes (192-194; 197).
Ad36 infection and subsequent adiposity are both transmittable. Ad36 infection could be
transmitted within 12 hours from experimentally infected animal to uninfected cage mates(192).
When blood obtained 36 h after infecting chickens with Ad36 was injected intravenously into a
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new set of animals, the recipient animals became infected with Ad36 and developed obesity
(192). In addition to fulfilling Koch’s postulate, this experiment demonstrates blood-borne mode
of transmission of Ad36.
A species specific effect of Ad36 on adiposity has been observed as described below
(192-194; 197). In chickens, Ad36 did not increase weight significantly, however, acutely and
significantly increased body fatness. Rodent and marmoset models show a more gradual onset
of significant weight gain. Six months after Ad36 infection, marmosets show a 3 fold increase in
body weight gain and 56% greater body fat compared to uninfected controls. Prevalence of
obesity ranged from 60 to 100% in various animal experiments compared to 12 to 23%
prevalence in the uninfected controls.
Ad36 spreads to several organs, including the kidneys, liver, lungs, heart, spleen, skeletal
muscle and adipose tissue only 2 days following infection, as determined by Ad36-specific DNA
(198). The presence of Ad36 in adipose tissue is particularly intriguing considering the role of
Ad36 on adiposity. The amount of Ad36 DNA in adipose tissue significantly correlated with the
amount of adipose tissue (193). Viral mRNA is also detectable in adipose tissue, suggesting
active viral replication. Collectively, these studies indicated that Ad36 may directly influence
adipose tissue and induce its expansion.
As expected, the increase in adiposity by Ad36 is also accompanied by the up-regulation
of the adipogenic gene cascade. Ad36 robustly up-regulates PPARγ (peroxisome proliferator
activator receptor gamma), C/EBPβ (CCAAT enhancer binding protein β), and G3PDH (glycerol
3-phosphate dehydrogenase) compared to uninfected controls (197). However, Ad36 increases
adiposity as well, which may confound the comparison of adipogenic gene expression in adipose
tissue of lean vs. obese (Ad36 infected) animals. Therefore, the adipose tissue gene expression
was compared between selected animals from the Ad36 infected and uninfected groups matched
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for body weight and adiposity. This comparison showed that although their adipose tissue mass
was matched, Ad36 increased the adipose tissue expression of PPARγ up to 30 fold as well as
the expression of C/EBPβ and G3PDH by several fold (197) .
A criticism of animal studies with Ad36 induced adiposity is that high, experimental
doses of virus may not reflect natural infection. Significant adiposity does occur, however, in
naturally infected rhesus monkeys (194). Over a 90 month period rhesus monkeys at the
Wisconsin Regional Primate Research Center were tested for Ad36 seropositivity due to
spontaneous natural infection. Their data were compared 18 months before and 18 months after
seroconversion. After the seroconversion, monkeys gained 15% body weight reduced serum
cholesterol by 23% (194). Body weights of these monkeys were stable previous to the time of
infection. All 15 monkeys in the study eventually became infected throughout the 90 month
study, indicating a high transmissibility and relative epidemic in this population of monkeys.
The drop in cholesterol and increase in body weight was independent of age upon natural
infection, thus these effects were not due to age but were specific to the virus. This is the only
prospective study to date on natural infection of Ad36 and the induction of adiposity, and it is
indicative of the ability of Ad36 to induce weight gain in an otherwise healthy population.
In addition to increased adiposity, Ad36 also induces better insulin sensitivity in male
Wistar rats (197). While fasting glucose levels do not differ, fasting insulin levels are
significantly lower and HOMA index is improved in Ad36 infected animals. Despite increased
body fatness, rats maintained euglycemia with nearly half the insulin level of control mice.
Thus, Ad36 increases adiposity, yet prevent the development of adiposity induced insulin
resistance. This action is reminiscent of anti-diabetic TZDs. Ad36 also induces higher
circulating levels of leptin, which suppresses norepinephrine (NE) signaling in the
paraventricular nucleus of the hypothalamus that would normally induce corticosterone secretion
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and inflammation to fight infection (199). Rats did indeed show lower NE and corticosterone
levels (197). Corticosterone prevents fat deposition and glucose uptake in adipocytes and
liberates fatty acids for energy and glycerol for gluconeogenesis, therefore at lower levels of
corticosterone, fatty acid deposition can take place and lipolysis is inhibited. Perhaps this
endocrine cycle also contributes to insulin sensitivity and increased adiposity in Ad36 infected
animals.
1.5.2 In Vitro Studies

Numerous in vitro studies have demonstrated the ability of Ad36 to induce adipogenesis.
Since adipose tissue is infected by Ad36 (198), it is logical to investigate the direct effect of
Ad36 on adipocytes in cell culture as a mechanism for Ad36 induced adiposity. Ad36 infected
3T3-L1 preadipocytes or human adipose tissue derived stem cells (hASC) differentiate and
accumulate lipid to a greater extent than Mock infected or Ad-2 infected negative control cells
(200; 201). Ad36 infection is abortive in the 3T3-L1 cell line. Ad36 initiates mRNA expression
in 3T3-L1, but virus particles are not formed. Ad36 mRNA expression is enough to induce an
adipogenic effect. Cidofovir, an anti-adenoviral agent, abrogates the adipogenic effect of Ad36
on 3T3-L1 cells (200). Importantly, Ad36 can induce adipogenic differentiation even in the
absence of the adipogenic induction with an adipogenic cocktail of methylisobutylxanthine,
dexamethasone, and insulin (MDI), or even in hASC exposed to osteogenic media (202).
Detailed investigation of the effect of Ad36 preadipocyte biology has further characterized how
Ad36 may lead to increased adiposity in vivo. The adipogenic gene cascade has revealed the
entire process from increased cAMP and Wnt-10b down-regulation, to increased phosphatidylinositol kinase activity and aP2 is induced with or without MDI in both 3T3-L1 (200; 201) and
hASC’s (203).
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One of six genes expressed from adenoviral early gene E4 (204), E4orf1 is a candidate
for the differentiation and proliferation of preadipocytes because of its role in cell cycle
regulation. It contains a PDZ-domain binding motif (PBM) which is critical for its ability to
induce adipogenesis(203). The E4orf-1 gene of Ad9, which is highly homologous to that of
Ad36, is known to activate PI3K (41, 42). Since Ad9 is also known to cause lipid accumulation
in 3T3-L1 cells (43), E4orf-1 of Ad36 was investigated as the inducer of adipogenesis as well
and was found to be sufficient and necessary to induce adipogenesis, and relies on the PI3K
pathway for this induction (188). The PBM of Ad36 E4orf1 is necessary for the adipogenic
effect of E4orf1 (203).
1.5.3 Human Studies
Ethical considerations preclude experimental infection of humans to demonstrate a cause
and effect relationship of Ad36 and obesity in humans. For this reason, only indirect evidence
for an association can be obtained. Several reported epidemiological associations between
individuals seropositve to Ad36 and BMI, however, are supportive and congruent with evidence
from animal and in vitro cell culture studies. Seropositivity to Ad36 is associated with obesity in
the United States; 30% of obese individuals have been infected, whereas only 11% of lean
persons have antibodies to Ad36 (195). Other adenoviruses (Ad-31, Ad-2, and Ad-37) do not
have an association with BMI, suggesting the effect is not a characteristic of all adenoviruses in
humans. Seropositive individuals had significantly greater BMI compared to their seronegative
counterparts within obese as well as non-obese groups. Italian adults also showed a positive
association of Ad36 seropositivity and BMI (205), whereas a cohort from the Netherlands and
Belgium, and another cohort of United States military personnel did not show this association
(206; 207). Antibody positive twins have higher BMI and adiposity than their seronegative twin
(195). Increased adiposity in Ad36 infected twins occurs despite identical genetic background.
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Ad36 infection is also associated with adiposity in children (208; 209). In Korean children, Ad36 seropositivity is associated with higher BMI z-score and waist circumference (209; 210). In
the United States, prevalence of Ad36 antibodies is 15% overall in adolescents aged 8-18, and of
the seropositive children, 78% are obese, while 4% are non-obese (208). This indirect evidence
coupled with direct causative effect in animal studies indicates that Ad36 may promote greater
adiposity in humans. Ad36 may therefore be another environmental factor, other than diet and
exercise that may contribute to increased adiposity.
1.5.4 Ad36 and Insulin Sensitivity
Several lines of evidence suggest that Ad36 induces metabolic changes that may
favorably alter insulin sensitivity. Ad36 increases glucose uptake by preadipocytes, adipocytes,
adipose tissue and skeletal muscle and reduces leptin secretion by adipocytes (188; 189; 211).
Local adipocyte hypoleptinemia could contribute to improved adipogenesis and lipid
accumulation. Lipid accumulation in Ad36 infected adipocytes may partly be due to de novo
lipogenesis increased by the virus (188). Overall, it appears that Ad36 promotes adipogenic
commitment and differentiation of adipocyte progenitors, increases glucose uptake by these
cells, and increases the conversion of glucose to lipid. This may explain increased adiposity on
one hand, and better glycemic control on the other hand that is observed in Ad36 infected animal
models.

Human ex-vivo studies, as outlined below, have provided further insight into this

paradoxical phenomenon of improved insulin sensitivity caused by adipogenic Ad36 and its
potential relevance to metabolically healthier human obesity.
Despite increased adiposity in seropositive subjects, Ad36 infection is associated with a
decrease in serum cholesterol and triglycerides (195). Ad36 seropositive diabetic and nondiabetic
subjects have lower fasting blood glucose and Hb A1C levels than seronegative subjects (188;
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190). In addition, Ad36 seropositivity is associated with a lower prevalence of NAFLD (212),
which may be related to the mechanism for Ad36 induced improvements in glycemic control.
Ex-vivo human studies demonstrate Ad36 increases glucose disposal in primary skeletal
muscle cells and adipose tissue explants from both diabetic and nondiabetic individuals in the
basal and insulin stimulated conditions (188; 189). Although Ad36 down-regulates IRS-1
activation, it increases Ras-mediated PI3K activation and Glut4 translocation, leading to
increased glucose uptake in both skeletal muscle and adipose tissue (188; 189). Thus, Ad36
infection down-regulates proximal insulin signaling, yet up-regulates the distal insulin signaling.
In adipose tissue, increased adiponectin, Glut1, PI3K activation, PPARγ, and decreased
inflammatory cytokines such as MCP-1 mRNA expression induced by Ad36 also appear to
contribute to improved glucose uptake (188). Collectively, this evidence suggests Ad36 may be
able to improve glucose disposal and lipid storage, despite impairing proximal insulin signaling.
Possibly, Ad36 recruits adipose tissue, liver and skeletal muscle to effect this change.
The effect of Ad36 on glycemic control was first observed experimentally in rats (197).
Infected rats had lower HOMA-IR and maintained normoglycemica with half the fasting insulin
levels of control mice, suggesting Ad36 has an insulin-sparing effect (197). This observation
was then verified in C57BL/6J mice (190). Ad36 infected mice were fatter, but had had
consistently lower fasting glucose and fasting insulin compared to those infected with Mock or
Ad2 infected mice (190). In another experiment, Ad36 improved hyperglycemia in mice
induced by a high fat diet. Ad36 lowered fasting glucose and insulin up to 20 weeks post
infection, and significantly improved glucose clearance following a glucose tolerance test
compared to Mock or Ad2 infected mice (190). Probably due to the overwhelming adipogenic
effect of high fat diet, there was no difference in adiposity between the three groups of mice.
Ad36 appears to increase glucose clearance through a Ras-PI3K mediated Glut4 pathway in
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adipose tissue and skeletal muscle (190). Ad36 may also induce fatty acid oxidation in liver and
skeletal muscle through increased adiponectin expression in adipose tissue (190). Glucose output
may also be suppressed by Ad36, as indicated by lower hepatic Glut2 expression (190). Gene
expression indicated that hepatic fatty acid oxidation and export may be up-regulated by the
virus(190). Thus despite a high fat diet, Ad36 infection recruited multiple tissues for attenuation
of dysglycemia. Ad36 may circumvent impaired proximal insulin signaling through a Rasmediated pathway for glucose uptake in adipose tissue and skeletal muscle, and suppress hepatic
lipid accumulation and glucose output. Collectively, these effects may lead to in vivo Ad36induced improvements in glycemic control.
1.5.5 Ras Activation- Glucose Uptake, Angiogenesis, and Cell Transformation
While Ras proteins are a family of GTPases that have been most studied as oncogenes,
they have a vital role in signal transduction and regulation of multiple processes that would be
vital to viral replication including differentiation, proliferation and cell cycle. Ras has three
major isoforms: H-Ras, N-Ras, and K-Ras. Major downstream Ras effectors include the mitogen
activated protein kinase (MAPK/ERK) pathway, the p38 MAPK pathway, and the PI3K/mTOR
pathway(213). Importantly, Ras regulates many processes that may contribute to glycemic
control through these downstream effectors as described below.
Ras plays a role in adipogenesis. Ras is both sufficient(214) and necessary(215) to
induce adipogenesis through the PI3K/AKT pathway(216; 217) and the p38 pathway(218).
MAPK/ERK activation by Ras may also be involved in the initiation of adipogenesis (219), but
this pathway is down-regulated upon progression of adipogenesis (220; 221). Activator complex
exchange of CEBPβ, the initiator of adipogenesis, is also stimulated by Ras activation (222). In
addition, Ras may function to increase glucose disposal. While Ras does not contribute to
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insulin dependent glucose uptake(223), it alone is sufficient to induce glucose uptake(224).
Overexpression of H-Ras in adipose tissue is sufficient to increase insulin sensitivity in mice
(225), and in general Ras is thought to have insulin mimicking effects on glucose transporter
translocation (226; 227). Assuming Ad36 requires Ras to increase glucose uptake, this would
explain why insulin has an additive effect in vitro on increased glucose uptake in Ad36
infection(188; 189). Finally, Ras downstream effectors can induce angiogenesis via p38 or PI3K
activation (228-234), which is crucial for the prevention of hypoxia and insulin resistance in
adipose tissue(229). Thus it is possible that Ad36 acts through Ras to improve glycemic control
in vivo.
Although Ras is known as an oncogene, its activation alone is not sufficient to induce
tumor formation. For instance, dysregulated focal adhesion kinase is necessary for Ras
activation to result in cell transformation (235). In addition, transgenic over expression of HRas in adipose tissue, the specific isoform activated by E4orf1, does not cause tumor formation
(225). In several Ad36 infection experiments lasting up to 7 months, animals did not develop
tumors (192-194; 197). Therefore, we hypothesize that E4orf1 is not likely to be oncogenic,
although this needs to be tested more thoroughly in vivo.
1.5.6 E4orf1: A Candidate Gene of Ad36 for Improving Glycemic Control
Identifying the viral protein responsible for glucose uptake induced by Ad36 is the next
step in isolating the therapeutic potential of the virus, since infection is not a viable treatment
option. Many viruses have been exploited for beneficial purposes, and can be used as tools to
combat disease. For example, bacteriophages have been explored as antibacterial agents (236),
and lytic properties of other viruses have been used to selectively infect and destroy cancer
cells(237).
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E4orf1 was chosen as a candidate for the glucose clearance effect of Ad36.
Adenoviruses have a set of several early genes that encode proteins for evading the host immune
system and changing cell function for favorable viral replication, and several late genes that
encode structural proteins. Adenoviral gene E4orf1 is transcribed from the first open reading
frame of Ad36 early gene 4, and is a 17 kDa, 125 amino acid protein. It is highly homologous to
the human ancestral dUTPase gene, and has a PBM region through which it interacts with other
proteins containing PDZ regions for scaffolding. E4orf1 of adenovirus Ad9 binds to Dlg1
through its PBM region(238), the complex then translocates to the membrane, where it activates
Ras, which in turn activates PI3K (238-240). The E4orf1 protein of Ad36 is 96% homologous to
that of Ad9. This entire mechanism is not worked out with Ad36 E4orf1, however, available
information suggests a similar mechanism of action for Ad36 E4orf1. For instance, Ad36
requires Ras and PI3K for its adipogenic action, and Ad36 E4orf1 is sufficient and necessary for
PI3K activation in hASC’s(203). Intact Ad36 E4orf1, but not its PBM mutated form, binds to
Dlg1 (unpublished observations). Therefore, we hypothesized that E4orf1 of Ad36 may be
sufficient to activate the Ras-PI3K pathway and to increase glucose uptake.
Based on this background, we planned the following objectives for this study:
1.6 Objectives
1.6.1 Objective 1. To Determine If Ad36 Infection Is Associated with Better Glycemic
Control in Children
1A. Association of Ad36 Infection with Glycemic Control in Prepubertal
Caucasian and African American Children
1B. Association of Ad36 Infection with Glycemic Control in Hispanic Children
•

Rationale and Expected Outcome: Association of Ad36 seropositivity and
improved glycemic control has been established in adults (188; 190), however,
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any relationship between seropositivity and glycemic control in children is
unknown. Adenoviruses are a common childhood infection, and Ad36 is
associated with obesity in children (208; 210). Childhood is a critical time for
adipose tissue deposition, and obesity in childhood is associated with greater
likelihood of developing obesity and metabolic complications later in life (241).
Therefore, childhood represents a unique opportunity to prevent obesity and its
metabolic complications. Identifying factors which may be protective and
determining the mechanism may aid in preventing metabolic abnormalities in this
vulnerable population. Sera of already characterized prepubertal Caucasian and
African American children from the “Mechanisms of the Metabolic Syndrome in
Prepubertal Youth (MET)” study (242), and from adolescent Hispanic children
from the “LA VIVA FAMILIA” study (243) will be screened for neutralizing
antibodies to Ad36. Associations between seropositivity for fasting insulin,
glucose, and HOMA IR, and intrahepaic lipid will be tested, and we hypothesize
that Ad36 antibody prevalence will be associated with improved glycemic
control.
1.6.2 Objective 2. Identify the Characteristics of Adipose Tissue and Liver Associated with
Ad36 Induced Improvements in Glycemic Control
In animal models, Ad36 infection improves glycemic control in chow fed animals and attenuates
high fat diet induced hyperglycemia. In humans, natural Ad36 infection is associated with
improved glycemic control. Changes in adipose tissue and liver morphology and metabolism
induced by Ad36 will be indicative of the mechanism involved in Ad36 induced improvements
in glycemic control and will lay the foundation for future research.
2A. Adipose Tissue
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2A.1 Adipocyte Metabolism
2A.1.1 Spread of Ad36 Infection in Human Adipose Derived Stem Cells
•

Rationale and Expected Outcome: The effect of Ad36 on 3T3-L1
murine preadipocyte differentiation is well characterized, but its effect on
differentiation of human preadipocytes has not been determined. Human
multipotent hASC’s may be a pertinent model for the study of Ad36 on
human preadipocyte differentiation, but successful infection and spread of
Ad36 needs to be verified and characterized. We hypothesize that Ad36
will successfully infect and spread in hASC. Mock infected cells will
serve as a negative control.

2A.1.2 Lipid Accumulation in hASC Following Ad36 Infection with and
without MDI
•

Rationale and Expected Outcome: Many agents that up-regulate
adipocyte differentiation improve insulin sensitivity. Ad36 induces
differentiation and lipid accumulation in 3T3-L1, even without the
induction by differentiation cocktail. If Ad36 increases lipid accumulation
in hASC, that may explain improved glycemic control despite increased
adiposity associated with Ad36 infection and would indicate relevance to
human adipose tissue. Fluorescent BODIPY lipid and DAPI nuclei
staining will be used to quantify lipid per cell on a Flexstation fluorescent
plate reader, which quantifies intensity of fluorescence. Ad36 infection
with and without MDI will be the experimental groups, Mock infected
cells with MDI will serve as a positive control, and Mock infected cells
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without MDI will be a negative control. We hypothesize that Ad36 will
increase lipid accumulation in hASC compared to Mock, with or without
MDI.

2A.1.3 The Effect of Ad-36 Infection on Lipid Accumulation with Respect to
Confluency
•

Rationale and Expected Outcome: Determining optimal conditions for
lipid accumulation following Ad36 infection will both, provide optimal
conditions for future experiments, and also provide insight into the
mechanism of Ad36 induced lipid accumulation. The response of 3T3-L1
to Ad36 is previously well characterized, but the effect of cellular
confluence relative to the time of infection on lipid accumulation is
unknown, and will therefore be determined. 3T3-L1 will therefore be
infected 1 or 2 days prior to confluence and on the day of confluence, and
fixed either 9 days post infection or 9 days post confluence. With this
design, cells will either have equal time after virus infection, or equal time
post confluence for lipid accumulation. After fixation, cells will be
stained with BODIPY for lipid and DAPI nuclei for calculation of lipid
per cell, and quantified using Flexstation fluorescent plate reader. We
expect that Ad36 may interact synergistically with confluence for
induction of lipid accumulation, since the differentiation process begins in
response to confluency in 3T3-L1.
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2A.1.4 De Novo Lipogenesis Time Course Following Ad36 Infection in 3T3L1
•

Rationale and Expected Outcome: Ad36 increases cellular lipid
accumulation in adipocytes. Increased lipid uptake, or greater de novo
lipogenesis from glucose are the two potential sources of this accumulated
lipid. Previous data suggested that Ad36 increases lipid uptake in
adipocytes. Considering the increased glucose uptake promoted by Ad36,
conversion of this glucose to lipids is also a possible mechanism, which
will be determined. [14C]-Glucose incorporation into lipids will be
determined in a time course following infection with Ad36, Ad2, and
Mock. Mock will serve as a negative control, and Ad2 as a control for
viral infection. Because Ad36 increases lipid accumulation, we
hypothesize that it will up-regulate denovo lipogenesis.

2A.1.5 Modulation of Glucose and Palmitate Oxidation in 3T3-L1 by Ad36
•

Rationale and Expected Outcome: Lipid uptake and storage and glucose
uptake is up-regulated by Ad36, however, the fate of these substrates is
otherwise unknown. Understanding glucose and lipid disposal
mechanisms by Ad36 in different tissues may help explain increased
clearance of these substrates by the virus. [14C]- Glucose and [14C]Palmitate oxidation will therefore be determined in Mock, Ad2, and Ad36
infected 3T3-L1. Mock will serve as a negative control, and Ad2 as a
control for viral infection, since it is unknown how viral infection would
affect these parameters. We expect that Ad36 may up-regulate glucose
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and palmitate oxidation, since it increases uptake and clearance of both
substrates, and since viral replication has high energy demands.

2A.2 Effect of Ad36 on Adipose Tissue Morphology
2A.2.1 Change in Adipocyte Cell Size in C57BL/6J Mice on Chow and High
Fat Diet
•

Rationale and Expected Outcome: Considering that small adipocyte size
is correlated with insulin sensitivity, and large adipocyte size is associated
with insulin resistance, the effect of Ad36 infection on adipocyte size will
be determined. Mock, Ad36 and Ad2 infected adipose tissue from
C57BL/6F mice on chow and high fat diet (HFD) will be fixed and
processed for staining, and adipocyte diameter will be measured using
Image J software after image acquisition. Since Ad36 is an adipogenic
agent, we expect that it may increase the population of smaller adipocytes,
which may contribute to increased insulin sensitivity in chow and high-fat
fed mice infected with Ad36.

2A.2.2 Effect of Ad36 on Macrophage Infiltration in C57BL/6J Mice on
Chow and HFD
•

Rationale and Expected Outcome: Macrophage infiltration of adipose
tissue is associated with obesity and insulin resistance.
Immunohistochemistry staining for macrophages in adipose tissue from
Mock, Ad36 and Ad2 infected chow and HFD fed C57BL/6J mice will be
quantified using Image J software following image acquisition.
Adenoviruses are excellent at evading the host immune system, therefore,
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we hypothesize Ad36 may suppress macrophage infiltration in adipose
tissue in chow or HFD C57BL/6J mice, which may contribute to improved
insulin sensitivity in Ad36 infected animals.
2A.2.3 Effect of Ad36 on Adipose Tissue Vascularization and Angiogenesis
•

Rationale and Expected Outcome: Adipose tissue angiogenesis is
associated with better insulin sensitivity and Ras and PI3K signaling is
involved in angiogenesis. Because Ad36 activates Ras and PI3K, we
hypothesized that it may increase adipose tissue vascularization, prevent
hypoxia, and thus improve insulin sensitivity in mice. Adipose tissue
vascularization in Ad36 infected C57BL/6J mice fed chow or HFD will be
determined. To test the direct effect of Ad36 on angiogenesis, and to
determine the potential relevance of this effect in humans, angiogenesis
will be determined in human adipose tissue explants exposed to Ad36.
Lastly, the effect of Ad36 on murine endothelial cell tube formation will
be determined to elucidate a direct effect of the virus on endothelial cells.
For all experiments, Mock, Ad2, and Ad36 infection will be used. We
hypothesize that Ad36 may up-regulate angiogenesis, thereby improving
hypoxia and insulin resistance through increase in adipose tissue
vascularization.

2B. Effect of Ad36 on Hepatic Steatosis
2B.1 Effect of Ad36 on Hepatic Steatosis and Glycogen Stores in C57BL/6J Mice on
HFD
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•

Rationale and Expected Outcome: Hepatic lipid accumulation can contribute to
insulin resistance, and hepatic glycogen stores are often reduced in T2DM.
Glycogen content and lipid accumulation will be determined in the livers of high
fat fed C57Bl/6J mice infected with Ad36, Ad2, or Mock. A liver specimen from
a chow-fed mouse will be used as a positive control for healthy liver. We expect
Ad36 may decrease hepatic lipid and increase glycogen content, which may
explain attenuated dysglycemia in infected mice on HFD.

1.6.3 Objective 3. Determine If the E4orf1 Protein of Ad36 Enhances Glucose Disposal in
Adipose Tissue and Liver, and If It Alters Lipid Metabolism in Liver for Lower Lipid
Stores
Identifying the viral protein employed by Ad36 to improve glucose disposal and hepatic lipid
metabolism could be of therapeutic value. Because E4orf1 is sufficient to induce PI3K
activation, we hypothesized that it may regulate glucose and lipid metabolism in these two key
tissues for glucose homeostasis. We hypothesize it may increase glucose uptake in adipocytes
through the Ras-PI3K pathway used by the virus. We also hypothesize that it may suppress
glucose output from the liver, and alter hepatic lipid metabolism for lower hepatic triglyceride
accumulation. Although the effect of the whole virus on hepatic metabolism has not been
previously characterized, since we are examining the therapeutic potential of E4orf1, we will
determine the direct effect of E4orf1 on hepatic metabolism.
3A. Effect of E4orf1 in Adipocytes
3A.1 Is E4orf1 Necessary for Ad36 Induced Glucose Uptake?
•

Rationale and Expected Outcome: To determine if Ad36 requires E4orf1 for
enhancing cellular glucose uptake, E4orf1 will be knocked down by using a
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targeted siRNA after Ad36 infection in 3T3-L1. We expect that that knockdown
of E4orf1 will abate Ad36 induced glucose uptake.
3A.2 Is E4orf1 Sufficient to Increase Glucose Uptake?
•

Rationale and Expected Outcome: If E4orf1 is responsible for Ad36 induced
glucose uptake, its expression alone should be sufficient to increase glucose
uptake. This will be tested using multiple systems. First, glucose uptake will be
determined following transfection of E4orf1 plasmids in 3T3-L1 preadipocytes
and adipocytes, and will be compared to transfection of Null vector control, in
presence or absence of insulin. We hypothesize that E4orf1 will increase glucose
uptake compared to Null vector in basal and possibly insulin stimulated
conditions. Next, an inducible stable E4orf1 expressing 3T3-L1 cell line will be
created. This will be used to determine a controlled dose response glucose uptake
effect of E4orf1 expression, and we hypothesize that E4of1 expression will induce
a dose-response effect. The E4orf1 cell line without induction and an empty
vector control cell line will be used as a negative control for comparison.

3A.3 The Effect of E4orf1 on De Novo Lipogenesis in 3T3-L1 Preadipocytes
•

Rationale and Expected Outcome: E4orf1 is adipogenic and increases lipid
accumulation, but it is unknown if this is a result of lipid uptake or de novo
lipogenesis. If E4orf1 induces glucose uptake, it may increase incorporation of
glucose into lipid. [14C]-Glucose incorporation into lipid will be determined
following transfection of 3T3-L1 cells with plasmids expressing E4orf1 or Null
vector. We hypothesize that E4orf1 will up-regulate de novo lipogenesis.

3A.4 Cell Signaling Involved in E4orf1 Induced Glucose Uptake in 3T3-L1
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3A.4.1 Total and Isoform-specific Ras Activation by E4orf1
•

Rationale and Expected Outcome: Ad36 requires Ras / PI3k pathway to
increase glucose uptake. Also, Ad36 E4orf1 activates PI3K signaling. Therefore,
E4orf1 may be sufficient to activate Ras, which is upstream of PI3K. In addition,
E4orf1 protein of Ad9, which is highly homologous to that of Ad36, increases
Ras activation. Identifying the specific isoform of Ras activated by E4orf1 would
allow for specific elucidation and modification of the pathway with any future
therapeutic agent. Activation of total Ras and its isoforms will be detected in the
E4orf1 inducible stable 3T3-L1 cell line. We hypothesize that induction of
E4orf1 expression will activate total Ras. Considering that siRNA against H-Ras
abrogated the effect of Ad36 on glucose uptake(190), Ad36 E4orf1 is expected to
specifically activate the H-Ras isoform.

3A.4.2 The Effect of Ad36 and E4orf1 on Cell Transformation
•

Rationale and Expected Outcome: If E4orf1 activates Ras, a potential
oncogene, its ability to oncogenically transform cells needs to be determined,
considering the therapeutic potential of E4orf1. This will be determined in 3T3L1 that constitutively express E4orf1 and in 3T3-L1 infected with Ad36 using a
soft agar anchorage-independent colony formation assay. A549 bronchial
carcinoma cells will be used as a positive control. Because Ad36 has not induced
tumor formation in animal models, and because Ras activation alone is not always
sufficient to induce tumor formation, we hypothesized that Ad36 and E4orf1 will
not transform cells.

3A.4.3 The Effect of E4orf1 on Distal Insulin Signaling, Adiponectin, and Glut1
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•

Rationale and Expected Outcome: Ad36 up-regulates glucose uptake, PI3K
activation, and Glut4, Glut1, and adiponectin expression, all of which may
contribute to improved glycemic control by the virus. This experiment will
determine if E4orf1 mirrors the effects of Ad36 on distal insulin signaling,
adiponectin and Glut1. The E4orf1 inducible stable 3T3-L1 cell line will be used,
and changes in these signaling components will be determined. We hypothesize
that E4orf1 will be sufficient to increase Glut4, Glut1, and adiponectin
abundance, and increase AKT phosphorylation.

3A.4.4 Effect of E4orf1 on Adiponectin and Inflammatory Cytokine mRNA
Expression
•

Rational and Expected Outcome: Adenoviruses are known to acutely suppress
inflammation and host cell immune response, and acute infection of Ad36
suppresses inflammatory cytokines in adipose tissue. This may be due to early
adenoviral gene expression, which may be highly expressed immediately after
infection. If E4orf1 is sufficient to suppress inflammatory chemokines and
cytokines, that would add to its therapeutic potential in fighting insulin resistance,
which is fueled by inflammation. The E4orf1 inducible expressing E4orf1 3T3L1 cell line will be used to determine changes in inflammatory cytokines by using
quantitative real-time PCR. In addition, adiponectin is known to be antiinflammatory, so its modulation by E4orf1 will be verified at the mRNA level.
Overall, we hypothesize that E4orf1 will down-regulate inflammatory cytokines
and up-regulate adiponectin mRNA expression.

3A.5 Can E4orf1 Induce Glucose Uptake Independent of PPARγ?
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•

Rationale and Expected Outcome: Although E4orf1 is a potent stimulator of
adipogenesis and PPARγ, it is unknown if E4orf1 requires PPARγ for glucose
uptake. PPARγ agonists for the treatment of T2DM cause excess weight gain
and may be associated with increased risk of cardiovascular events, therefore,
alternative agents that improve glycemic control without upregulating PPARγ are
currently under investigation. If E4orf1 is sufficient to increase glucose uptake
independent of PPARγ, it would be a novel agent for determining how these two
effects may be uncoupled. PPARγ knock out (KO) mouse embryonic fibroblasts
will be transfected with E4orf1 or Null plasmid to determine if E4orf1 increases
glucose uptake independent of PPARγ. Recent (unpublished) data from our
laboratory indicated that Ad36 can increase glucose uptake in PPARγ independent
manner. Therefore, it is likely that Ad36 E4orf1 may increase glucose uptake
independent of PPARγ.

3B. The Effect of E4orf1 on Hepatic Glucose and Lipid Metabolism
3B.1 The Effect of E4orf1 on Glucose Output in Hepatocytes
•

Rationale and Expected Outcome: Uncontrolled hepatic glucose output often
contributes to hyperglycemia in T2DM, which could be regulated by PI3K
activation. E4orf1 is sufficient to activate PI3K, and therefore may be able to
suppress hepatic gluconeogenesis and glucose output. HepG2 human hepatocytes
as well as murine primary hepatocytes will be transfected with Ad36 E4orf1, Ad2
E4orf1, or Null plasmid and glucose output will be measured in gluconeogenic
conditions. Ad2 is not adipogenic, and does not significantly improve glycemic
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control in vivo, and therefore will be used as a control for the presence of an
adenoviral gene to ensure any effect on hepatic metabolism is specific to Ad36
E4orf1.
3B.2 The Effect of E4orf1 on Hepatic Lipid Accumulation
Ad36 protects mice from HFD induced hepatic steatosis. This may be an important
contributor to better glycemic control observed in this model. Three key
determinants of hepatic lipid stores include a) de novo lipogenesis, b) lipid oxidation,
and c) lipid export. The following experiments will determine if E4orf1 modulates
any of these pathways.
3B.2.1 The Effect of E4orf1 on Hepatic Fatty Acid Oxidation
•

Rationale and Expected Outcome: Ad36 reduces hepatic lipid accumulation in
response to high fat diet(190), but the mechanism is unknown. Gene expression
data indicated that it may be through increased fatty acid oxidation and fat export.
Ad36 viral DNA and RNA expression was detected in the liver, indicating it may
be a direct effect of infection on hepatocytes. Ad36 may also increase fatty acid
oxidation indirectly, through an up-regulation of adiponectin in adipose
tissue(190). To determine if Ad36 may have a direct effect on hepatic fatty acid
oxidation through E4orf1, HepG2 [14C]-Palmitate total, complete (CO2), and
partial oxidation will be determined in response to Ad36 E4orf1, Ad2 E4orf1, or
Null vector transfection. We hypothesize that Ad36 E4orf1 up-regulates fatty
acid oxidation directly in hepatocytes, and that E4orf1 may contribute to a local
effect of Ad36 infection on suppression of hepatic lipid accumulation.

3B.2.2 The Effect of E4orf1 on Hepatic De Novo Lipogenesis
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•

Rationale and Expected Outcome: Genes of de novo lipogenesis (Sterol
regulatory element binding protein-1c (SREBP-1c) and Forkhead Transcription
factor FOXO1) were nearly significantly down regulated in Ad36 infected
livers(190). Therefore, Ad36 may also reduce hepatic lipid accumulation through
local suppression of hepatic de novo lipogenesis. The effect of E4orf1 on de novo
lipogenesis will be tested in HepG2 cells following transfection with Ad36
E4orf1, Ad2 E4orf1, or the Null vector. We hypothesize that E4orf1 may
suppress de novo lipogenesis, which may contribute to lower hepatic lipid
accumulation.

3B.2.3 The Effect of E4orf1 on Hepatic ApoB Secretion
•

Rationale and Expected Outcome: Ad36 may also increase lipid export, as
indicated by hepatic gene expression (higher levels of microsomal triglyceride
transfer protein and ApoB expression), thereby decreasing hepatic lipid stores.
Excretion of ApoB-containing very low density lipoprotein will be measured in
conditioned media from HepG2 cells transfected with Ad36 E4orf1, Ad2 E4orf1
or the Null vector. We hypothesize that E4orf1 may be sufficient to increase lipid
export in hepatocytes, thereby decreasing hepatic lipid accumulation.
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Chapter 2. Methods
2.1 Research Design
2.1.1 Objective 1. To Determine If Ad36 Infection Is Associated with Better Glycemic
Control in Children
1A. Association of Ad36 Infection with Glycemic Control in Prepubertal Caucasian
and African American Children
Sera given from the “Mechanisms of the Metabolic Syndrome in Prepubertal Youth”
(MET) study of 45 children were screened for the presence of neutralizing antibodies to
Ad36 via serum neutralization, as previously described(195). Means for fasting glucose,
insulin, HOMA-IR, and intra-hepatic lipid were compared with respect to Ad36
seropositivity as described in the statistics section. These parameters had been previously
measured by Dr. Melinda Sothern and her colleagues. A preliminary study, “Study of
Insulin Sensitivity in Louisiana Low, high or normal weight Youth (SILLY)”(242; 244),
developed the protocols for the MET study. The final protocols were approved by the
Institutional Review Board, and are described in detail elsewhere(190). Briefly, DXA
(Hologic QDR 4500A Bedford,MA) was used to measure body composition. Fasting
glucose and insulin was assayed after a 12 hr fast, with Ortho Clinical Diagnostics
VITROS® 5,1 FS (Rochester, NY) and EIA kit from ALPCO (Salem, NH), respectively.
Intrahepatic lipid was determined by proton magnetic resonance spectroscopy (1H-MRS)
to non-invasively evaluate lipid stores.
1B. Association of Ad36 Infection with Glycemic Control in Hispanic Children
Baseline Sera from “LA VIVA FAMILIA” study of obese and nonobese Hispanic
children in Texas were screened for the presence of neutralizing antibodies to Ad36 as
described previously (243). Means for fasting glucose, insulin, and HOMA-IR were
compared with respect to Ad36 seropositivity as described in the statistics section. These
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parameters were measured by Dr. Nancy Butte and colleagues. This study was
previously approved by the Institutional Review Board of Baylor College of Medicine.
Fasting insulin levels were measured via radioimmunoassay kit (Linco Research Inc, St
Charles, MO), and fasting glucose with a glucose oxidase assay after an overnight fast.
Body composition was measured via DXA with the Hologic Delphi-A whole-body
scanner (Hologic Inc, Waltham, MA).
Statistics
For the MET study samples, fasting insulin, HOMA IR, and intrahepatic lipid data were
skewed and was therefore transformed (logarithmic). SAS 9.1 software was used to
implement a general linear models approach to compare means of fasting glucose,
transformed fasting insulin, HOMA IR, and intra-hepatic lipid between antibody positive
and antibody negative subjects. Age, race, body fat and sex were included as covariates
in the model. The least squares adjusted means were back-transformed to the original
scale after analysis for skewed variables. Two-sided 95% confidence limits were
calculated, and also back-transformed for the least squares means that were asymmetric
about the estimated means. Significance was considered at p<0.05 for one directional
alternative hypothesis.
For the LA VIVA FAMILIA study, two statistical methods were implemented to detect
differences in fasting glucose, insulin, and HOMA-IR between antibody positive and
antibody negative subjects. First a general linear models approach was used in SAS 9.1.
Fasting insulin and HOMA-IR were first transformed logarithmically due to skewed
distributions. Age, body fat, family and sex were included in the model initially. The
least squares adjusted means were back-transformed to the original scale after analysis
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for skewed variables. Two-sided 95% confidence limits were calculated, and also backtransformed for the least squares means that were asymmetric about the estimated means.
Significance was considered at p<0.05 for one directional alternative hypothesis.
Next, logistic regression was performed using SAS 9.1. The odds ratio for parameters
being below the median for Ad36 seropositive individuals relative to the odds for
seronegativity were compared. Sex, adiposity, and family were included in the model,
and significance was considered if p< 0.05 for one directional alternative hypothesis.
2.1.2 Objective 2. Identify the Characteristics of Adipose Tissue and Liver Associated with
Ad36 Induced Improvements in Glycemic Control
2A. Adipose Tissue
2A.1 Adipocyte Metabolism
2A.1.1 Spread of Ad36 Infection in Human Adipose Derived Stem
Cells
Human adipose derived stem cells were plated in 96 well glass bottom
plates and infected with Ad36 at 3.8 plaque forming units per cell
(PFU/cell) or mock infected as described in techniques and assays. Day 3,
5, 7, 9, and 13 post infection, cells were fixed and stained for DAPI for
visualization of nuclei, and with anti-adenoviral hexon antibody as a
marker of Ad36 infection as described in techniques and assays. As
expected Ad36 infected cells stained positively for Ad36 hexon, whereas
Mock infected cells did not. For each well, a representative 20X picture
was taken on a Zeiss Axiovert 40 CFL microscope. The percent of Ad36
infected cells was quantified by counting cells expressing Ad36 hexon
protein and dividing by the total number of nuclei (DAPI staining) in the
given picture. Three wells per group were counted in this manner.
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2A.1.2 Lipid Accumulation in hASC Following Ad36 Infection with
and without MDI
Human adipose derived stem cells (hASC’s) were plated on 96-well glass
bottom plates and Mock or Ad-36 infected at 70% confluence, and 3.8
PFU/cell. Day 3, 5, 7, or 9 post infection, cells were fixed and stained
with BODIPY (lipid specific stain) and DAPI for nuclei, as described in
techniques and assays. 10X and 20X images were taken on a Zeiss
Axiovert 40 CFL microscope. Four biological replicates per group were
quantitated. The 96-well plate was read on Molecular Devices
FlexStation, and BODIPY staining was quantitated at 485/538 nm, and
DAPI at 405/477 nm. Several unstained wells were quantitated for
subtraction of background fluorescence. Data were then expressed as the
mean BODIPY:DAPI ratio, as a reflection of lipid per cell.
2A.1.3 The Effect of Ad-36 Infection on Lipid Accumulation with
Respect to Confluency
3T3-L1 cells were plated at sub confluence on glass bottom 96-well plates,
and infected with Ad36 (1 PFU/cell) at confluence, or 1 or 2 days prior to
confluence. One set of plates was fixed 9 days post confluence, and
another set was fixed 9 days post infection. This allowed for cells to
accumulate lipid with a constant number of days post infection or post
confluence. After fixation, cells were stained with BODIPY and DAPI as
described in techniques and assays, and data were expressed as ratio of
BODIPY:DAPI for lipid per cell. Thirty biological replicates per group
were used.
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2A.1.4 De Novo Lipogenesis Time Course Following Ad36 Infection in
3T3-L1
Seventy percent confluent 3T3-L1 were plated in 24 well plates and Ad36
(3.8 PFU/cell) or Mock infected. An assay to determine DNL was
conducted as described in techniques and assays Day 1, 3, and 6 post
infection. Six biological replicates per group were used. Lipogenesis was
normalized to optical density of a bicinchoninic acid assay (BCA) (Sigma
Aldrich # B9643, #C2284) assay to control for protein content of each
well. .
2A.1.5 Modulation of Glucose and Palmitate Oxidation in 3T3-L1 by Ad36
Seventy percent confluent 3T3-L1 plated in 24 well plates were Mock or Ad36
infected (3.8 PFU/CELL). Day 1, 3, 6, or 8 post infection, glucose oxidation and
palmitate oxidation assay were conducted as described in techniques and assays.
Six biological replicates per group were used for each time point, and oxidation
was normalized to protein content for each well.
2A.2 Effect of Ad36 on Adipose Tissue Morphology
For adipose tissue morphology studies, two separate models were used (190).
The first was chow fed C57BL/6J mice, infected with Mock, Ad36 or Ad2 and
sacrificed 12 weeks post infection. Retroperitoneal fat pads were harvested for
analysis. The second model was C57BL/6J mice on a HFD, then infected with
Mock, Ad36 or Ad2, and sacrificed 20 weeks post infection. Epididymal fat pads
were harvested for analysis from this model. The chow fed model was infected at
4 weeks of age, whereas the HFD mice were started on the high fat diet at 6
weeks of age and infected 8 weeks later. Adenoviral DNA and RNA was
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detected in adipose tissue of mice from both models, indicating the infection was
present in these tissues. Details of these animal models are described previously
(190).
2A.2.1 Change in Adipocyte Cell size in C57BL/6J Mice on Chow and High
Fat Diet
Retroperitoneal adipose tissue from chow fed C57BL/6J mice was obtained 12
weeks post infection and fixed in 4% paraformaldehyde immediately after
harvesting and stored at 4ºC. Epididymal adipose tissue was obtained from mice
on HFD and also fixed in 4% paraformaldehyde immediately after harvesting and
stored at 4ºC. Fixed adipose tissue from both chow and HFD mice were paraffin
embedded and sliced to 8 µM thickness on slides. For the HFD model, 6 mice
from Mock, 5 from Ad36, and 4 from Ad2 group were processed. One slide per
mouse with two specimens per slide were made and deparaffinized. Slides were
then stained for macrophages as described in techniques and assays, and cells
could be easily visualized after this staining. Four pictures per specimen were
taken with Zeiss Axioskop 40 and analyzed for cell size (8 pictures per mouse).
For the chow model, 6 mice from Mock, 3 from Ad36 and 3 from Ad2 were
processed. Three specimens per mouse were placed on one slide, and three
pictures per specimen were taken so 9 pictures per mouse). Slides were then
fixed and stained for CD31 as described in techniques and assays, and adipocytes
could be easily visualized after this staining. Pictures were taken with the Zeiss
Axioskop 40. For the analysis, Image J (National Institutes of Health
http://rsb.info.nih.gov/ij/download.html) software was used. The pictures were
divided into four quadrants, and four cells per quadrant were measured for
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adipocyte diameter, quantified by the program in pixels after manually drawing a
line across the adipocyte. Adipocyte diameter means and tertiles were then
compared as described in the statistics section.
2A.2.2 Effect of Ad36 on Macrophage Infiltration in C57BL/6J Mice on
Chow and HFD
Slides were created for both chow and HFD mice as described in research design
for A.2.1 (same groups, number of animals per group, and number of specimens
per slide) and stained for macrophages using Mac-2 antibodies (Lifespan
BioSciences, INC # LS-C62936) as described in techniques and assays. After
staining, pictures were taken on Zeiss Axioskop 40. Macrophage staining was
quantified by using Image J threshold analysis, where the threshold was set so that
only positive staining could be seen, and quantified as pixels2 by the software for
each picture. For the HFD animals, larger adipose tissue sections were available,
therefore 5X pictures were taken. For chow fed animals, smaller sections were
available, so 10X pictures were taken for quantification of macrophage staining.
Data were analyzed as described in the statistics section.
2A.2.3 Effect of Ad36 on Adipose Tissue Vascularization and Angiogenesis
First CD-31 staining was conducted in the chow and HFD C57BL/6J mice as
described in techniques and assays. Slides were processed as described in the
research design for A.2.1 (same groups, number of animals per group, and
number of specimens per slide). Pictures were taken after staining on Zeiss
Axioskop 40. CD-31 staining was quantified by using Image J threshold analysis,
where the threshold was set so that only positive staining could be seen, and
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quantified as pixels2 by the software for each picture. Data were analyzed as
described in the statistics section.
Next, an angiogenesis assay was conducted with human adipose tissue explants
from three donors as described in techniques and assays and as previously
described(245). Tissue was infected with Mock, Ad36, or Ad-2 (2 million viral
particles per well), and galic acid treatment was used as a negative control. 30
replicates per group were used, and angiogenesis was scored every 2-4 days post
infection for 15 days. Data were expressed as mean angiogenic index score for
each group and each time point. The assay was repeated three times with tissue
from three donors.
And lastly, a tube formation assay was conducted with SVEC4-10 murine
endothelial cells as described in techniques and assays. Cells were infected with
Mock, Ad36, or Ad2 (3.8 PFU/cell). The acute effect of infection was observed 5
hours post infection, and a 24 and 75 hr time point was also observed to test for a
more long-term effect. For each time point, pictures were taken on Zeiss
Axioskop 40, and three biological replicates per group were used.
2B. Effect of Ad36 on Hepatic Steatosis
2B.1 Effect of Ad36 on liver steatosis and glycogen stores in C57BL/6J mice
on HFD
Livers from C57BL/6J mice on HFD were harvested 20 weeks post infection as
described elsewhere (190) and immediately flash frozen in liquid nitrogen, and
stored at -80ºC until processing. Adenoviral DNA and RNA was detected in
these livers, which indicates successful infection of these tissues in vivo. Samples
were thawed and soaked in 30% sucrose for 1 week at 4ºC. Samples were then
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embedded in O.C.T. Compound freezing medium (TissueTek # 62550) cryomolds
and cryosectioned at 8 µM thickness on positively charged slides. Slides were
stained for glycogen as described in techniques and assays. Image J threshold
analysis was used to quantitate lipid, and total picture area minus glycogen
staining was considered an approximation of lipid, since lipid leaves the sample
during the glycogen staining process, as described elsewhere(246).
Statistics
All cell based metabolism and lipid accumulation assays were completed with a
minimum of three replicates, and a student’s t-test was used to compare means.
The comparison of interest was Ad36 compared to Mock, to determine if Ad36
changed parameters compared to the Mock condition. We expected Ad2 to not be
significantly different from Mock, and a comparison between Ad36 and Ad2 was
not of interest. One tailed tests were used for lipid accumulation and DNL
experiments with hASC and 3T3-L1, since we hypothesized that Ad36 would
increase lipid accumulation based on previous findings (247). For glucose and
palmitate oxidation studies, a two tailed t-test was performed since no specific
direction was expected for either parameter following Ad36 infection. All assays
were adjusted to cell number either by DAPI staining or by estimating protein
content of individual wells.
For immunohistochemistry studies of adipose tissue or liver from HFD or chow
fed mice, at least three mice per group were analyzed, with 8-9 pictures taken per
mouse for analysis. Student’s t-test was first used to compare between groups.
For adipocyte size analysis, tertiles were also calculated based on the range of cell
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sizes of all groups pooled together. For each group, the percentage of cells falling
in the upper and lower tertile was then calculated. A paired t-test was used to
determine if within a group, more cells fell within the lower or upper tertile. A
one-sided t-test was conducted for macrophage staining, with the hypothesis that
infection would increase macrophage infiltration. CD-31 t-test was two sided,
with no specific hypothesis. Liver glycogen and lipid content t-tests were also
two sided.

2.1.3 Objective 3: Determine if the E4orf1 Protein of Ad36 Enhances Glucose Disposal in
Adipose Tissue and Liver, and if it Alters Lipid Metabolism in Liver for Lower Lipid
Stores
3A. Effect of E4orf1 in Adipocytes
3A.1 Is E4orf1 Necessary for Ad36 Induced Glucose Uptake?
3T3-L1 preadipocytes were plated in 12-well plates at 60% confluence and
transfected with either E4orf1 siRNA (Ambion #AM16100) or non-targeting(NT)
siRNA(Thermo Scientific, #D-001810-02-05) as described in techniques and assays,,
then immediately after transfection the cells were infected with Ad36 (5 PFU per cell)
or mock infected. The resulting groups were tested: Mock with E4orf1 siRNA, Ad36
with NT siRNA, and Ad36 with E4orf1 siRNA. Mock-infected cells with E4orf1
siRNA served as a baseline control, and Ad36 infected cells with either NT siRNA, or
E4orf1

siRNA

were

the

two

experimental

groups.

Two

days

post

transfection/infection, basal 2-Deoxy-D-glucose (2DG) uptake was determined as
described in techniques and assays. Eight biological replicates were assayed per
group. Glucose uptake was normalized to protein content, which was measured via
BCA assay. This experiment was repeated three times and data are presented as fold
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change relative to Mock with E4orf1 siRNA. RNA was harvested in parallel, and
knockdown was verified by detection of E4orf1 mRNA levels using quantitative real
time PCR as described in techniques and assays.
3A.2 Is E4orf1 Sufficient to Increase Glucose Uptake?
3T3-L1 preadipocytes and adipocytes were transfected with V5 tagged E4orf1
expressing pcDNA or Null pcDNA plasmids as described in techniques and assays.
Two days post transfection, 2DG uptake assay was conducted under basal and insulin
stimulated (100 nM) conditions as described in techniques and assays. Eight
biological replicates per group were assayed, and glucose uptake was normalized to
protein content. Glucose uptake assay was repeated twice for adipocytes, and once
for preadipocytes in this system.
Next, to determine the dose response effect of E4orf1 on glucose uptake, Ad36
E4orf1 (E4pTRE) and empty vector (pTRE) control inducible stable 3T3-L1 cell lines
were created using the TetON Advanced system (Clonetech# #630930) as described
in techniques and assays. 24 hours post induction with 0, 750, or 1,000
ng/mLDoxycycline (Clonetech #631311) for different expression levels of E4orf1, a
2DG glucose uptake assay was conducted as described in techniques and assays.
Eight replicates per group were used. pTRE was treated with 100 nM insulin as a
positive control for the assay, and this cell line was also treated with 1,000
ng/mLDoxycycline (n=2) to ensure the induction media did not affect glucose uptake.

3A.3 The Effect of E4orf1 on DNL in 3T3-L1 Preadipocytes
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Sixty percent confluent 3T3-L1 were plated in 12-well plates and with V5-E4orf1 and
Null plasmids as described in techniques and assays. Two days post transfection, a
DNL assay was conducted with and without 100 nM insulin as described in
techniques and assays. Conversion of [14C]-Glucose to fatty acid was determined
and normalized to protein content. Eight biological replicates per group were used.
3A.4 Cell Signaling Involved in E4orf1 Induced Glucose Uptake in 3T3-L1
3A.4.1 Total and Isoform-specific Ras Activation by E4orf1
For determination of isoform-specific activation of Ras, the E4pTRE and pTRE
cell lines were exposed to 1,000 ng/mLDoxycycline for 24 hours, and the
activation was detected via a pull down assay for the Ras binding domain (RBD)
of Raf as described in techniques and assays. Before pull down, 6% of the whole
cell lysate was collected and loaded to SDS-PAGE to determine total Ras
abundance. Activation was detected by Western Blot (WB) with isoform specific
antibodies against H-Ras, N-Ras, K-Ras or total Ras (all isoforms) as described in
techniques and assays. Using NIH Image J, total Ras abundance was normalized
to β-actin expression, and the ratio of activated to normalized total Ras is
expressed in the figures. The same densitometry approach was also used for
isoform specific WB.
3A.4.2 The Effect of Ad36 and E4orf1 on Cell Transformation
3T3-L1, A549 and 3T3-L1 E4orf1 constitutively expressing cell line were plated
in 60 mm dishes for the soft agar assay as described in techniques and assays.
Constitutive cells were created as described elsewhere (203). Cells were fixed at
day 7, 14, and 21 for determination of colony formation. Four 10X images, one
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per plate quadrant, were counted for viable cells and colonies. The percent of
viable cells that formed colonies was calculated.
3A.4.3 The Effect of E4orf1 on Distal Insulin Signaling, Adiponectin, and
Glut1
The E4pTRE and pTRE cell lines were treated with 1,000 ng/mLDoxycycline and
harvested 24 hours later for WB. Total and phosphorylated AKT (as an indicator
of PI3K activation), and Glut4, Glut1, and adiponectin abundance were
determined by WB as described in techniques and assays.

Proteins were

normalized to β-actin expression, and Image J was used for densitometry
calculations. Activated AKT was calculated as the ratio of p-AKT (ser308) to
total AKT. Three biological replicates per group were used for WB.
3A.4.4 The Effect of E4orf1 on Adiponectin and Inflammatory Cytokine
mRNA Expression
The E4pTRE and pTRE cell lines were exposed to 1,000 ng/mLDoxycycline and
harvested 24 hours later for RNA. The expression of adiponectin, Monocyte
chemotactic protein-1, (MCP-1), Macrophage colony stimulating factor (MCSF),
Tumor necrosis factor alpha (TNF-α), Interferon-gamma (INF-γ), Interleukin-10
(IL-10), and Toll-like receptor-4 (TLR-4) was measured via quantitative real-time
PCR as described in techniques and assays. Eight biological replicates per group
were used.
3A.5 Can E4orf1 Induce Glucose Uptake Independent of PPARγ?
PPARγ knock-out Mouse embryonic fibroblasts (MEF) were obtained from Bruce
Spiegelman (248) and plated for 80% confluence and transfected with V5-E4orf1 or
Null plasmids using Lipofectamine 2000 (Invitrogen # 11668-019) as described in
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techniques and assays. Twenty four hours post transfection, a 2DG uptake assay was
conducted as described in techniques and assays. Eight replicates per group were
used.
3B. The Effect of E4orf1 on Hepatic Glucose and Lipid Metabolism
3B.1 The Effect of E4orf1 on Glucose Output in Hepatocytes
HepG2 cells were transfected with V5-Ad36 E4orf1, V5-Ad2 E4orf1 or Null
plasmids via electroporation as described in techniques and assays. Two days post
transfection, cells were serum starved for 4 hours, washed with phosphate buffered
saline (PBS) and treated with serum free, glucose free media (Invitrogen, #11966)
with or without 10 nM insulin for 3 hours. Glucose content in the media was
determined using a glucose oxidase assay as described in techniques and assays, and
BCA assay was conducted for each well to normalize glucose output to mg protein
per well. This experiment was repeated twice, with six biological replicates per
group, so data of both experiments are represented as fold change relative to Null.
Next, HepG2 were again transfected with V5-Ad36 E4orf1 or Null plasmids, and
treated for glucose output 2 days post transfection. Cells were serum starved for 4
hours, then washed with PBS and treated with cAMP (1 mM) and Dexamethasone
(500 nM) as gluconeogenic stimulators, with or without 10 nM insulin for 3 hours.
At that point a glucose oxidase assay was used to determine glucose content in the
media, and glucose output was again normalized to protein content. Eight biological
replicates were tested per group.
Lastly, primary hepatocytes from C57BL/6J, 129Sv, and FVB mixed
background(249) were transfected with V5-Ad36 E4orf1, V5-Ad2 E4orf1, or Null
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plasmids as described in techniques and assays, and a glucose output assay was
conducted 2 days post transfection. In this experiment, the serum free, glucose free
condition with and without 100 nM insulin was tested. A preliminary experiment
with 8 replicates was conducted to standardize transfection and assay conditions,
followed by another experiment where 24 replicates per group were tested.
3B.2 The Effect of E4orf1 on Hepatic Lipid Accumulation
3B.2.1 The Effect of E4orf1 on Hepatic Fatty Acid Oxidation
A series of two experiments was used to determine the effect of E4orf1 on fatty
acid oxidation. First, HepG2 cells were transfected with V5-Ad36 E4orf1, V5Ad2 E4orf1, or Null plasmids with PolyJet (SignaGen #SL100688) as described
in techniques and assays. Two days post transfection, a palmitate oxidation assay
was conducted as described in techniques and assays. Eight biological replicates
per group were tested, and total and complete palmitate oxidation was normalized
to protein content.
Next, HepG2 cells were transfected with V5-Ad36 E4orf1, V5-Ad2 E4orf1, or
Null plasmids and another palmitate oxidation assay was conducted to verify the
changes in the ratio of complete to partial fatty acid oxidation via E4orf1
observed in the first experiment. The assay was conducted 2 days post
transfection, and again included eight biological replicates. The ratio of partial to
complete oxidation, and the percent partial oxidation was calculated as fold
change relative to Null of data from the first and second experiments.
3B.2.2 The Effect of E4orf1 on Hepatic DNL
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HepG2 cells were transfected with V5-Ad36 E4orf1, V5-Ad2 E4orf1, and Null
plasmids with PolyJet as described in techniques and assays. Two days post
transfection, a DNL assay was conducted as described in techniques and assays.
This experiment was replicated twice, each time with eight biological replicates
per group, and results are expressed as fold change relative to Null.
3B.2.3 The Effect of E4orf1 on Hepatic ApoB Secretion
HepG2 cells were transfected with V5-Ad36 E4orf1, V5-Ad2 E4orf1, or Null
plasmids with PolyJet as described in techniques and assays. Twenty four hours
post transfection, cells were switched to Dulbecco’s minimum essential media
(DMEM) without phenol red (Invitrogen # 31053-036) plus 1.5% Bovine Serum
Albumin (BSA) for the next 24 hours. The media samples were then collected
and stored at -20ºC. ApoB secretion was determined via ELISA (Alerchek #
A70102) according to manufacturer’s instructions, and 1:50 dilution of media was
used instead of the suggested 1:1000 dilution based on results from a preliminary
experiment where several dilutions were tested. Protein was measured via BCA,
and ApoB secretion was normalized to protein content. Eight biological
replicates per group were tested.
Statistics
All metabolic assays were conducted with at least 8 biological replicates, and
student’s t-test was used to determine significant differences with Bonferroni
correction when more than one comparison was tested. E4orf1 siRNA
experiment was repeated three times, adipocyte glucose uptake following
transfection was repeated twice, HepG2 glucose output, fat oxidation, and denovo
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lipogenesis assays were repeated twice. All metabolic assays were normalized to
protein content. For the ApoB ELISA, two technical replicates were used for
each sample.
For WB, three biological replicates were tested for each group. Student’s t-test
was used to determine significant differences between groups. All proteins were
normalized to housekeeping protein. For Ras activation, assays were loaded to
SDS-PAGE by volume, so total Ras was normalized to protein, and activation
was expressed as the ratio of activated to total normalized expression. AKT is
expressed as the ratio of phosphorylated to total AKT.
Quantitative real-time PCR experiments were determined for eight biological
replicates per group. Student’s t-test was used to test for significant differences
between groups. Each gene was normalized to a housekeeping gene, and each
sample was tested with two technical replicates.
2.2 Techniques and Assays
2.2.1 Cell Culture
3T3-L1 cells were obtained from American Type Culture Collection (ATCC #CCL92-1, Manassas, VA) and maintained in high glucose Dulbecco’s Modified Eagle
Medium (DMEM) (Invitrogen, #11995), 10% normal calf serum (#SH30072.03,
Hyclone) and an antibiotic-antimyotic agent

(1%) (Sigma Aldrich #A5955).

E4pTRE and pTRE clones were maintained in Tet-free fetal bovine serum
(Clonetech, #631101) with 0.25 μg/mL puromycin and 0.05 μg/mL hygromycin
(Invitrogen, #10687-010).
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For adipogenic differentiation, two days post confluence, 3T3-L1 preadipocytes
plated in 10cm dishes were induced to differentiate by adding DMEM containing
10% FBS (#SH30071.03, Lot: ASL30786, Hyclone), 20 ng/mL insulin, 115 ng/mL
isobutylmethylxanthine, and 0.39 ng/mL dexamethasone. Forty-eight hours after the
induction, cells were switched to maintenance media of DMEM containing 10% FBS,
and 5 ng/mL insulin.
HepG2 cells were obtained from Dr. Jianping Ye at the Pennington Biomedical
Research Center, LA. They were maintained in high glucose DMEM, 10% fetal calf
serum, and an antibiotic-antimyotic agent (1%).
Primary mouse hepatocytes were obtained from Dr. Charlie Dong, Harvard
University, Boston, MA. They were maintained in William’s Medium E (Invitrogen
# 12551-032) supplemented with 2 mM glutamate, 10% FBS, and primocin
(Invivogen # ant-pm-1).
2.2.2 Viral Infection
Ad36 was obtained from American Type Culture Collection (ATCC # VR-913) and
propagated in A549 cells after plaque purifying three times as described (192; 193).
Ad2 was also obtained from American Type Culture Collection (ATCC#). Viral titers
were determined by plaque assay and cell inoculations were expressed as plaque
forming units (PFU) per cell (192; 193). Cells were generally infected at 70%
confluence unless stated otherwise. The necessary amount of stock virus for a given
viral dose (PFU/cell) was added to serum free DMEM, and the viral media incubated
for 1 hr with cells.

Cells were replenished with fresh media after the one hr

incubation.
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2.2.3 Ad36 Hexon and DAPI Staining of hASC
Cells were washed with PBS and then fixed for 20 minutes with 4%
paraformaldehyde. After fixation, cells were permeabilized in 0.1% Triton PBS for
10 minutes, , blocked in 10% goat serum in 1% BSA for one hr , and then incubated
with a rabbit antibody for Ad36 hexon protein overnight at 4º C. After washing in
PBS 3X for 10 minutes, they were then incubated with a secondary Alexaflour goat
antirabbit IgG (red) (Invitrogen # A-21245) for 1 hour. Cells were then washed 3X
with PBS for 10 minutes each. DAPI (Invitrogen # D3571) was diluted 1:1000 in
PBS and incubated with cells for 20 minutes at room temperature. Cells were washed
1X in PBS after DAPI staining, and images were captured.
2.2.4 BODIPY Staining of hASC
Cells were washed with PBS and then fixed with 4% paraformaldehyde (USB
Corporation, #19943) for 20 minutes. BODIPY 493/503 (Invitrogen #D3922) was
diluted to 10 ug/mL in PBS and incubated with cells after fixation for 20 minutes.
Cells were then washed 1X with PBS for 10 min, and incubated with DAPI diluted
1:1000 in PBS for 10 min. Cells were then washed 2X in PBS before images were
captured.
2.2.5 Glucose Oxidation Assay
Cells were serum starved for 1 hr in glucose free DMEM (Invitrogen #, 11966025)
then incubated with 500 µL high glucose DMEM (Invitrogen # 11995081) with 1
µCi/mL [14C]-Glucose (PerkinElmer #NEC042A001MC) for 3 hours. During the
incubation, plates were wrapped in parafilm to minimize CO2 loss. After incubation,
400 µL of media was transferred to a well of a CO2 trapper (custom made as
described (250)), adjacent to 200 µL of 1 M NaOH. When all samples were loaded,
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the trapper was sealed, and 40 µL of 70% perchloric acid (Sigma Aldrich # 311421)
was injected into the media. After rotating the CO2 trapper for 1 hour, 200 μL of
NaOH containing [14C]-CO2 was removed and placed in a scintillation vial with 5
mL scintillation fluid. The samples were read after 15 minutes on a Beckman
scintillation counter (LS 6500). After media was harvested, cells were solubilized in
0.05% sodium dodecyl sulfate (SDS) and protein content was measured via BCA.
All BCA assays were read at 595 nM on a Biorad Benchmark Plus microplate
spectrophotometer. For calculations, a blank vial for background subtraction and the
original media with isotope was read, and the total activity was used to calculate nmol
glucose oxidized in 3 hr per mg of protein.
2.2.6 Palmitate Oxidation Assay
Cells were incubated with 500 µL high glucose DMEM (Invitrogen # 11995081) with
1 µCi/mL [14C]-Palmitate (PerkinElmer # NET043001MC), 100 µM palmitate
(Sigma Aldrich, #P9767-10G), 0.25% Bovine serum albumin (Sigma Aldrich #
A7030), 1 mM carnitine (Sigma Aldrich #C0158), 12.5 mM HEPES buffer for 3
hours. During the incubation, plates were wrapped in parafilm to minimize CO2 loss.
After incubation, 400 µL of media was transferred to a well of a CO2 trapper, adjacent
to 200 µL of 1 M NaOH. When all samples were loaded, the trapper was sealed, and
40 µL of 70% perchloric acid (Sigma Aldrich # 311421) was injected into the media.
After rotating the CO2 trapper for 1 hour, 200 µL of NaOH containing [14C]-CO2 was
removed and placed in a scintillation vial with 5 mL scintillation fluid. After media
was harvested, cells were solubilized in 0.05% sodium dodecyl sulfate SDS and
protein content was measured via BCA. The acidic media was collected in eppendorf
tubes and stored at 4ºC over night, and spun down at 15,000 g for 10 min at 4ºC
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(Eppendorf centrifuge 5417R). Two hundred µL of the supernatant was collected and
placed in a scintillation vial detection of acid-soluble metabolites. The samples were
read after 15 minutes on a Beckman scintillation counter. For calculations, a blank
vial for background subtraction and the original media with isotope was read, and the
total activity was used to calculate nmol palmitate oxidized in 3 hr per mg of protein.
2.2.7 De Novo Lipogenesis
Cells were treated with the same [14C]-palmitate media used in for the palmitate
oxidation assay (as described in “E”) for 3 hours. After the three hours treatment,
media was aspirated and cells washed in cold PBS. Two hundred µL of 0.05% SDS
was then used to solubilize cells, and the cell lysates were collected in 2 mL eppendorf
tubes. Samples were spun down for 5 min at 4ºC, at 15,000 g. Twenty µL of sample
was collected at this time for BCA protein determination. After resuspending the
pellet, 1 mL of chloroform:methanol (2:1) was added to each sample. The samples
were then rocked for 15 minutes at room temperature, and then 0.5 mL of ddH2O was
added. The samples were then again rocked for 15 minutes, and tubes were spun for
10 min at 4ºC, at 3,000 rpm. The upper phase was discarded, and the lower organic
phase was collected in scintiallation vials for reading on the Beckman scintiallation
counter. Calculations were normalized to protein content.
2.2.8 Macrophage Immunohistochemistry
Slides were deparaffinized with two 15 minutes changes in xylene, and two 15
minutes changes in 100% ethanol. They were then placed in Methanol containing 2%
H2O2 by volume for 30 minutes. Next, they were rehydrated with a series of 5
minutes changes in 95%, 70%, and 50% ethanol. Before blocking, slides were washed
3X in PBS. Blocking with 1%BSA, 5% normal horse serum at room temperature for 1
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hr was followed by overnight incubation with 1:3,000 dilution of primary Mac-2
antibody (Lifespan BioSciences, INC # LS-C62936) in 1%BSA at 4ºC. The next day,
slides were washed 3X in PBS and incubated with 1:222 dilution of anti-mouse
secondary (Vecastain ABC kit, Vector Laboratories #PK-4004) in 1% BSA for 1 hr at
room temperature. After washing 3X with PBS, the ABC solution (Vecastain ABC
kit) was added to slides for 30 min. Slides were then washed 3X in PBS and
diaminobensidine solution plus 1.6 μL H2O2 was added per mL was used to develop
the slides for 2 min. Slides were washed 3X with PBS, then with tap water 2X, and
then dehydrated in a series of alcohol (50%, 70%, 95%, and 100%) before mounting
with Citifluor (Ted Pella, Inc., #19472) and coverslipping.
2.2.9 CD-31 Immunohistochemistry
Slides were stained with a CD31 staining kit (Biocare Medical # RT 517 SK)
according to the manufacturer’s protocol. The CD31primary antibody (BD
Biosciences, #550274) was used at 1:50 dilution.
2.2.10 Adipose Tissue Explant Angiogenesis Assay
The angiogenesis assay was conducted as previously described (245). Briefly,
explants were embedded in a thrombin media and infected with Ad36 or Ad2 the
following day with 2 million PFU/well or Mock infected. A blinded observer scored
the explants every 3-5 days for angiogenic growth as described.
2.2.11 Tube Formation Assay
Assay was conducted as described previously (102). Briefly, 40,000 cells per well
SVEC4-10 were plated in 96 well plates coated with basement membrane extract (BD
Biosciences, #354230), and tube formation was observed 5 hours post plating and
images were captured. For an acute effect of infection, Ad36 or Ad2 were added
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directly as cells were plated. For Day 1 and Day 3 post infection time points, SVEC410 were infected on 10 cm plates, and trypsinized and plated for tube formation either
Day 1 or Day 3 post infection. A viral dose of 5 PFU/cell was used for all time points,
with 5 replicates per group.
2.2.12 Glycogen Staining
Slides of liver sections were fixed with Carnoy’s fixative for 15 minutes (6 parts
ethanol, 3 parts chloroform, and 1 part glacial acetic acid), then washed in distilled
water for several minutes. Periodic acid solution (1%) (Sigma 395132-1L) was then
added for 5 minutes before adding Schiff’s reagent for 8 minutes (Sigma 3952016500ml). Samples were then washed in running tap water for 10 minutes, and
dehydrated in a series of increasing concentrations of alcohol (50, 70, 85, and 100%
ethanol). The slides were then air dried and mounted with Permount (Fisher Scientific
# SP15) and coverslipped.
2.2.13 [3H]-2-Deoxyglucose Uptake Assay
Cells in 12 well plates were serum starved for 2 hours, and then washed 2X with PBS
before adding 450 μL KRP (136 mM NaCl, 4.7 mM KCl, 10 mM NaPO4, 0.9 mM
CaCl2, 0.9 mM MgSO4) with or without 100 nM insulin (Sigma Aldrich, #15500),
depending on the experiment, for 15 minutes. Two to three wells were treated with
KRP plus 100 nM cytochalasin (Sigma Aldrich, #C6762) for subtraction of nonspecific
glucose uptake. Fifty µL of 10X isotope solution was then added to each well for a
final concentration of 100 nM cold 2-deoxy glucose and 0.5 µCi/mL [3H]-2Deoxyglucose (PerkinElmer #NEC720A250UC) for 5 minutes. Immediately after the
5 minute incubation, cells were washed in ice-cold PBS. 500 μL of 0.05% SDS was
then added to each well, and after incubation of cells for 30 min at 37ºC, 450 µL of
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lysate was added to a scintiallation vial and the remaining 50 µL was used for protein
determination via BCA assay. Samples were read on a Beckman scintillation counter
the following day.
2.2.14 E4orf1 siRNA Transfection
3T3-L1 preadipocytes were plated into 12-well plates (80,000 cells/well) and
transfected the next day with Lipofectamine (Invitrogen #18324-012). A ratio of 2 µL
Lipofectamine and 100 pmol Ad36 E4orf1 siRNA or NT siRNA was used for
transfection, which produced 60% knockdown of E4orf1 expression as determined by
quantitative real-time PCR. Knockdown was confirmed two days post transfection by
harvesting RNA and detecting E4orf1 mRNA via quantitative real time PCR. The
following E4or1 siRNA sequence was custom designed by Ambion (#AM16100) :
Sense siRNA Strand (5'→3'): GAGAGUGAUUUUUCCUUCATT
Antisense siRNA Strand (5'→3'): UGAAGGAAAAAUCACUCUCTC
2.2.15 Quantitative Real-time PCR for Detection of E4orf1
E4orf1 was detected using quantitative real time PCR. RNA was harvested and isolated
using a RNA Mini Easy Kit (Qiagen, #74104), and cDNA was synthesized via RT PCR
(Applied Biosystems # 4368814) according to manufacturer’s instructions. An Ad36
E4orf1 FAM nonflourescent primer-probe was custom designed and synthesized
(Integrated DNA Technologies). The E4orf1 primer probe is as follows:
Probe 5'-/56-FAM/TGC TGC TCT /ZEN/TTA ACC ACA CGG ACC G/3IABkFQ/-3'
Primer 1 5'-CCC TCG CGG ACATAC AAA A-3'
Primer 2 5'-GCC GGG AGA AGA CAT GAT CTC-3'
100 ng of cDNA was loaded per well in duplicate for detection of E4orf1. GAPDH
primer probe was used as a housekeeping gene (Applied Biosystems, assay ID#
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Mm99999915_g1), and 2 ng per well was loaded in duplicate for each sample. Taqman
Universal PCR Mix was used for both genes according to manufacturer’s instructions
(Applied Biosystems #4304437). Expression was detected with the Applied Biosystems
7900 Sequence Detection System and the ΔΔCt method.
2.2.16 Plasmid Preparation and Transfection
The plasmid pcDNA-V5-E4orf1 was cloned using Invitrogen GateWay system that
included two steps. 1) Direct TOPO cloning of Ad36 E4ORF1 cDNA and Ad2
E4ORF1 into

pENTR-D

TOPO

vector

(Invitrogen

#K2400-20)

according

to

manufacturers manuals. 2) pENTR-E4ORF1 vectors from first step was used for
recombination with pcDNA-V5 vector (Invitrogen #12489-019) using LR Clonase
enzyme (Invitrogen # 11791-019) to obtain pcDNA-V5-E4orf1 which was used for cell
transfection.
3T3-L1 preadipocytes were transfected with Lipofectamine. Cells were plated into 12
well plates (80,000 cells/well), and transfected the next day with a 3:1 ratio of
Lipofectamine to plasmid DNA according to the manufacturer’s instructions.
Transfection was verified via protein harvest and WB for the detection of V5-tagged
E4orf1 using V5 antibodies.
3T3-L1 adipocytes were transfected on day 6 post adipogenic induction.

After

trypsinizing with 0.25% trypsin, cells were counted and transfected by electroporation
with AMAXA kit nucleofection solution L (Lonza, #VCA-1005) according to the
manufacturer’s protocol except that each cuvette contained 2.5 million cells and was
plated to two wells of a 12 well plate. The AMAXA Nucleofector II Device was used for
electroporation. The next day after the cells had settled on the plate, media was gently
65

removed and replaced with fresh media to remove any remaining transfection solution
and the cells that did not survive transfection. Transfection was verified via protein
harvest and WB for the detection of V5- tagged E4orf1 with V5 antibodies.
2.2.17 Generation of Ad-36 E4orf-1 Stable Inducible 3T3-L1 Cell Lines
2.2.17a Outline
1. Transfection standardization of 3T3-L1 with Lipofectamine and TetON plasmid.
2. Puromycin kill curve to determine selection concentration
3. pTetON transfection and stable selection
a. pTetON transfection
b. Selection process
4. Screening of TetON Clones
a. pTIGHT-Luc transfection and Luciferase assay standardization
b. Screening of clones
5. pTRE TIGHT and pTRE TIGHT-E4orf1 selection and screening
a. pTRE TIGHT and pTRE TIGHT E4orf1 transfection selection
b. E4orf1 clone screening.
6. E4 clone characterization

2.2.17b Detailed Procedure
Clontech’s TetON Advanced system (Clonetech, #630930) was used to create an
inducible 3T3-L1 Ad36 E4orf-1 expressing cell line. This system was chosen for
tightly controlled, robust expression of E4orf1. 3T3-L1 were first transfected with the
pTet-On Advanced vector and selected for stable transfectants using Lipofectamine.
This vector contains a tetracycline responsive transcriptional transactivator, which in
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the presence of Doxycycline, binds to a pTIGHT inducible promoter and activates
transcription of a downstream gene of interest. After selecting for the best pTet-On
clone by luciferase assay following transient transfection with pTRE-TIGHT-Luc,
that clone was expanded and transfected with either pTRE-TIGHT (empty vector
control) or pTRE-E4orf1-TIGHT. Stable transfectants were then selected, expanded,
and screened for E4orf1 expression by quantitative real-time PCR. Each step is
described in detail below.
1. Transfection Standardization
3T3-L1 were plated in 12-well plates for 50, 70 and 80 percent confluence
and transfected the next day with pMAX-GFP (green fluorescent protein)
(Lonza) at 3:1, 6:1 and 6:2 ratio of μL Lipofectamine: mg plasmid DNA per
well according to manufacturer’s instructions. Cells were fixed for 15
minutes with 10% formalin at 48 hours post transfection and stained with
DAPI for nuclei staining for a total cell count. Three 10X pictures were taken
with the Zeiss Axioskop 40 per condition, and percent of cells expressing GFP
was calculated. The 3:1 ratio at 50% confluence was selected as the best
condition, with 86% transfection efficiency.
2. Puromycin and Hygromycin Kill Curve
To determine the dose for selection of transfected 3T3-L1, a dose and duration
experiment was conducted. 3T3-L1 were plated for 50% confluence and
treated the next day with 0.25, 0.5, 1, 2, 3, 5 or 10 μg/mL of puromycin
(Clonetech # 631306). For hygromycin, doses of 0.01, 0.05, 0.15, 0.2, and 0.5
μg/mL were chosen. Every three days, a set of cells for each dose was
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trypsinized, viable cells were counted with a hemocytometer after staining
with trypan blue, and fresh media was replaced on the remaining time points.
Based on the resulting kill curves, 1 μg/mL was chosen as an optimal dose for
puromycin selection, and 0.1 μg/mL was chosen as an optimal dose for
hygromycin selection.
3. pTetOn Advanced Transfection and Stable Selection
a. 3T3-L1 were plated in 12 well plates at 50% confluency and transfected
the following day with 3:1, 6:2, or 12:4 ratio of µL Lipofectamine to µg
plasmid DNA, and each condition was also co-transfected with a linear
puromycin marker (Clonetech #ST0207) (with 1:20 marker to plasmid
DNA ratio). 48 hours post transfection, cells were observed with Zeiss
Axioskop 40 for transfection efficiency, since the pTetOn plasmid
expresses GFP. The 3:1 condition of pTetOn Advanced showed
approximately 20% efficiency, 6:2 showed 40% efficiency, and 12:4
showed 80% efficiency. Cells were stressed, however, with increasing
amount of Lipofectamine. After verifying successful transfection, cells
were trypsinized and each well was replated in a 10 cm dish so that cells
would spread out to single cells for the development of colonies after
selection.
b. Doses of 1 μg/ml, 2 μg/mL, and 3 μg/mL of puromycin were used for
selection. Two methods were applied for selection: either the selection
dose was applied immediately after transfer to the 10 cm plates
(“immediate dosing”), or it was applied gradually (“gradual dosing”) with
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0.25X at 2 days, 0.5X at 4 days, 0.75X at 6 days, and 1X at 8 days post
transfer to the 10 cm plate. The 3:1 condition stopped expressing GFP
after transfer to the 10 cm plate, and all plates of this condition were
discarded. The 6:2 condition and 12:4 condition continued to express GFP
well. Immediately treating the plates with 2 ug/mL and 3 ug/mL
puromycin resulted in cell death, and these plates were discarded. The 1
μg/mL “gradual” and 1 μg/mL “immediate” plates, and the 2 μg/mL
“gradual” plates survived well and after selection grew colonies.
After 15 days post transfer to 10 cm plates, isolated clones were selected
visually, and marked with a permanent marker using an inverted
microscope. Each clone was scraped manually using a de-tipped 200 μL
pipette tip and placed in a 96-well plate. Then, as each clone grew to
confluence, it was trypsinized and expanded to a 48-well, 24-well, 12well, 6-well and finally a 10 cm plate. At the 10 cm stage, each clone was
frozen down in 80% Tetracycline free fetal bovine serum (FBS)
(Clonetech, #631101) 10% DMEM, and 10% dimethyl sulfoxide freezing
media so that all clones could be screened together, since all clones were
growing at different rates. A total of 22 clones were selected and
expanded for screening.
4. TetOn Advanced Clone Screening
a. The first three clones (named 3a, 1b, and 1c) isolated were used to
standardize the luciferase assay for screening clones. All clones were
plated for 50% confluence in 12 well plates and transfected the next day
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with a 6:2 ratio of Lipofectamine to pTre TIGHT-Luc plasmid DNA. 48
hours post transfection, cells were treated with 0, 0.1, 1, 10, 100, or
1,000ng/mL of Doxycycline. In addition, to test if the Hyclone FBS
contains Tetracycline, which can cause high background induction in this
system, Tetracycline free FBS from Clonetech was used as another
condition with 0 and 1,000 ng/mL Doxycycline. Twenty four hours post
treatment, the luciferase assay (Promega #1531) was carried out. Cells
were washed with cold PBS, and cells were lysed using 70 μL per well of
the lysis buffer. After vortexing, samples were spun down at 12,000 g for
two minutes and the supernatant was transferred to a new 1.5 mL
Eppendorf. Twenty µL of the sample was loaded in duplicate into a 96
well plate. After addition of the Luciferase assay buffer, the plate was
read using a Luminescense plate reader (Berthold Technologies,
MicroLumat Plus). Normal FBS showed no dose response or clear
indication of luciferase activity, however, clone 3a showed a 3-fold
induction of luciferase activity with Tet-free FBS with 1,000 ng/mL
Doxycycline compared to 0 ng/mL Doxycycline. This indicated the FBS
may have some tetracycline contamination, which can induce a similar
effect to Doxycycline treatment in this system. Therefore, from then on,
all clones were maintained in Tet-free FBS.
To determine the best time point post Doxycycline treatment and to
determine the effect of a wider range of Doxycycline treatments for
screening the clones, clone 3a was then plated and again transfected with
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pTre TIGHT-Luc, and treated with 0, 100, 1,000, or 10,000 ng/mL
Doxycycline in duplicate two days post transfection. The luciferase assay
was then conducted as described above at 1 hr, 6 hr, 12, hr, 24, and 48
hours, and an untransfected group was added in order to subtract luciferase
assay background (Figure 1). The resulting data is displayed in the figure
below, and 12 hours was selected as the best time point with 1,000 ng/mL
Doxycycline as the optimal dose for screening. This time point
demonstrated the clearest dose response, and 1,000 ng/mL dose had the
highest luciferase expression.
b. Next, all clones were screened by first transfecting with pTre TIGHTLuc, treating each clone in duplicate 48 hours post transfection with either
0 or 1,000 ng/mL Doxycycline, and conducting a luciferase assay 16
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Figure 1. Luciferase Assay Standardization. 3T3 TetON Clone 3a was treated with
several doses of Doxycycline for 1, 6, 12, and 48 hours, and a luciferase assay was
conducted to determine the optimal dose and time point for screening all clones.
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hours post Doxycycline treatment. The 22 TetOn Advanced clones were
screened in two batches. If luciferase activity was induced by at least 1.5
fold with 1,000 ng/mL Doxycycline exposure, it was expanded and frozen
down. The two best clones showed approximately 2.5 fold induction of
luciferase with Doxycycline treatment.
5. pTRE TIGHT and pTRE TIGHT-E4orf1 Selection and Screening
a. The TetOn Advanced clone with the highest luciferase expression was
split into 12-well plates for 50% confluency and transfected the next day
with a 6:2 ratio of µL Lipofectamine to mg of either pTRE TIGHT or
pTRE TIGHT-E4orf1 plasmid DNA. The linear hygromycin marker
(Clonetech, #ST0206) was co-transfected with 0.1 mg per well. Two days
post transfection cells were trypsinized and reseeded in a 10 cm plate,
hygromycin treatment was started for selection. Doses of 0.05, 0.15, and
0.25 µg/mL of hygromycin were used either immediately, or gradually,
similar to the way TetOn Advanced clones were selected. The 0.15 and
0.25 “immediate” and “gradual” doses were very toxic following
transfection, so another transfection was conducted and doses of 0.05, 0.1,
and 0.15 “gradual” µg/mL hygromycin were used. The TetON/pTRE
clones grew extremely slowly and were switched to 20% Tet-free FBS
with maintenance 0.05 ug/mL hygromycin after the 15 day selection
period. Then, three rounds of harvesting over the next 10 days were
conducted, visually marking the clones with a marker and manually
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scraping with a de-tipped 200G tip. Clones were expanded over one
month to the 10 cm stage for freezing and screening.
b. Once the clones had grown to the 10 cm plate stage, each clone was
trypsinized and distributed into four wells of a 6-well plate, and one 10 cm
plate. The 10 cm plate was frozen down and stored at -80º C, and the 6well plate was treated with either 0 or 1,000 ng/mL Doxycycline and
harvested for RNA after 16 hours.
Once RNA had been collected from all clones, two step quantitative realtime PCR was used to detect E4orf1 expression. The Teton/pTRE empty
vector control clone with and without Doxycycline was used as the
calibrator for the delta delta Ct calculation. The best clone was chosen
with 6.5 fold increase in E4orf-1 expression for expansion and further
characterization.
6. E4orf1 Clone Characterization
The pTRE TIGHT-E4orf1 clone with the highest expression during screening was
plated in 6 well plates and treated with either 0, 500, 1,000, 5,000, or 10,000
ng/mL Doxycycline and harvested for RNA at either 16 hr, 24 hr, or 48 hr post
treatment. Two passages were treated with these conditions, one that was frozen
at -80º C right after selection (maintenance passage 1) and one that was passage
14 post selection (maintenance passage 14). E4orf1 expression at all conditions
was detected via quantitative real-time PCR, and expressed as fold expression
relative to pTRE empty vector control cell line (Figure 2). A loss of controlled
dose response of E4orf1 expression to Doxycycline treatment occurs by passage
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14 of the cell line. Early passages of the E4orf1 clone were therefore used for
experiments.
2.2.18 Ras Activation Assay
Ras activation assay (#17-218, Upstate) was conducted according to manufacturer’s
protocol. After the Ras activation assay, four separate gels were loaded with 6% of the
whole cell lysate for determination of total Ras and the slurry for determination of
activated Ras. Each WB was probed with either 1:200 dilution of H-, N-, or K-Ras
antibodies (Santa Cruz # sc-520, sc-519, and sc-30, respectively) for the detection of each
isoform, or the Anti-Ras CLONE10 antibody provided with the activation kit for
determination of total Ras activation.
2.2.19 Western Blotting
Cells were harvested in RIPA buffer complete with anti-protease (Sigma Aldrich,
#P8340) and anti phosphatase inhibitor cocktail (Thermo Scientific #78420). Protein
concentration was determined with a BCA assay, and samples were prepared with 5X
lane marker reducing buffer (Thermo Scientific #39000) and ddH2O so the sample
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Figure 2. Characterization of E4orf1 Expression in E4pTRE Cell Line. E4orf1
expression standardization for pTRE TIGHT-E4orf1 clone. A) Maintenance passage
1 E4orf1 expression, expressed as mean expression relative to pTRE empty vector
clone. B) Maintenance passage 14 of same clone, expressed as mean expression
relative to pTRE empty vector clone.
volume was constant for loading. SDS-PAGE was performed and proteins were
transferred to PVDF membrane. For detection of activated Ras, the slurry and 6% of
whole cell lysate was loaded in a 15% gel, and isoform specific antibodies for H-, N-, and
K-Ras (Santa Cruz #(Santa Cruz # sc-520, sc-519, and sc-30, respectively) were used at
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1:200 dilution. Twenty μg protein was loaded in a 7% gel for detection of Glut4 with
monoclonal antibody (RandD Systems # MAB1262) at 1:1,000 dilution. Fifteen μg
protein was loaded in to a 10% gel for determination of Ras (Cell Signaling #3965S) at
1:1,000 dilution. Fifteen μg protein was loaded in to a 10% gel for determination of
adiponectin at 1:1,000 dilution (Millipore #MAB3608). Fifteen μg protein was loaded in
to a 10% gel for determination of Glut1 at 1:200 dilution (Santa Cruz Biotechnologies
#sc-7903). For detection of successful transfection of V5-tagged E4orf-1, V5 antibodies
(Invitrogen #46-0705) were used at 1:1000 dilution. Lastly, 10% gels were loaded with
15 μg and probed for p-AKT and total AKT (1:1000) (Cell Signaling #’s 9271 and 9271,
respectively).

For all proteins, β-actin was used as a loading control (Santa Cruz #sc-

69879)(1:500 dilution). Densitometry was conducted using Image J software by the
National Institutes of Health, and all graphs are represented as the ratio of the protein of
interest to β-actin.
2.2.20 Soft Agar Assay
Briefly, 2 mL per plate of minimal essential medium (MEM) 10% FBS, 0.6 % agar was
allowed to solidify at room temperature. Then, 0.5 mL of 80,000 cells/mL suspended in
MEM 10% FBS, 0.3% agar was added. After the agar solidified at room temperature,
another 2 mL of MEM 10% FBS, 0.6 % agar was added as a top layer. Cells were re-fed
with 0.5 mL of 2X MEM, 20% FBS every seven days. Cells were fixed at day 7, 14, or
21 with 1 mL 0.01% crystal violet in 10% formalin overnight at 4o C.
2.2.21 Quantitative Real-time PCR for Detection of Adiponectin and Inflammatory
Cytokines
RNA was harvested and isolated using a RNA Mini Easy Kit (Qiagen, #74104), and
cDNA was synthesized via RT PCR (Applied Biosystems # 4368814) according to
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manufacturer’s instructions. GAPDH primer probe was used as a housekeeping gene
(Applied Biosystems, assay ID# Mm99999915_g1), and all inflammatory cytokines were
detected with Applied Biosystems Gene Expression Primer Probe Assays (Applied
Biosystems, INFγ #Mm99999071_m1, TLR-4 # Mm00445274_m1, MCP-1
#Mm00441243_g1, TNF-α #Mm00443259_g1, MCSF#00432688_m1, IL-10
#Mm00439615_g1). Two 2 ng per well was loaded in duplicate for each sample.
Taqman Universal PCR Mix was used according to manufacturer’s instructions(Applied
Biosystems #4304437). For adiponectin mRNA detection, a primer was designed, and βactin was used as a housekeeping gene. Both primers were ordered from IDT. The
primers are as follows:
Adiponectin:
Forward: 5’-AAG GAC AAG GCC GTT CTC T -3’
Reverse: 5’- TAT GGGTAGTTG CAGTCA GTT GG -3’
β-Actin:
Forward: 5’-ACG TTG ACA TCC GTA AAG AC-3’
Reverse: 5’-GAT CTT CAT GGT GCT AGG AG-3’
SYBR green master mix (Biorad #170-8884) was used according to manufacturer’s
instructions for detection of adiponectin and β-actin. Expression of all genes was
detected with the Applied Biosystems 7900 Sequence Detection System and using the
standard curve method.
2.2.22 Mouse Embryonic Fibroblast Transfection
Cells were plated for 90% confluence without antibiotic and transfected the next day with
Lipofectamine 2000 (Invitrogen # 11668-019) according to manufacturer’s instructions.
Briefly, 1.6 µg plasmid DNA and 4 µL of Lipofectamine 2000 per well were allowed to
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complex for 15 minutes in Opti-MEM (Invitrogen #51985-091). Meanwhile, 800 µL of
fresh serum free DMEM was added to each well.

After complexation, 200 µL of

transfection complex was added to each well and incubated for 6 hours before
transfection media was replaced with fresh DMEM + 10% FBS.
2.2.23 HepG2 Plasmid Transfection
HepG2 cells were transfected for glucose output assays using the AMAXA Nucleofector
II device, Cell Line Nucleofector Kit V (Lonza #VACA-1003) with either pcDNA-V5AD36-E4orf1 or pcDNA-V5-DEST plasmids and plated in 96-well plates.

Nearly

confluent HepG2 cells were trypsinized, counted, and 2 μg of plasmid and 2 million cells
were used per cuvette. Nucleofector program T-028 was used for transfection, and after
resuspension 40,000 cells per well were plated on 96-well plates for the glucose output
assay. Transfection was verified via protein harvest and WB for the detection of V5tagged E4orf1 with V5 antibodies.
For HepG2 lipid oxidation, DNL, and ApoB secretion studies, PolyJet (SignaGen
#SL100688) was used for transfection according to manufacturer’s instructions. For each
well, 4.5 µL plasmid and 1.5 mg plasmid was complexed, and transfection complex was
left on cells overnight for 14-16 hours.
2.2.24 Glucose Oxidase Assay
A colorimetric assay was used for determination of glucose output into media (Raichem,
#R80038). Manufacturer’s instructions were followed, and 10 μL of media was loaded
into each well, and a standard curve starting from 5 mM glucose diluted in serum free,
glucose free media was used to determine exact molar concentration of glucose for
unknown samples. Glucose output was adjusted to protein concentration as measured by
BCA (Sigma Aldrich # B9643, #C2284) after solubilization of cells with 0.05% SDS.
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Primary hepatocytes were solubilized in RIPA buffer, and were subjected to several rapid
freeze-thaw cycles before lysing. Each sample was removed and spun down at 14,000 rpm
for 10 minutes at 4 ºC, and the supernatant was taken for BCA assay.
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Chapter 3. Results
3.1 Objective 1. To Determine If Ad36 Infection Is Associated with Better Glycemic
Control in Children
1A. Association of Ad36 Infection with Glycemic Control in Prepubertal Caucasian
and African American Children
To determine an association of previous Ad36 infection with improved glycemic control,
sera from 45 children from a previously characterized cohort, the MET study (32
Caucasian (71%), 10 Black(22%), 3 other races (6%), 22 males (48%), 23 females (52%),
age 7-9 years), were screened for the presence of Ad36 neutralizing antibodies. Ad36
seropositivity is significantly associated with lower fasting glucose (p=0.04) and insulin
(p=0.04), lower HOMA IR (p=0.03), and less intra-hepatic lipid (p=0.04) (Table 1).
Table 1. Association of Glycemic Control with Ad36 in MET Study. Prepubertal boys and
girls (n=45; Black/White/other: 10/32/3). Meana (95%CI) adjusted for sex and body fat mass.
Intra-hepatic lipid normalized to spleen density. Higher HU value equates to lower lipid content.
Krishnapuram et al, American Journal of Physiology Endocrinology and Metabolism, 2011, Am
Physiol Soc, used with permission. (190)
Ad36 Ad36 +
P
N=42

N=35

N=10

Fasting glucose (mg/dL)

74.5 (71.6-77.4)

68.7 (62.9-74.6)

0.04

Fasting Insulin (μU/ml)

3.1 (2.4-4.1)

1.8 (1.1-3.0)

0.04

HOMA IR

0.51 (0.39-0.69)

0.28 (0.16-0.48)

0.03

Intra-hepatic lipid (%
water peak)

0.005 (0.002-.006)

0.003 (0.004-0.008)

0.04

a

Arithmetic mean for glucose; Geometric mean for insulin, HOMA-IR and intra-hepatic lipid

1B. Association of Ad36 Infection with Glycemic Control in Hispanic Children
Sera of 585 Hispanic children from the VIVA LA FAMILIA study were screened for the
presence of neutralizing antibodies to Ad36. Out of 585, 42 subjects tested seropositive
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to Ad36 (7%). Prevalence of Ad36 infection in this cohort is lower than other
populations previously tested. Several subjects were related in this cohort, therefore
fasting blood glucose, insulin, and HOMA IR were adjusted for family and body fat
mass. Fasting blood glucose was significantly lower for Ad36 seropositive subjects
(p=0.04). In addition, Ad36 seropositive subjects had a significantly greater odds ratio
for fasting glucose, fasting insulin, and HOMA IR to fall below the median of the overall
group (p=0.02, 0.04, and 0.02, respectively)(Table 2). Thus, Ad36 seropositivity is
associated with improvements in glycemic control in Hispanic, Caucasian, and African
American children.
3.2 Objective 2. Identify the Characteristics of Adipose Tissue and Liver Associated with
Ad36 Induced Improvements in Glycemic Control
2A. Adipose Tissue
2A.1 Adipocyte Metabolism
2A.1.1 Spread of Ad36 Infection in Human Adipose Derived Stem Cells
The spread of Ad-36 infection in hASC’s was determined. A time course of
Ad36 infection was tracked by staining of nuclei and Ad36 hexon protein to
determine of the percent of cells infected with Ad-36 (Figure 3). Spread of
infection in hASC’s was initially slow, but progresses quickly after Day 5 post
infection. A 3-fold increase in the percent of infected cells occurred between Day
3 and Day 5 post infection, while a nearly 6-fold increase in the percent of
infected cells occurred between Day 5 and Day 7, and a 2.5-fold increase between
Day 7 and Day 9 (Figure 3B). This indicates that Ad-36 infection of hASC’s is
replicative, that it spreads well in this cell type, and they provide an excellent
model for the study of Ad36 and lipid metabolism.
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Table 2. Association of Glycemic Control with Ad36 in VIVA LA FAMILIA Study.
Hispanic boys and girls (n=585). Odds ratio adjusted for sex, body fat mass and family.
Meana (95% CI), adjusted for adiposity and familyb . NS: p>0.05. Krishnapuram et al,
American Journal of Physiology Endocrinology and Metabolism, 2011, Am Physiol Soc,
used with permission. (190)
Ad36 Ad36 +
P
N=585

N=543

N=42

Fasting glucose (mg/dL)

92.2 (91.3-93.0)

89.1 (85.8-92.4)

0.04

Fasting Insulin (μU/ml)

15.9 (15.2-16.6)

16.6 (13.9-19.8)

NS

HOMA IR

3.58 (3.42-3.76)

3.65 (3.03-4.40)

NS

OR for Ad36+ to be below the median of the overall group
OR

95% CI

P

Fasting glucose

2.5

1.1 – 5.7

0.02

Fasting Insulin

1.8

0.9 – 3.4

0.04

HOMA IR

2.4

1.1 – 5.3

0.02

a

Arithmetic mean for glucose; Geometric means for Insulin and HOMA IR. bInitial
models included age and sex but neither was a significant predictor so both were
excluded from the final analytical model; however, the resulting p-values were
unchanged.
2A.1.2 Lipid Accumulation in hASC Following Ad36 Infection with and
without MDI
Next, a lipid accumulation time course of hASC’s with and without differentiation
inducer MDI revealed that lipid accumulation is increased by Ad36 infection. In
the presence of MDI, both Mock and Ad36 infected groups accumulated lipid at a
similar rate initially, and lipid accumulation in Ad36 group surpassed Mock after
Day 7, with significantly more lipid per cell Day 9 post infection (Figure 4)
(p=0.003). Without induction by MDI, Ad-36 alone was sufficient to increase
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Figure 3. Ad36 Hexon and DAPI Staining Time Course in hASC. Time course
of Ad36 infection in hASC, post infection with 3.8 PFU/cell. A) Representative
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20X pictures of DAPI and Ad36 Hexon staining for various time points. B)
Percent of cells infected for each time point, expressed as mean percent + SD.
lipid accumulation compared to Mock (p=0.01 for Day 3, Day 5, Day 7, p=0.06
for Day 9)(Figure 4). Ad-36 increases lipoprotein lipase (LPL) expression and
translocation (202), which may explain the increased lipid accumulation here.
2A.1.3 The Effect of Ad-36 Infection on Lipid Accumulation with Respect to
Confluency
The effect of Ad-36 on 3T3-L1 lipid accumulation is well documented (200; 247),
but the effect of confluency at the time of infection is unknown. 3T3-L1 cells are
a particularly good model for this as infection is not replicative in these cells
(200). How confluency of 3T3-L1 effects Ad36 induced lipid accumulation was
determined in 3T3-L1. 3T3-L1

infected at confluence accumulate significantly

more lipid than those infected 2 days prior to confluence (Figure 5). In the first
experiment, cells were incubated with virus for the same amount of time
regardless of the time of infection relative to confluency (Figure 5A). In the
second experiment, cells were incubated for the same amount of time post
confluence (Figure 5B). In both experiments, cells have greater lipid
accumulation when infected at confluence compared to those infected 2 days prior
(p=0.00001 and 0.0003, respectively). Therefore, regardless of incubation time
with the virus or time post confluence, Ad36 infection demonstrated a synergistic
effect with confluence.
2A.1.4 De Novo Lipogenesis Time Course Following Ad36 Infection in 3T3L1
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Although Ad36 increases glucose uptake in adipose tissue, the fate of intracellular
glucose and if it contributes to lipid accumulation is unknown. Ad36 significantly
increases de novo lipogenesis in 3T3-L1 (p<0.05 Day 6 post infection) (Figure 6).
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Figure 4. Time Course of Lipid Accumulation Following Ad36 Infection. Lipid
accumulation in hASC after Mock or Ad36 infection (3.8 PFU/cell), with or without
MDI. A) Representative images of BODIPY staining in hASC’s following Ad-36
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infection w or w/o MDI. Published first elsewhere (Pasarica et al., Stem Cells, Issue 26,
p.19, AlphaMed Press)(202) B) BODIPY fluorescence quantified and normalized to
DAPI florescence for quantification of lipid per cell, expressed as mean + SD for each
condition and time point.
Specifically, between Day 3 and Day 6 post infection, DNL is up-regulated. This
time period post confluence and post infection is when preadipocytes are rapidly
accumulating lipid, becoming mature adipocytes. Therefore, as cells infected
with Ad-36 differentiate, they may accumulate lipid through increased conversion
of glucose to lipid. This may result in concomitant glucose clearance from
circulation and lipid accumulation in cells.
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Figure 5. Lipid Accumulation Per Cell in Ad36 Infected 3T3-L1. Lipid accumulation
in 3T3-L1 infected with 1 PFU/cell different days relative to confluence. A) Mean lipid
per cell + SD in 3T3-L1 infected at -2, -1, and 0 days relative to confluence, fixed and
quantitated 9 days post infection. Cells accumulate more lipid if infected at confluence
(p=0.00001). B) Mean lipid per cell + SD in 3T3-L1 infected at -2, -1, and 0 days relative
ton confluence, fixed and quantitated 9 days post confluence. Cells accumulate more
lipid if infected at confluence (p=0.0003). These data were first published
elsewhere(247).
2A.1.5 Modulation of Glucose and Palmitate Oxidation in 3T3-L1 by Ad36
Oxidation of glucose and palmitate were monitored in 3T3-L1 infected with
Mock, Ad36, or Ad-2. A time course following infection (Figure 7) indicated that
Ad36 consistently reduces glucose oxidation (Figure 7A) (p<0.05 for Day 3, 6
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and 8) , and up-regulates palmitate oxidation (Figure 7B)(p<0.05 for Day 8)
compared to Mock- infected cells, and Ad2 infection did not have a similar effect
on 3T3-L1 substrate utilization. The ratio of palmitate to glucose oxidation is
consistently higher following Ad36 infection compared to Mock (Figure 7C),

nmol/3hr/mg prot

indicating the Ad36 infected cells preferentially oxidize fatty acids.
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Figure 6. DNL Following Mock, Ad36, and Ad2 Infection of 3T3-L1.
DNL Expressed as mean nmol glucose/3 hr/ mg protein + SD. Ad36 has
significantly greater lipid accumulation than Mock infected cells by Day 6
post infection (p=0.05).
2A.2 Effect of Ad36 on Adipose Tissue Morphology
2A.2.1 Change in Adipocyte Cell Size in C57BL/6J Mice on Chow and High
Fat Diet
Adipocyte size in healthy, chow fed C57BL/6J mice was determined in Mock,
Ad36, or Ad2 infected animals. Animals were sacrificed 12 weeks post infection,
and epididymal adipose tissue was stained for either CD68 (macrophage marker)
or CD31 endothelial cell marker) as described in methods. From this staining,
10X or 5X images were taken, to measure adipocyte diameter as described in
methods. Mean adipocyte diameter of Ad36 infected mice was significantly
smaller compared to Mock-infected mice (77.9 + 4.3 vs. 101.3 + 15.14 pixels,
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respectively, p=0.04), whereas Ad2 infected mice adipocyte diameter is not
significantly different than Mock (Figure 8A). The percent of adipocytes in Ad36
infected adipose tissue in the “small” category, which fall in the bottom tertile (as
defined by the range adipocyte sizes of all groups) is significantly higher than the
percent in the “large” category, which fall within the upper tertile (63% + 3.8%
vs. 12.4% + 2.5% , respectively, p=0.005) (Figure 8B). This indicates that Ad-36
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shifts the adipocyte cell size distribution to smaller adipocytes (Figure 8C).
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Figure 7. Time Course of [14C]-Glucose Oxidation and [14C]-Palmitate Oxidation.
Time course glucose and lipid oxidation in 3T3-L1 Mock, Ad2 or Ad36 infected (3.8
PFU/cell). A) [14C]-Glucose oxidation in Mock, Ad36, and Ad2 infected cells. Ad36
decreases glucose oxidation (p<0.05 for Day 3, 6 and 8) B) [14C]-palmitate oxidation, in
Mock, Ad36, and Ad2 infected 3T3-L1. Ad36 increases fat oxidation in 3T3-L1) (p<0.05
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for Day 8) C) The ratio of palmitate: glucose oxidation, which is consistently higher in
Ad36 group compared to Mock.

Adipocyte diameter is also altered by Ad36 infection in C57BL/6J mice on a high
fat diet. The mean adipocyte diameters for Mock, Ad36, and Ad2 infected mice
are not significantly different, however, the distribution of adipocyte sizes differs
between groups. A larger percentage of Ad36 infected adipocytes falls in the
“large” category (upper tertile of Mock range of adipocyte diameters) than the
“small” category (42.5 + 9.1 vs. 21.6% + 7.8%, respectively, p=0.04) (Figure 9A).
The opposite trend is apparent in Ad-2 infected adipose tissue, with more
adipocytes falling in the “small” category than the “large” category (43% + 7.8%
vs. 23.3% + 3.9%, respectively, p=0.008). These changes in cell size distribution
are presented in the box plot graph of all three groups (Figure 9B).
2A.2.2 Effect of Ad36 on macrophage infiltration in C57BL/6J mice on chow
and HFD.
Macrophage infiltration into adipose tissue is considered a marker of
inflammation and insulin resistance, and can occur with a high fat diet. Because
Ad36 improves glycemic control, we hypothesized that it may modulate
macrophage infiltration. Immunohistochemistry staining of macrophages in both
chow fed and HFD fed C57BL/6J mice was quantified using Image J. In the
chow fed model Ad2 infection increased macrophage infiltration (p=0.01)
compared to Mock infected animals (Figure 10). While Ad36 infection shares a
similar trend, this relationship is not statistically significant when compared to
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Mock in this model. Variation in macrophage staining is especially high in Ad36
infected chow fed mice, suggesting that in this condition, another variable factor
140
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Figure 8. The Effect of Ad-36 on Adipocyte Size in Chow Fed C57BL/6J Mice. Adipocyte
diameter in Mock, Ad36 and Ad2 infected C57BL/6J mice on chow diet. A) Mean adipocyte
diameter + standard deviation. Ad-36 infected adipose tissue has a lower mean adipocyte size
than Mock infected adipose tissue (p*=0.04). B). Percent of total adipocytes falling in the lower
90

or upper tertile, as defined by the range of adipocyte diameter measurements pooled from all
groups. Percentage was calculated for each mouse and averaged, mean + SD for each group.
Ad36 has a greater number of adipocytes in the lower tertile compared to the upper
tertile(p=0.005), whereas Mock and Ad2 does not. C) Box plot of all adipocyte diameter
measurements pooled for each group. Outliers are labeled by measurement number.

such as the level of local Ad36 infection in adipose tissue may be impacting
macrophage levels.
In the HFD model, no significant differences in macrophage infiltration were
detected by this method (Figure 10B). This may be due macrophage infiltration
induced by the high fat diet, which may be overwhelming any effect of infection.
2A.2.3 Effect of Ad36 on Adipose Tissue Vascularization and Angiogenesis
Adipose tissue growth without adequate angiogenesis can lead to poor adipose
tissue vascularization and consequently hypoxia, inflammation, and insulin
resistance(113). To determine how Ad36 modulates vascularization, adipose
tissue of chow and HFD C57BL/6J mice was stained for CD-31 as a marker of
endothelial cells and thus vascularization. In both models, Ad36 and Ad2
significantly increased adipose tissue CD31 staining compared to Mock infected
mice (Figure 11, p<0.05), indicating this may be a general effect of adenoviral
infection.
Next, to determine if Ad36 and Ad2 may increase adipose tissue vascularization
through induction of angiogenesis, an assay that specifically measures
angiogenesis in human adipose tissue explants was used(245). The assay was
repeated three times. Overall, Ad36 inhibits angiogenesis, much like the negative
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control (galic acid treatment), while Ad2 levels of angiogenesis are very similar to
the baseline Mock-infected control group (Figure 12). For the third trial
A.
% of adipocytes

60

*

*

50

% in lower tertile

40
% in upper tertile

30
20
10
0
Mock

Ad36

Ad2

B.

Figure 9. The Effect of Ad-36 on Adipocyte Size in HFD C57BL/6J Mice. Adipocyte
diameter in C57BL/6J mice on HFD. There is no significant difference between mean diameters
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of Ad-36, Ad2, or Mock infected adipocytes. A) Percent of total adipocytes falling in the lower
or upper tertile, as defined by the range of adipocyte diameter measurements pooled from all
groups. Percentage was calculated for each mouse and averaged, mean + SD for each group.
Ad36 has a greater number of adipocytes in the upper tertile compared to the bottom
tertile(p=0.04), whereas Ad2 has significantly more falling into the smaller category compared to
the large category (p=0.008). C) Box plot of all adipocyte diameter measurements pooled for
each group. Outliers are labeled by measurement number.

conducted, the adipose tissue did not respond as well, with very low levels of
angiogenesis and the Mock group had very similar levels of angiogenesis to the
negative control (GA) until Day 15 of the assay (data not shown). Similar trends
were seen, however, with the infected groups in this third assay. Neither viruses,
therefore, are strongly angiogenic in human adipose tissue ex vivo.
Lastly, the effect of Ad2 and Ad36 on induction of tube formation in SVEC4-10
murine endothelial cells plated on basement membrane extract was determined.
A tube formation assay measuring the acute (5 hr post infection) and long-term
response of SVEC4-10 cells (Days 1 and 3 post infection) was conducted with
Mock, Ad36, and Ad2 infected cells. Five hours post infection, neither adenovirus
enhanced the length of tubes formed by SVEC4-10 cells (Figure 13). One day
post infection, Ad36 caused a different morphology all together, with cells
stacking on top of each other, while Ad2 allowed cells to align but not create
complete networks of tubes. By Day 3 post infection, Ad2 infected cells had
died, and Ad36 continued to inhibit tube formation by SVEC4-10 endothelial
cells. Thus both adenoviruses impaired tube formation, and Ad2 was particularly
virulent in this cell type.
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Figure 10. Macrophage Infiltration in Adipose Tissue of C57BL/6J Mice on Chow
and HFD. A) Macrophage staining of chow fed mouse adipose tissue, quantified by
Image J. Mean + SD. Ad2 has significantly more macrophage staining than Mock
(p=0.01). B) Quantification of macrophage staining of HFD mice adipose tissue. Mean
+ SD. There were no significant differences macrophage staining for this model. C)
Representative images of macrophage staining, which appear as a dark brown stain.
Chow fed are 10X (top), HFD are 5X (bottom).
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Figure 11. CD-31 Staining of Adipose Tissue from Mice on Chow Diet and HFD. Adipose
tissue vascularization in C57BL/6J mice on chow or HFD. A) Image J quantification of CD31
staining in chow fed C57BL/6J mice adipose tissue. Expressed as Mean + SD. Ad36 and Ad2
infected mice have significantly higher CD31 staining compared to Mock infected mice
(p=0.003 and 0.04, respectively). B) Quantification of CD31 staining in HFD fed C57BL/6J
mice adipose tissue. Expressed as Mean + SD. Ad36 and Ad2 infected mice have significantly
higher CD31 staining compared to Mock (p=0.03 and 0.02, respectively). C) Representative
10X images of CD31 staining. CD-31 staining appears as a dark brown color.
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Figure 12. Human Adipose Tissue Angiogenesis Assay. Human adipose tissue
angiogenesis in response to Mock, Ad2 and Ad36 infection. Mean angiogenesis index +
SD. Galic acid treatment inhibits angiogenesis and is a negative control, whereas M199
is the media + Mock infection as a baseline control. Adipose tissue from A) 42 years old,
female, Caucasian, BMI=24.7) B) A 34 year old female, Caucasian, BMI=26.2.
2B. Effect of Ad36 on Hepatic Steatosis
2B.1 Effect of Ad36 on Liver Steatosis and Glycogen Stores in C57BL/6J Mice on
HFD
To determine if Ad36 may improve glycemic control by preventing hepatic steatosis and
improving glycogen stores, liver sections from Mock, Ad36, and Ad2 infected C57BL/6J
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Day 1

Day 3

Mock

Ad36

Ad2

Figure 13. Tube Formation Assay Following Mock, Ad36 and Ad2 Infection. 5X
images of tube formation assay of SVEC4-10 murine endothelial cells and various time
points post infection with Mock, Ad36, or Ad2. Normally, SVEC4-10 cells align and
form networks as seen Mock infected images. Ad36 and Ad2 infection inhibits the
formation of these tubes.

mice on a HFD were stained for glycogen. Throughout processing, lipid leaves the
sample and leaves white space in the tissue. Therefore, both approximate lipid and
glycogen content can be quantified using Image J software. Interestingly, Ad36
significantly reduced hepatic lipid accumulation and increased glycogen stores, even in
the presence of a HFD (p=0.02)(Figure 14). Ad2 infection, on the other hand, increases
high fat diet induced steatosis and decreases hepatic glycogen stores. The prevention of
steatosis by Ad36 may be a strong contributor to its attenuation of dysglycemia.
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Figure 14. Glycogen and Lipid Quantitation in Liver of Mice on a HFD. Liver glycogen and
lipid quantification in C57BL/6J mice on HFD. A) Quantification of hepatic lipid content,
measured as glycogen staining-total pixel area of 10X photo. Mean + SD. Ad36 has
significantly less lipid than Mock, whereas Ad2 has significantly more lipid than Mock (p=0.02
and 0.02, respectively). B) Quantification of hepatic glycogen content, Mean + SD. Compared to
the Mock group, glycogen content was greater in Ad36 group (p=0.02), and lesser for Ad2 group
(p=0.02). C) Representative 10X images of liver section stained for glycogen. Pink color is
glycogen, white is lipid. 1. Liver of mouse on chow diet, 2. Ad36 HFD, 3. Ad2 HFD, and 4.
Mock HFD. Krishnapuram et al, American Journal of Physiology Endocrinology and
Metabolism, 2011, Am Physiol Soc, used with permission. (190)
3.3 Objective 3. Determine if the E4orf1 Protein of Ad36 Enhances Glucose Disposal in
Adipose Tissue and Liver, and If It Alters Lipid Metabolism in Liver for Lower Lipid
Stores
3A. Effect of E4orf1 in Adipocytes
3A.1 Is E4orf1 Necessary for Ad36 Induced Glucose Uptake?
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To determine if E4orf1 is necessary for Ad36 induced glucose uptake, E4orf1 siRNA
was used to knock down E4orf1 expression following Ad36 infection in 3T3-L1
adipocytes, and a glucose uptake assay was conducted the next day. As expected,
Ad36 transfected with nontargeting siRNA has a 70% increase in glucose uptake
compared to Mock infected cells transfected with E4orf1 siRNA (p=0.05).
Knockdown of E4orf1 in Ad36 infected cells, however, abrogated glucose uptake
increased by Ad36 (Figure 15). E4orf1 therefore is necessary for Ad36 induced

Fold change in glucose
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+ E4 siRNA

glucose uptake.
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Figure 15. Glucose Uptake in 3T3-L1 with E4orf1 Knock Down.
Glucose uptake in 3T3-L1 cells, three groups: Mock cells transfected with
E4siRNA, Ad36 infected cells transfected with nontargeting siRNA and
Ad36 infected cells transfected with E4orf1 siRNA. Expressed as fold
change relative to M+E4siRNA + SD because three separate experiments
with statistically significant results are combined. Ad36 + NT siRNA has
significantly greater glucose uptake than Mock + E4 siRNA group
(p=0.05).

3A.2 Is E4orf1 Sufficient to Increase Glucose Uptake?
The ability of E4orf1 expression alone, without Ad36 infection, to increase glucose
uptake was determined in 3T3-L1 preadipocytes and adipocytes. V5-Ad36 E4orf1 or
Null plasmids were transfected into preadipocytes and differentiated adipocytes, and
a 2DG uptake assay was conducted. In preadipocytes, basal glucose uptake was
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greater in E4orf1 transfected cells compared to cells transfected with Null vector by
about 2-fold (p<0.0001) (Figure 16A), and E4orf1 did not add to the effect of insulin
in preadipocytes. In adipocytes, on the other hand, glucose uptake was significantly
more in the basal and insulin stimulated conditions (p<0.0001 and = 0.003,
respectively)(Figure 16B).

This is perhaps because adipocytes are more responsive

to respond to insulin than preadipocytes.
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Figure 16. Glucose Uptake in 3T3-L1 After E4orf1 Transfection. 2DG uptake in
3T3-L1 after transfection with V5-Ad36 E4orf1 or Null plasmids. A) 2DG glucose
uptake in 3T3-L1 preadipocytes transfected with either V5-Ad36 E4orf1 or Null
vector, treated with or without 100 nM insulin. E4orf1 transfection increased basal
glucose uptake compared to the Null vector transfected group (p=0.0001). Data
expressed as mean + SD. B) 2DG glucose uptake in 3T3-L1 adipocytes transfected
with either V5-Ad36 E4orf1 or Null vector, treated with or without 100 nM insulin.
E4orf1 transfection increased basal and insulin stimulated glucose uptake compared
to the Null vector transfected group (p=0.0001 and 0.003, respectively). Data
expressed as mean + SD.

The ability of E4orf1 to increase cellular glucose uptake in a dose dependent manner
was next determined. The E4pTRE cell line was exposed to varying levels of E4orf1
expression in response to 0, 750, or 1,000 ng/mL Doxycycline for 24 hr and glucose
uptake was determined. Compared to the E4orf1 cell line without Doxycycline
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treatment, treatment with both 750 and 1,000 ng/mL Doxycycline for 2 levels of
E4orf1 expression induces greater glucose uptake (p=0.05 and p=1.8*10-6,
respectively), although this relationship is only statistically significant for E4orf1
with 1,000ng/mL Doxycycline after a Bonferroni correction for multiple comparisons
(Figure 17). Glucose uptake in E4orf1 with 1,000 ng/mL Doxycycline is also
significantly more than in the pTRE empty vector cell line (p=2.6*10-7). Therefore, a
trend in glucose uptake in response to E4orf1 expression is evident, and E4orf1 is
able to induce glucose uptake in two different systems (transfection and inducible).
3A.3 The Effect of E4orf1 on DNL in 3T3-L1 Preadipocytes
DNL was determined in 3T3-L1 transfected with V5-Ad36 E4orf1 and Null plasmids.
Compared to transfection with Null vector, E4orf1 transfection significantly increased
DNL from [14C]-Glucose in the basal and insulin stimulated conditions. (p=0.038
for both) (Figure 18). Thus not only does E4orf1 increase glucose uptake, but it also
promotes conversion of that glucose to lipids.
3A.4 Cell Signaling Involved in E4orf1 Induced Glucose Uptake in 3T3-L1
3A.4.1 Total and Isoform-specific Ras Activation by E4orf1
Ad36 activates Ras, and requires Ras for increasing cellular glucose uptake (188).
We therefore hypothesized that E4orf1 may be sufficient to activate Ras. The
E4pTRE cell line was used to determine Ras activation, after 24 hours of E4orf1
expression in response to 1,000 ng/mL Doxycycline. The E4pTRE cell line had
significantly more total and activated Ras compared to pTRE exposed to 1,000 ng/mL
Doxycycline (p=0.04 and 0.01, respectively)(Figure 19), and specifically
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Figure 17. Glucose Uptake in E4pTRE or pTRE Cell Lines. Dose response in
2DG uptake in E4pTRE and pTRE cell lines. pTRE cell line was used as a baseline
control, and the E4pTRE cell line was exposed to varying levels of E4orf1 expression
in response to 0, 750, or 1,000 ng/mL Doxycycline treatment for 24 hr. pTRE was
also treated with 100 nM insulin as a positive control for the assay, and 1,000 ng/mL
Doxycycline (n=2) as a control for Doxycycline treatment. E4pTRE exposed to
1,000 ng/mL Doxycycline had significantly greater glucose uptake compared to
E4pTRE exposed to 0 ng/mL Doxycycline, and compared to the pTRE cell line
(p=1.8*10-6 and 2.6*10-7). Data expressed as Mean + SD.
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Figure 18. DNL in 3T3-L1 Following E4orf1 Transfection. DNL following
transfection of 3T3-L1 preadipocytes with V5-Ad36 E4orf1 or Null plasmids,
with or without 100 nM insulin. Data expressed as pmol [14C]-glucose in the
lipid fraction divided by protein content, Mean + SD. DNL is significantly
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greater with E4orf1 transfection in the basal and insulin stimulated condition
(p=0.04 for both).

the H-Ras isoform was activated (p=0.01). While the total N-Ras isoform
abundance was up-regulated by E4orf1 (p=0.0001), N-Ras was not significantly
activated by E4orf1. The K-Ras isoform was not easily detectable in 3T3-L1, and
no change in abundance or activation was apparent (data not shown). Therefore,
H-Ras may be the predominant form activated by E4orf1 for its downstream
actions.
3A.4.2 The Effect of Ad36 and E4orf1 on Cell Transformation
Ras, an oncogene in certain cases, is activated by Ad36 and E4orf1. Therefore, to
determine if Ad36 or E4orf1 induce cell transformation, a soft agar anchorageindependent growth assay was performed for E4orf1 constitutive expressing and
Ad36 infected 3T3-L1. A549 bronchial carcinoma cells served as a positive
control, and formed colonies within the agar as expected. Neither Ad36 infection
or constitutive E4orf1 expressing cells developed colonies, even 21 days post
plating, indicating both are unable to transform 3T3-L1 (Figure 20).
3A.4.3 The Effect of E4orf1 on Distal Insulin Signaling, Adiponectin, and
Glut1
Ad36 can up-regulate distal insulin signaling (PI3K and Glut4) despite impaired
proximal IR and IRS-1/2 signaling(188). Because E4orf1 is sufficient to increase
glucose uptake, we hypothesized that it may be sufficient to up-regulate distal
insulin signaling. The inducible E4orf1 expressing 3T3-L1 cell line was exposed
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Figure 19. Ras Activation by E4orf1. E4pTRE or pTRE cell lines were exposed to
E4orf1 for 24 hr in response to 1,000 ng/mL Doxycycline. A pull down for the Ras
binding domain of Raf was conducted for the detection of activated Ras (Act) and
before the pull down, 6% of the total lysate was loaded for normalization to total Ras
(Tot). A) WB of Total, H-Ras, and N-Ras. B) Densitometry data for total Ras
normalized to β-actin, expressed as Mean + SD. E4pTRE clone has significantly
more total Ras than pTRE (p=0.04) C) Densitometry for activated Ras, expressed as
the ratio of activated to normalized total Ras, Mean + SD. E4pTRE clone has
significantly more total Ras activation than pTRE (p=0.01)D) Densitometry for
activated H-Ras, expressed as the ratio of activated H-Ras to normalized total H-Ras.
E4pTRE clone has significantly more H-Ras activation than pTRE (p=0.01)
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to 1,000 ng/mL Doxycycline, and protein was harvested 24 hours later to determine
AKT activation and Glut4 abundance. E4orf1 expression increases both AKT
phosphorylation (p=3.5*10-5), which is indicative of PI3K activity, and Glut4
abundance (p=0.05) (Figure 21). This may be the pathway by which E4orf1 increases
glucose uptake, and this is especially likely since this pathway is required for Ad36induced increase in cellular glucose disposal.
3A.4.4 Effect of E4orf1 on Adiponectin and Inflammatory Cytokine mRNA
Expression
Ad36 may also mediate its favorable effects on systemic glucose metabolism
through adiponectin(190). Adiponectin, in addition to its favorable effects on
glucose metabolism, is anti-inflammatory in adipose tissue (68). Early genes of
adenoviruses are also known to be anti-inflammatory. If E4orf1 is sufficient to
increase adiponectin levels and decrease inflammatory cytokine expression in
adipose tissue, this may benefit the metabolic profile of adipose tissue. To
determine the effect of E4orf1 on adiponectin and inflammatory cytokines, the
E4pTRE and pTRE cell lines were exposed to 1,000 ng/mL Doxycycline and
RNA was harvested 24 hours later. Real-time PCR was used to quantitate
adiponectin and inflammatory cytokine mRNA expression levels. E4orf1
significantly increased adiponectin expression (p=0.05), and suppressed MCP-1,
MCSF, and TLR-4 expression (p=4.9*10-4, 1.43*10-7, and 7.5*10-5, respectively)
(Figure 22). These data suggest that E4orf1 may increase adipose tissue
adiponectin levels and suppress inflammation.
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Figure 20. Soft Agar Anchorage Independent Growth Assay. Soft agar colony
formation. Representative 10X images of colony formation, Day 21 post plating.
A549 developed colonies, whereas Ad36, E4orf1 constitutives, and Mock infected
3T3-L1 did not.
Table 3. Percent of Viable Cells that Formed Colonies in Soft Agar Assay. Mean + SD.
Day 7

Day 14

Day 21

A549

11.3+9.1

9.2+2.1

9.9+8.6

Ad36

0

0

0

Mock

0

0

0

E4orf1

0

0

0
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3A.5 Can E4orf1 Induce Glucose uptake Independent of PPARγ?
E4orf1 induces adipogenesis and up-regulates PPARγ similar to the action of TZDs.
We therefore determined if glucose uptake induced by E4orf1 requires PPARγ. MEF
PPARγ KO cells were transfected with V5-E4orf1 and Null-V5 plasmids. Even in the
absence of PPARγ, E4orf1increased glucose uptake by nearly 2-fold (p=2.5*10-5)
(Figure 23). Considering PPARγ is required for preadipocyte differentiation, this
indicates that E4orf1 does not require adipocyte differentiation for increasing glucose
uptake, and that the two effects may be uncoupled if the molecular mechanism can be
further elucidated.
3B. The Effect of E4orf1 on Hepatic Glucose and Lipid Metabolism
3B.1 The Effect of E4orf1 on Glucose Output in Hepatocytes
Uncontrolled hepatic glucose output contributes to hyperglycemia in insulin
resistance. If E4orf1 is able to suppress glucose output, that may explain improved
glycemic control in Ad36 infected animals. Glucose output by HepG2 cells was
determined following transfection with V5-Ad36 E4orf1, V5-Ad2 E4orf1, and Null
plasmid. In serum free, glucose free conditions, insulin suppressed glucose output as
expected. Ad36 E4orf1 markedly suppressed glucose output in both the basal and
insulin stimulated condition (p=7.3*10-7 and 0.002, respectively) (Figure 24A),
whereas Ad2 E4orf1 did not.

Interestingly, E4orf1 also suppresses glucose output in

the presence of cAMP and dexamethasone (gluconeogenic stimulators), in basal and
insulin stimulated conditions (p=0.00001 and 0.003, respectively) (Figure 24B).
Glucose output was also determined in primary mouse hepatocytes transfected with
V5-E4orf1 or Null plasmids in serum starved condition, and when challenged with
107

pTRE

A.

E4pTRE

Glut4

AKT

p-AKT (ser308)

Glut 1

Adiponectin
*

0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

1.5
1
0.5
0

pTRE

Adiponectin Normalized
to Beta Actin

*

2
pAKT/total AKT

Glut4 normalized to
Beta Actin

B.

E4pTRE

pTRE

*

3

0.4
Glut1 normalized to
beta actin

2.5
2

1.5
1

0.5
0
pTRE

*

0.3
0.2
0.1
0
pTRE

E4pTRE

E4pTRE

E4pTRE

Figure 21. Effect of E4orf1 on Distal Insulin Signaling, Glut1 and Adiponectin.
Signaling in E4pTRE and pTRE cell lines. A) WB of Glut4, total and phosphorylated
AKT, adiponectin, and Glut1 in E4pTRE and pTRE cell lines, both treated with 1,000
ng/mL Doxycycline. B) Densitometry for Glut4, AKT, Glut1, and adiponectin. Glut4,
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Glut1, and adiponectin are normalized to β-actin, and AKT activation is expressed as the
ratio of phosphorylated AKT to total AKT. Expressed as the Mean + SD. The E4orf1
expressing cell line had significantly greater abundance of Glut4 (p=0.05), Glut1
(p=0.01), adiponectin (p=0.006) and phosphorylated AKT (3.5*10-5) compared to the
pTRE empty vector control.

100 nM glucagon. In the serum and glucose starved condition, Ad36 E4orf1 and Ad2
E4orf1 both suppressed glucose output compared to the Null vector (p=0.0001 and
0.0003, respectively) (Figure 25A). When treated with glucagon, however, only
Ad36 E4orf1 was sufficient to suppress glucose output from primary hepatocytes
(p=0.02) (Figure 25B). Ad2 E4orf1 was not able to suppress glucose output from
human HepG2 cells; therefore, E4orf1 of Ad36 may be a stronger suppressor of
glucose output compared to Ad2 E4orf1.
3B.2 The Effect of E4orf1 on Hepatic Lipid Accumulation
3B.2.1 The Effect of E4orf1 on Hepatic Fatty Acid Oxidation
Ad36 attenuates high fat diet induced steatosis, but the mechanism is unknown. We
hypothesized that E4orf1 may alter hepatic lipid metabolism, resulting in less hepatic
lipid storage. First, palmitate oxidation was measured in HepG2 transfected with
Ad36 E4orf1, Ad2 E4orf1, or Null plasmid. Both complete oxidation and partial
[14C]- palmitate were measured. Although total (complete + partial) oxidation did
not differ between the Null and E4orf1 transfected cells (Figure 26A), the amount of
completely oxidized palmitate was significantly higher in Ad36 E4orf1 and Ad2
E4orf1 transfected cells (p=0.004 and 0.01, respectively) (Figure 26B). Because total
oxidation is not significantly altered by E4orf1, we hypothesized that the ratio of
complete to partial oxidation may differ. After Ad36 E4orf1, Ad2 E4orf1, and null
vector transfection, complete (CO2) and partial (acid soluble metabolites) were
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Figure 22. Effect of E4orf1 on Adiponectin and Inflammatory Cytokine mRNA
Expression. Inflammatory cytokine and adiponectin mRNA expression in E4pTRE and
pTRE cell lines. E4pTRE and pTRE cell lines were exposed to 24 hr E4orf1 expression
in response to 1,000 ng/mL Doxycycline. Normalized mRNA expression in E4orf1pTRE
and pTRE empty vector control inducible stable cell lines, Mean + SD. A) Adiponectin
expression is greater in E4pTRE than pTRE cell line (p=0.05), B) MCP-1 ( p=4.9*10-4),
C)MCSF, (p=1.43*10-7, and D) TLR-4 (p=7.5*10-5) had lower expression in E4pTRE
compared to pTRE.

measured. The percent partial oxidation was significantly lower in Ad36 E4orf1 and
Ad2 E4orf1 transfected cells compared to the Null vector (p=0.002 for both) (Figure
27A). In addition, E4orf1of both viruses significantly decreases the ratio of
incomplete to complete oxidation (p=0.003 and 0.007, respectively) (Figure 27B).
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This indicates that E4orf1 of Ad36 and Ad2 may up-regulate mitochondrial oxidation,
and minimize partial oxidation that can lead to the buildup of intermediate
metabolites.
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Figure 23. Glucose Uptake in MEF PPARγ KO Cells Following E4orf1
Transfection. Glucose uptake in MEF PPARγ KO cells following E4orf1
transfection. E4orf1 significantly increases glucose uptake (p=2.5*10-5), even
without PPARγ. Mean + SD.
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Figure 24. Glucose Output by HepG2 Transfected with E4orf1. Glucose output
by HepG2 cells following Ad36 E4orf1, Ad2 E4orf1, or Null Vector transfection. A)
Glucose output in serum and glucose starved condition, w/ and w/o 10 nM insulin,
expressed as fold change relative to Null. Mean + SD (fold change because data from
two separate experiments are combined). Ad36 E4orf1 suppresses glucose output
compared to basal and insulin stimulated Null transfected cells (p=7.3*10-7 and
0.002, respectively), whereas Ad2 E4orf1 does not. B) Glucose output in HepG2
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stimulated with gluconeogenic cAMP (1 mM) (C) and Dexamethasone (500 nM) (D)
in the absence or presence of insulin (I). Expressed as Mean mM glucose per mg of
protein, + SD.

3B.2.2 The Effect of E4orf1 on Hepatic De Novo Lipogenesis
A DNL assay determined if E4orf1 suppresses synthesis of lipid from glucose in
HepG2. HepG2 were transfected with Ad36 E4orf1, Ad2 E4orf1, or Null plasmid
and exposed to [14C]-glucose for determination of conversion of glucose to lipid.
Ad-36 E4orf1, but not Ad2 E4orf1, significantly suppressed DNL in HepG2 cells
(p=0.01) (Figure 28).
3B.2.3 The Effect of E4orf1 on Hepatic ApoB Secretion
Lipid export was determined in HepG2 cells transfected with Ad36 E4orf1, Ad2
E4orf1, or Null vector. We hypothesized that E4orf1 may up-regulate export of
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Figure 25. Glucose Output from Primary Hepatocytes Transfected with E4orf1.
Glucose output in primary mouse hepatocytes after transfection with Ad36 E4orf1,
Ad2 E4orf1, or Null vector. A) Glucose output by primary hepatocytes serum and
glucose starved for 1.5 hours, expressed as mean mM glucose per mg protein + SD.
Ad36 E4orf1 and Ad2 E4orf1 suppressed glucose output compared to Null vector
(p=0.0001 and 0.0003, respectively). B) Glucose output in primary hepatocytes
treated with 100 nM glucagon in serum free, glucose free media for 1.5 hr. Only
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Ad36 E4orf1 suppressed glucose output in this condition (p=0.02). Expressed as
mean mM glucose per mg protein, + SD.
lipid, which may contribute to lower hepatic lipid storage observed in Ad36
infected mice. ApoB secretion is indicative of VLDL export, therefore, an ELISA
determined ApoB levels in conditioned media following transfection. Ad36
E4orf1 significantly up-regulated ApoB secretion into media (p=0.01) (Figure
29), whereas Ad2 E4orf1 does not.
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Figure 26. Fatty Acid Oxidation in HepG2 Transfected with E4orf1.
HepG2 fat oxidation after E4orf1 transfection. HepG2 [14C]- palmitate
oxidation following Ad36 E4orf, Ad2 E4orf, or Null vector. A) Total
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palmitate oxidation (complete + partial), expressed as pmol palmitate/3hr/mg
protein, Mean + SD. No significant differences. B).Complete palmitate
oxidation, expressed as pmol palmitate/3hr/mg protein mean + SD. Ad36
E4orf1 and Ad2 E4orf1 have significantly greater complete oxidation of
palmitate than Null (p=0.004 and 0.01, respectively.
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Figure 27. Partial and Complete Fat Oxidation in HepG2 Transfected with
E4orf1. HepG2 complete and partial fat oxidation after E4orf1 transfection After
Ad36 E4orf1, Ad2 E4orf1, or Null transfection, change in percentage of complete and
partial [14C]-palmitate oxidation. A) Percent partial palmitate oxidation, expressed
as fold change in percent, mean + SD, compared to Null. Ad36 E4orf1 and Ad2
E4orf1 have significantly lower percent partial oxidation (p=0.002, respectively). B)
Ratio of acid soluble metabolites (incomplete oxidation) to CO2 (complete oxidation),
expressed as mean fold change relative to null + SD. Ad36 E4orf1 and Ad2 E4orf1
have significantly lower ratios compared to Null (p=0.003 and 0.007, respectively).
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Figure 28. DNL in HepG2 Transfected with E4orf1. DNL in HepG2
following E4orf1 transfection. HepG2 cells were transfected with Ad36 E4orf1,
Ad2 E4orf1, or Null vector. Expressed as mean fold change in pmol [14-C]glucose/mg protein relative to Null, + SD. Two separate experiments were
combined. Ad36 E4orf1, but not Ad2 E4orf1, significantly decreases DNL
compared to Null (p=0.01).
*

ug apoB/dL/mg prot

1.200
1.000
0.800
0.600
0.400
0.200
0.000
V5

Ad36 E4orf1

Ad2 E4orf1

Figure 29. ApoB Secretion from HepG2 Transfected with E4orf1.
HepG2 ApoB secretion following Null vector (V5), Ad36 E4orf1, and
Ad2 E4orf1 transfection. ApoB secretion in conditioned media from
HepG2 transfected with Ad36 E4orf1, Ad2 E4orf1, or Null vector.
Expressed as mean µg ApoB/dL/mg protein, + SD. Ad36 E4orf1
increased ApoB secretion into media compared to the Null vector
(p=0.01).
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Chapter 4. Discussion
4.1 Overview of Findings
Ad36 infection is an excellent tool for the study of metabolically healthy obesity, and its
anti-diabetic effects were demonstrated through three separate approaches. First, an association
of Ad36 with better glycemic control in humans was established. In Caucasian, African
American, and Hispanic children and adolescents, Ad36 seropositivity is associated with better
glycemic control compared to the uninfected population. Next, to determine the potential
mechanism, several in vitro experiments were conducted. Also, adipose tissue and liver from
Ad36 infected C57BL/6J mice on chow and HFD were analyzed for changes in morphology
following Ad36 induced improvement of glycemic control. Ad36 clearly up-regulates
adipogenesis in hASC, and induces DNL and preferential fat oxidation in 3T3-L1. Ad36
increased the proportion of small adipocytes in chow fed mice and the proportion of larger
adipocytes in mice on HFD. In both animal models, Ad36 did not affect macrophage infiltration.
Both Ad36 and Ad2 increased adipose tissue vascularization in both mouse models, however,
neither virus was able to induce angiogenesis in human adipose tissue or directly in endothelial
cells. Finally, the E4orf1 protein of Ad36 was identified as necessary and sufficient for
enhancing glucose disposal. Changes in glucose and lipid metabolism by viral protein E4orf1
were determined in 3T3-L1 preadipocytes and adipocytes, and HepG2 hepatocytes. In 3T3-L1,
E4orf1 was sufficient and necessary to induce glucose uptake, and was sufficient to activate the
same Ras-PI3K-Glut4 pathway employed by Ad36 for glucose uptake. Glucose uptake induced
by E4orf1 was not dependent on PPARγ. In addition, E4orf1 up-regulated adiponectin and
suppressed inflammatory cytokine production. In hepatocytes, E4orf1 suppressed glucose output
and up-regulated fatty acid oxidation, lipid export, and suppressed DNL. Therefore, Ad36 is
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likely to implement its favorable effect on glucose and lipid metabolism through its E4orf1
protein, which is a promising candidate for anti-diabetic therapy. These findings are discussed
more in detail herein.
4.2 Ad36 Seropositivity and Improved Glycemic Control in Humans
Identifying an association between Ad36 seropositivity and glycemic control is an
imperative first step towards harnessing any beneficial effect of the virus, since the phenomenon
must be relevant in humans. It is noted that an association does not necessarily imply causation.
Nevertheless, as reported in adults(188; 190), it is encouraging that seroprevalence of Ad36 in
children and adolescents from several ethnicities is associated with lower fasting glucose,
insulin, and HOMA IR independent of body fatness, gender, and familial relationship. Ad36 is
therefore associated with improved glycemic control in a diverse range of genetic backgrounds.
Hispanic children and adolescents are especially prone to developing insulin resistance (251;
252) and may have a stronger genetic predisposition towards metabolic complications. Despite
this, Ad36 infection still demonstrates improved glycemic control in this population.
Ad36 seropositivity was also associated with lower intrahepatic lipid content in
prepubertal children. This finding parallels the observation that Ad36 is associated with lower
prevalence of NAFLD in adults (190; 253). Ad36 is therefore likely to prevent hepatic lipid
accumulation in humans, which may contribute to the prevention of insulin resistance despite
increased adiposity associated with infection. Specifically, hepatic lipid is associated with
insulin resistance independent of body fatness (159; 171-175), therefore, the effect of Ad36 on
hepatic lipid accumulation may improve glycemic control despite its effects on adiposity.
This association of improved glycemic control in Ad36 seropositive children and
adolescents parallels what has been demonstrated in adults (188; 190). Antibody prevalence
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does not indicate the time of infection, so the dynamics of improvement in glycemic control
following infection are unknown. It is possible Ad36 infects and induces a lasting change in
metabolism before clearance by the immune system, which is referred to as a “hit and run”
effect. For example, gammaherpesvirus induces oncogenesis which persists long after infection
is cleared (254). Alternatively, active Ad36 infection may persist at low level or remain latent
and intermittently reappear to induce a change in glycemic control over time. Because
adenoviral infections are common in childhood, however, and the effect of Ad36 is consistent
from childhood to adulthood, it is likely that changes in glycemic control may be long-term
following initial infection. Longitudinal studies following Ad36 infection are needed in the
future to determine these dynamics.
Many infections have been linked to insulin resistance. “Pathogen load’, a score based on
presence of herpes simplex virus (HSV)-1, HSV-2, enteroviruses, and Chlamydia pneumonia, is
associated with insulin resistance after controlling for age and BMI (255). This relationship was
especially evident with Chlamydia pneumonia infection and enterovirus infection, and the
authors suggest infection of multiple pathogens may lead to consistent low-grade inflammation
that induces insulin resistance(255). Hepatitis C virus (HCV) is also associated with insulin
resistance (256). Certain genotypes of HCV impair hepatic lipid export (257) and change
hepatic lipid metabolism to promote viral replication(258). Parasitic Trypanosoma cruzi has a
high tropism for adipose tissue, and alters inflammation and adipokine secretion, resulting in
insulin resistance (259). Alternatively, lymphocytic choriomeningitis virus infection improves
diabetes in mice (260; 261). Certain infections are evidently sufficient to alter inflammation,
adipose tissue, and hepatic factors and in turn induce insulin resistance. It is therefore feasible
that infectious agents may be capable of long-term changes in metabolism. In the case of Ad36
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infection, adipose tissue and hepatic metabolism may be altered favorably for improvement of
insulin sensitivity.
Because adipose tissue plays a critical role in mediating inflammation and response to
infection, it is not surprising that infection may alter adipose tissue metabolism and insulin
sensitivity. Several adipokines, especially adiponectin and leptin, mediate the immune response
to infection (262). The function of macrophages and preadipocytes is so closely related that
preadipocytes can convert to macrophage-like cells (263; 264). Adipose tissue has demonstrated
antimicrobial activity, and the stromal vascular fraction of adipose tissue, which includes
preadipocytes and macrophages, displays phagocytic activity(265). Macrophage number
generally increases in response to infection. Therefore, if preadipocytes have macrophage
function, it can be hypothesized their number may increase in response to infection as well,
resulting in expansion of adipose tissue mass.
Although associations have been established, it is unclear if infections such as Ad36 play
a causative role in improving glycemic control in humans. While establishing an association is
an important first step, it is difficult to unequivocally establish causation. Several challenges are
presented in the study of such a phenomenon. First, obesity and insulin resistance have insidious
onset, and can develop over time. Linking a given factor to a causative role during this process
can be challenging as a result. Also, many factors influence glycemic control. If an agent such
as Ad36 is protective against the development of insulin resistance, controlling for all factors that
may influence glycemic control is difficult. Identifying a perfect control group is therefore,
challenging, since the glycemic control of the uninfected population could be influenced by
many other factors. Lastly, definitively establishing a causative role of Ad36 in protection from
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insulin resistance is not possible in humans because ethically, humans cannot be experimentally
infected.
An alternative approach must be taken to establish a relationship between Ad36 and
glycemic control in humans. Epidemiological associations, followed by prospective
epidemiological studies, must first demonstrate the relevance of a particular phenomenon. The
mechanism can be established through animal studies, and congruence between human and
animal data can serve as confirmation of the mechanism. For instance, establishing the
relationship between smoking and lung cancer, was accomplished in this manner. The Center for
Disease Control (http://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm#1) and National
Cancer Institute (http://www.cancer.gov/cancertopics/factsheet/Tobacco/cessation#r1) state that
smoking causes cancer, although all human studies on this topic are epidemiological. Extensive
albeit indirect evidence has made a compelling argument in favor of a causative role for smoking
in lung cancer. A similar approach will be needed to unequivocally determine any protective
effect of Ad36 infection against obesity induced insulin resistance.
4.3 Adipose Tissue and Hepatic Determinants of Ad36 Induced Insulin Sensitivity
To determine how Ad36 may improve glycemic control, a series of in vitro and post-hoc
studies of tissue from previous animal experiments were conducted. Changes in adipocyte
metabolism, and adipose tissue and liver morphology were determined in response to Ad36
infection.
4.3.1 Ad36 and Adipocyte Metabolism- In vitro Experiments
First, hASC were established as a model for the study of Ad36 induced differentiation of
human preadipocytes. Ad36 successfully infected and spread in hASC, suggesting Ad36 may
establish an active infection in human adipose tissue. Ad36 up-regulated differentiation and lipid
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accumulation in hASC (202), even in the absence of adipogenic inducers, and therefore may
induce preadipocytes to differentiate independent of mechanisms that normally regulate
adipocyte differentiation such as nutrient and hormonal signals. Even with adipogenic induction,
Ad36 infected hASC accumulated more lipid at a faster rate than uninfected control cells.
Agents that induce adipocyte differentiation, such as TZDs, improve insulin sensitivity (130).
The effect of Ad36 on adipogenesis has now been elucidated in 3T3-L1 and hASC (200; 247).
Adipogenesis is one potential mechanism for Ad36 induced improvement in insulin sensitivity,
in a manner similar to TZD treatment.
In 3T3-L1, Ad36 infection is not replicative, yet has an effect on adipogenesis(200).
Signaling changes induced by Ad36 following cell entry in 3T3-L1 may act synergistically with
those induced by confluence, since Ad36 induced greater lipid accumulation when cells were
infected at confluence(247). Normally, confluence initiates 3T3-L1 cell cycle arrest, followed
by 1-2 days of clonal expansion consisting of at least one mitotic division, which is then
followed by an unusual state of growth arrest called GD that defines terminal cell differentiation,
and begins the differentiation process (266; 267). Growth arrest is mediated by cAMP and
PPARγ (267; 268), and Ad36 E4orf1 increases cAMP and PPARγ(203). Although Ad36
infection is not replicative in 3T3-L1, early viral genes are still expressed, and viral gene
expression peaks 2-4 days post infection and only persists at very low levels up to day 7 post
infection (200). Therefore, infection of 3T3-L1 at confluence probably results in peak E4orf1
expression, and thus peak activation of PPARγ and cAMP, may coincide just as cells are
undergoing GD phase and initiating differentiation. This would explain the synergistic effect of
infection and confluence and maximal lipid accumulation. Infecting cells 1-2 days prior to
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confluence, on the other hand, may cause peak E4orf1 expression to be induced before this
critical phase, and hence yield relatively lower lipid accumulation.
Adequate adipose tissue expansion can promote clearance of glucose and lipid during
positive energy balance, and this process is important to prevent increased systemic free fatty
acids and hyperglycemia (119). Ad36 increases LPL expression and translocation in hASC
(202), suggesting it increases lipid clearance from circulation. In addition, Ad36 up-regulates
glucose uptake in adipose tissue (188). Up-regulation of DNL in 3T3-L1 by Ad36 indicates
glucose taken in cells may be converted into lipid, perhaps during the conversion of
preadipocytes to adipocytes. This process would explain improved glucose clearance despite
increased adiposity following Ad36 infection. Previous in vivo animal studies have also
suggested Ad36 induces greater adipogenesis and DNL in response to infection (197). Although
the contribution of adipose tissue DNL to lipid stores has been unclear in humans, it has been
recently demonstrated that human adipocytes have the capacity for DNL, even if the overall
contribution to lipid stores is minor (269; 270). Over a 9 week period, DNL can account for 20%
of newly deposited triglyceride in human adipose tissue (270). Because human adipose tissue
has the capacity for DNL, Ad36 should be tested in the future as an agent which may increase
glucose clearance through up-regulation of adipogenesis and DNL in humans.
Adipocyte substrate oxidation was also altered by Ad36 infection, which induced
preferential fatty acid oxidation in 3T3-L1. Interestingly, TZD treatment also increases fatty
acid oxidation in adipocytes (271). Increased fatty acid oxidation may improve systemic
clearance of free fatty acids, which is one proposed mechanism for the effect of TZD(272). In
general, TZDs increase whole body fatty acid oxidation(126) and seem to improve mitochondrial
dysfunction that is characteristic of insulin resistance. In fact, TZD treatment increases
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mitochondrial biogenesis and uncoupling protein-1 expression in white adipose tissue (273), both
of which promote fatty acid oxidation. Ad36 may have a similar effect on fatty acid oxidation
due to upregulation of PPARγ and adipocyte differentiation, and energy requirements for viral
replication.
Of note, Ad36 induces these phenomena despite only partial infection of cells in a given
group, which biases against the virus for any given effect. Only a certain percentage of hASC
and 3T3-L1 are infected by Ad36, and an effect is observed even though the remaining
uninfected cells are theoretically similar to those of the control group. Overall, in vitro studies
indicate Ad36 increased adipogenesis, DNL, and fatty acid oxidation, which may collectively
improve adipose tissue expansion and lipid and glucose clearance, thereby improving glycemic
control.
4.3.2 Ad36 Modulation of Adipose Tissue and Liver Morphology
In vivo, Ad36 may also alter adipose tissue morphology and the response of adipose
tissue to a high fat diet. Cell size, macrophage infiltration, and vascularization were determined
in response to infection in both C57BL/6J chow and high fat fed models through histochemical
techniques.
Changes in adipocyte cell size are an indication of adipose tissue remodeling. Small
adipocytes are usually a sign of hyperplasic adipose tissue expansion, and thus a larger capacity
for adipogenesis and improved insulin sensitivity(122; 129). Larger adipocytes are usually
indicative of adipocyte hypertrophy, which is associated with insulin resistance (151-156).
However, both hyperplasia and hypertrophy can occur at the same time in response to positive
energy balance, and the range of adipocyte size distribution is subsequently increased (274).
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Interestingly, the hyperplastic response of adipose tissue to a high fat diet is strain dependent in
mice, and an interaction between genes and diet on the hyperplastic response to positive energy
balance is apparent (274). Therefore, other factors may also influence the relationship between
cell size distribution and insulin resistance. While in some models small adipocyte size is
associated with insulin sensitivity (68; 275), in others models large adipocytes are associated
with insulin sensitivity(130; 276) as discussed in detail below.
In chow fed C57BL/6J mice, Ad36 increased glycemic control and the proportion of
small adipocytes compared to Mock and Ad2 infected mice in retroperitoneal fat pads. Small
adipocytes are a marker of adipogenesis, and characterize adipose tissue of several transgenic
animal models of insulin sensitive adiposity (68; 122; 125). Small adipocytes have greater
adiponectin secretion (122; 158), and this is congruent with previous observations that Ad36
increases adiponectin abundance in human adipose tissue. Therefore in normal healthy mice,
Ad36 may improve adipose tissue metabolic profile by enriching the population of small,
adiponectin secreting adipocytes.
In mice on HFD, on the other hand, Ad36 attenuate dysglycemia and increased the
proportion of large adipocytes in epididymal fat compared to Mock and Ad2 infected animals.
Normally large adipocytes are associated with inflammation, decreased secretion of adiponectin,
increased insulin resistance, impaired glucose uptake and increased lipolysis (151-156). Some
but not all parameters associated with large adipocyte size were apparent in Ad36 infected
adipose tissue. Proximal insulin signaling is impaired in adipose tissue of infected mice,
suggesting adipose tissue is more insulin resistant than Mock and Ad2 infected mice(190). In
addition, Ad36 increased TNF-α expression in adipose tissue, suggesting inflammation is
increases in adipose tissue (unpublished observations). Distal insulin signaling is not impaired,
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however, and increased AKT phosphorylation, Glut 1 and Glut4 abundance suggest glucose
uptake is not impaired in Ad36 infected adipose tissue. In addition, adiponectin abundance is
higher in Ad36 infected tissue. Also, considering Ad36 activates LPL and lipid uptake, it is
unlikely that lipolysis is increased in Ad36 infected tissue. This suggests that despite large
adipocyte size, Ad36 may increase glucose uptake, inhibit lipolysis, adiponectin secretion. The
differences in responses to Ad36 in the two mice models may also be due to differences in
adipose tissue depots or durations post infection.
Although the hypertrophic response of adipose tissue to Ad36 is somewhat
counterintuitive, considering most insulin sensitive models have smaller adipocytes, it is similar
to the response of Collagen VI knockout mice on a high fat diet, which have enlarged adipocytes
but markedly improved insulin sensitivity (130).

In addition, adequate storage of lipid

prevented systemic insulin resistance in Collagen VI knockout mice (130). Similarly, adipose
tissue expansion in this model may accommodate large adipocytes and prevent hypoxia and
inflammation that otherwise act as a signal for remodeling when storage capacity reaches an
upper threshold storage capacity (130).
Exposure to TZDs for a short term period of 8 days is sufficient to induce adipocyte
hypertrophy and improve lipid storage and insulin resistance, and it has been proposed that one
short term dose may be sufficient to induce lasting change in insulin sensitivity (276). This
approach to TZD treatment mirrors the idea of a “hit and run” hypothesis of Ad36 infection.
Adipocyte hypertrophy induced by Ad36 despite a high fat diet therefore may improve insulin
sensitivity in a similar manner, and increased LPL and lipid uptake by Ad36 may simply increase
adipocyte threshold size. This would improve systemic fatty acid clearance. Alternatively,
Ad36 infection may resist normal insulin resistance mechanisms associated with adipocyte
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hypertrophy through an alternative Ras mediated glucose uptake pathway. Regardless, Ad36
seems to be a factor that alters the relationship between insulin sensitivity and adipocyte size in
combination with a high fat diet.
The role of adipose tissue macrophage infiltration and inflammation in Ad36 induced
improvement in glycemic control is less clear. In chow fed C57BL/6J mice, macrophage
infiltration is not significantly different in Ad36 compared to Mock infected mice, whereas
macrophage infiltration is increased in Ad2 infected tissue. In the HFD model, groups show no
significant differences in macrophage infiltration, suggesting a high fat diet may overwhelm any
effect of either virus on macrophage infiltration. Suppression of macrophage infiltration does
not appear to be a major contributor to improved insulin sensitivity following infection in these
mouse models. In fact, chronic infection of Ad36 in combination with high fat diet increased
TNF-α expression in adipose tissue. TNF-α expression inhibits proximal insulin signaling
through serine phosphorylation of IRS-1 (86; 277). This may explain the inhibition of proximal
insulin signaling induced by Ad36 which may be due to up-regulation of TNF-α (190). It is
both interesting and of potential therapeutic value that Ad36 improves glycemic control and
glucose clearance in adipose tissue despite inflammation and inhibition of proximal insulin
signaling.
Lastly, the effect of Ad36 on adipose tissue vascularization was determined in C57BL/6J
mice. In both the chow fed and high fat fed mice, Ad36 and Ad2 infection increased adipose
tissue vascularization relative to Mock, but only Ad36 improved glycemic control. An increase
in vascularization is therefore likely to be an effect of infection, and may not contribute to
glycemic control in this model. HIF-1α mRNA expression is up-regulated by both viruses in
adipose tissue in the chow fed mice (unpublished observations). Ad36 increases H-Ras
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activation, and H-Ras is known to mediate HIF1α activation and its downstream effectors
independent of hypoxia (278). Therefore, adenoviral infection may increase HIF-1α through Ras
activation or other unknown mechanisms. Regardless, an increase in HIF-1α and subsequent
angiogenesis may therefore be an effect of adenoviral infection. In fact, adenoviral E4orf1
induces angiogenesis and is sufficient to establish a vascular niche (279). Anti-angiogenic
factors are often added to adenoviral vectors so that the vector does not induce angiogenesis and
promote tumor growth (280-282). Because both viruses increase angiogenesis and Ad36
significantly improves glycemic control in mice, and Ad2 does not, adipose tissue
vascularization is not likely to play a role in Ad36 induced improvements in glycemic control.
To verify the effect of Ad36 on adipose tissue angiogenesis, an angiogenesis assay was
conducted in human adipose tissue. Surprisingly, adipose tissue explants from two donors
showed no induction of angiogenesis by Ad36 or Ad2, and Ad36 in fact inhibited angiogenesis
in a manner similar to the negative control. This showed a lack of direct angiogenic effect of
adenoviruses on adipose tissue. Instead, the increase in vascularization observed in the animal
models may therefore be an in vivo phenomenon, or, may be a reaction of adenoviral infection
that is specific to rodent tissue. It is possible that in vivo adenoviral infection up-regulates
hypoxia and thus angiogenesis, but cultured explants are not susceptible to hypoxia due to
controlled conditions.
Finally, a tube formation assay was conducted in murine endothelial cells to determine a
direct angiogenic effect of Ad36 or Ad2 infection on endothelial cells. Ad36 did not improve
tube formation acutely or 1-3 days post infection and actually inhibited the process. Ad2 had a
similar effect, and was especially virulent in this cell type, killing cells by day 2 post infection.
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Therefore, any effect of these two adenoviruses on angiogenesis in mice is probably not likely to
be direct effect of infection on endothelial cells or adipose tissue.
Based on this morphological analysis of adipose tissue of C57BL/6J mice, it can be
hypothesized that if Ad36 exerts any effect on glycemic control through changes in adipose
tissue, it is most likely through changes in adipocyte metabolism and cell size, which are
indicative of adipocyte recruitment and adipose tissue expandability. Ad36 increased glucose
clearance in adipose tissue despite unchanged macrophage infiltration, and evidence of increased
inflammation, hypoxia, and inhibition of proximal insulin signaling (190). Angiogenesis and
adipose tissue vascularization is unlikely to play a role in improved glycemic control after Ad36
infection, since Ad2, which does not improve glycemic control, also increases adipose tissue
vascularization. In addition, Ad36 and Ad2 were not angiogenic in human adipose tissue.
In making these conclusions, however, several limitations must be considered. All
histochemical and morphological analysis of chow fed adipose tissue was of retroperitoneal
adipose tissue, because these animals were lean and other depots were used for signaling studies.
All adipose tissue histochemical analyses for the HFD model, on the other hand, were conducted
in epididymal fat pads. Therefore, findings from this analysis cannot be generalized to all
adipose tissue depots. Also, it is unknown if other depots would have demonstrated alternative
results in the parameters measured. In addition, histochemistry involves certain caveats, such as
ensuring the stained sample is representative of the entire tissue. For this reason, an effort was
made to collect tissue from the same general area of the particular depot, and as many animals
per group were analyzed as possible. Slide to slide variation can also cause variability in results,
so all slides in a given analysis were stained at the same time, and great care was taken to ensure
each slide was treated as equally as possible. Lastly, it is possible to bias results by taking
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unrepresentative images of certain groups. Therefore, pictures were taken in a blinded fashion,
and several pictures were taken of each slide so that the overall morphology was represented in
those pictures. Therefore, these data are likely to accurately represent morphology associated
with Ad36 infection, within the limitations of histochemical techniques.
4.3.3 Ad36 and Hepatic Lipid and Glycogen Accumulation
Other viruses such as HCV have been implicated in altering hepatic lipid metabolism
during the process of viral replication(256-258). It is therefore conceivable that an adenoviral
infection of the liver may alter hepatic lipid metabolism. A potential role of liver in Ad36
induced improvement in glycemic control was determined by staining liver of Mock, Ad36, and
Ad2 infected mice on HFD for glycogen content. During processing, lipid leaves the sample,
and therefore could be quantified as white space in the image. Ad36 significantly increased
hepatic glycogen stores and reduced lipid accumulation compared to Mock and Ad2 infected
animals, despite a high fat diet. This evidence is supported by increased expression of genes
involved in lipid export and fatty acid oxidation, both of which would reduce hepatic triglyceride
accumulation(190). This effect may be due to presence of the virus in the liver, since viral DNA
and RNA were detected in liver following Ad36 infection(190). Moreover, Ad36 DNA in the
liver correlated with glycemic control in mice(190).
Reduced hepatic lipid accumulation may be mediated indirectly through the effect of
Ad36 on adipose tissue or a direct effect of the virus on liver. Ad36 increases adiponectin
abundance in adipose tissue, and adiponectin is a strong activator of AMPK and fatty acid
oxidation in the liver and is associated with lower hepatic lipid accumulation (141; 283). In
addition, Ad36 infection increases adiponectin receptor levels(190), which would also increase
adiponectin action. Upregulation of adiponectin receptors is mediated by PI3K mediated
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FOXO1 nuclear exclusion (138). Ad36 significantly up-regulates AKT phosphorylation in the
liver (190), which is indicative of PI3K activation and may be due to local infection in the liver.
It could therefore be hypothesized that PI3K activation by Ad36 infection of the liver could work
synergistically with the effect of Ad36 on adiponectin in adipose tissue for concomitant increase
in both the hormone and the receptor. These dynamics will need to be tested in the future to
determine which tissues are key players in improvement of hepatic metabolism and glycemic
control induced by Ad36. In addition, these data are subject to the same limitations mentioned
for the adipose tissue histochemistry data; however, the same precautions were taken to ensure
the staining was as representative as possible. Also, it is encouraging that the gene expression
data supported these conclusions(190).
4.4 E4orf1 Modulates Glucose and Lipid Metabolism of Adipocytes and Hepatocytes
E4orf1 was investigated as the candidate anti-diabetic protein of Ad36 in order to harness
its therapeutic potential. It has been demonstrated that E4orf1 is sufficient and necessary for
induction of adipogenesis(203), and it is well known that some adipogenic factors improve
insulin sensitivity. In addition, E4orf1 is sufficient and necessary for PI3K activation by the
virus, one of the main components up-regulated by Ad36 infection for induction of glucose
uptake (188).
In 3T3-L1 cells, E4orf1 was sufficient and necessary to increase glucose uptake.
Knockdown of E4orf1 suppressed increased glucose uptake increased by Ad36, and E4orf1
transfection increased glucose uptake in preadipocytes and adipocytes. In adipocytes, glucose
uptake was significantly greater in E4orf1 transfected cells compared to Null in both the basal
and insulin stimulated condition. E4orf1 did not suppress insulin stimulated glucose uptake. In
fact, E4orf1 increased it further compared to the insulin treated Null group. Therefore, it is
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likely that E4orf1 does not suppress proximal insulin signaling. This is in contrast to infection
with Ad36, which inhibits IRS1 signaling (188).
Because Ad36 relies on Ras mediated activation of PI3K signaling for Glut4 upregulation
and glucose uptake, it was next determined if E4orf1 is sufficient to activate the same pathway in
3T3-L1. Importantly, induction of E4orf1 robustly up-regulated Ras abundance and activation.
Specifically, H-Ras isoform was activated by E4orf1, which is the same isoform that improves
insulin sensitivity upon overexpression in adipose tissue of transgenic mice (225). Distal insulin
signaling was also increased by E4orf1, and up-regulation of AKT phosphorylation and Glut4
abundance supports glucose uptake and upregulation of the same pathway used by Ad36 for
glucose disposal. Ras activation is known to mimic the effect of insulin on glucose
transporters(226), and therefore may be particularly important for glucose clearance when insulin
signaling is impaired, as is often the case in T2DM or obesity. Glut1 abundance is also
increased by the virus and E4orf1, which may contribute to glucose disposal. Glut1 is
commonly expressed in response to Ras activation, and is involved in glucose clearance in
transformed cells (278). Therefore, E4orf1 is sufficient to increase the same Ras-PI3K pathway
used by the whole virus for glucose uptake, and may also promote glucose uptake through Glut1.
E4orf1 also increases DNL in 3T3-L1 preadipocytes. This effect needs to be verified in
humans since the contribution of DNL to lipid accumulation is unclear in human adipose tissue,
as discussed for this effect of Ad36. E4orf1 appears to increase both glucose uptake in to an
adipocyte, and its conversion to lipid. Therefore, synergy between glucose disposal and
adipogenesis induced by E4orf1 may be beneficial for insulin sensitivity.
Because Ras activation is increased by E4orf1, the ability of E4orf1 to transform cells
was tested. E4orf1 constitutive expression was not sufficient to induce cell transformation, and
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Ad36 infection did not induce cell transformation either. This supports the idea that E4orf1 is
unlikely to be tumorgenic in vivo. For progression of Ras-PI3K induced tumors, dysfunctional
focal-adhesion kinase signaling is required, which suggests that Ras-PI3K activation alone is not
sufficient to induce cell transformation (235). In addition, neither the H-Ras overexpression in
mice induced tumor formation (225), nor the Ad36 infection of several mammal models induced
tumors(192-194; 197; 198). Importantly, the E4orf1 gene of Ad9, which is highly homologous
to that of Ad36, induces Ras-PI3K activation. It is sufficient to transform cells and induce
estrogen-dependent mammary tumors in rats , but these tumors do not undergo metastasis and
appear to be benign (284). In addition, adenoviruses are not associated with cancer in humans.
Therefore, if E4orf1 is targeted to adipose tissue for anti-diabetic therapeutic purpose, it may be
unlikely to cause tumor formation, although this needs to be tested thoroughly in vivo. E4orf1
also increases adiponectin mRNA and protein in 3T3-L1, and suppresses inflammatory cytokine
mRNA expression. The beneficial effect of E4orf1 may consequently not be limited to glucose
disposal in adipose tissue, but may be beneficial at the level of systemic insulin sensitivity.
Adiponectin up-regulates hepatic and skeletal muscle fatty acid oxidation, and is associated with
insulin sensitivity (141; 157). In addition, adiponectin is anti-inflammatory and may prevent
insulin resistance in adipose tissue if expressed at high levels (68; 285). In line with the potential
anti-inflammatory actions of E4orf1 induced adiponectin secretion, E4orf1 also suppressed gene
expression of several inflammation genes in 3T3-L1.
MCP-1, MCSF, and TLR-4 expression were down-regulated by E4orf1 in 3T3-L1.
Although chronic infection of Ad36 in combination with high fat diet may increase adipose
tissue inflammation (unpublished observations), acute Ad36 infection suppresses inflammation
in adipose tissue (198). Several early adenoviral genes suppress immune function to aid initial
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viral entry and replication, which may be responsible for acute suppression of inflammation by
Ad36 infection. The ability of E4orf1 to suppress inflammatory cytokines may add to its
therapeutic potential. MCP-1 expression is associated with insulin resistance, adipose tissue
macrophage infiltration, and hepatic lipid accumulation (90; 157). In addition, MCP-1 mediates
the switch of macrophages to a pro-inflammatory state(286). Reduction of TLR-4 by E4orf1
may also be of benefit, since TLR-4 activation in adipocytes can lead to TNF-α secretion(287).
Although suppression of inflammatory cytokines by E4orf1 may improve inflammation
associated with insulin resistance that does not necessarily mean this reduction will automatically
lead to increased glucose uptake (288). The glucose uptake and anti-inflammatory effects of
E4orf1 seem to be independent of each other, and one may not influence the other. Future studies
are needed to determine these dynamics.
Interestingly, E4orf1 is sufficient to increase glucose uptake in mouse embryonic
fibroblasts that lack PPARγ. Considering the key role of PPARγ in adipogenesis, this suggests
that E4orf1 can potentially induce glucose uptake without its adipogenic effect, and that these
two phenomena may be uncoupled from each other. Because PPARγ activation as a treatment
for T2DM has many unwanted side effects(289-291), agents which up-regulate glucose uptake
independent of PPARγ may be the next generation of ant diabetic drugs(292; 293). E4orf1 may
be such an agent, and its signaling pathways can be studied in the future for identification of the
divergence of these two effects. E4orf1 activates PI3K, which activates both AKT1 and AKT2.
AKT1 activation induces adipogenesis and PPARγ(285; 294; 295), while AKT2 activation
induces Glut4 translocation (296). Therefore, AKT1/AKT2 signaling may be where E4orf1
induced signaling diverges for these two independent effects and future studies will further
elucidate this hypothesis. If E4orf1 does indeed depend on AKT1 for its adipogenic effect, a
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drug cocktail of E4orf1 or an E4orf1 analog and an AKT1 inhibitor may be a promising new
anti-diabetic drug.
The effect of E4orf1 in hepatocytes is also promising for improvement of glycemic
control. E4orf1 suppressed glucose output in HepG2 in glucose starved and gluconeogenic
conditions, and had a similar effect in primary mouse hepatocytes in serum and glucose starved
and glucagon stimulated conditions. In HepG2, E4orf1 suppressed glucose output in the basal
and insulin stimulated condition, which again suggests E4orf1 does not interfere with insulin
mediated suppression of glucose output or insulin signaling, in contrast to Ad36 infection(190).
In addition, Ad2 E4orf1 did not suppress glucose output in HepG2 cells; however, it was able to
suppress glucose output in primary mouse hepatocytes in the glucose starved, but not glucagon
stimulated condition. This suggests that Ad2 E4orf1 may have some effect on glucose output in
murine, but not human hepatocytes. In murine hepatocytes, Ad36 E4orf1 was more effective
suppressor of glucose output compared to Ad2 E4orf1, since it was able to suppress output in the
presence of glucagon.
E4orf1 also demonstrated several effects on hepatic lipid metabolism, and E4orf1 may be
sufficient for prevention of steatosis by Ad36. Several metabolic processes can contribute to
hepatic lipid accumulation and insulin resistance such as impaired fatty acid oxidation, decreased
lipid export, and increased DNL, although impaired export and increased DNL are the two major
contributors to NAFLD (164-166). E4orf1 did not increase total fatty acid oxidation, however, it
up-regulated complete oxidation and decreased the ratio of partial to complete oxidation. As a
result, E4orf1 may prevent buildup of fatty acid intermediates and subsequent inhibition of
insulin signaling (182). Ad2 E4orf1 also decreased the ratio of partial to complete oxidation, and
since Ad2 infection did not prevent hepatic lipid accumulation or insulin resistance in HFD
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mouse model, alterations in fatty acid oxidation by E4orf1 may not play a large role in Ad36
induced improvements in hepatic insulin sensitivity. Ad36 E4orf1 did, however, suppress DNL
and increase ApoB secretion, which is indicative of lipid export, in HepG2 cells, whereas Ad2
E4orf1 did not. Since these are two main hepatic lipid metabolism parameters that contribute to
development of NAFLD, Ad36 E4orf1 may be sufficient for suppression of hepatic triglyceride
accumulation demonstrated in HFD C57BL/6J mice. This hypothesis will be tested in future
studies. Such a finding could have profound implications for prevention of NAFLD and insulin
resistance.
The mechanism for how Ad36 E4orf1 may modulate hepatic lipid metabolism is
unknown at this time. It is interesting that E4orf1 has a marked direct effect on hepatic lipid
metabolism; this suggests the presence of E4orf1 in the liver alone may be sufficient to improve
steatosis. Adiponectin secretion from adipose tissue induced by Ad36 E4orf1 may, however, add
to these benefits in vivo, and produce a more pronounced effect on fatty acid oxidation. Future
studies will determine if these tissues act independently or synergistically for improvement of
glycemic control and hepatic steatosis, in response to E4orf1.
Several limitations of the aforementioned studies with E4orf1 must be considered. First,
all conclusions are based on in vitro studies and need to be verified in vivo. Although E4orf1
alters glucose and lipid metabolism in preadipocytes, adipocytes, and hepatocytes, improvement
in glycemic control in vivo due to E4orf1 remains undetermined. Second, HepG2 cells have a
low capacity for DNL from [14C] glucose; however, radioactive counts per minute (CPM)
readings of [14C]-Glucose incorporation into lipid were low, but detectable and above the blank
readings. Also, E4orf1 has several limitations as a potential therapeutic protein. It is not a
secretory protein, and therefore does not have a cell surface receptor for cell entry. As a result, a
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delivery mechanism such as nanoparticle delivery or adenoviral vector must be developed.
Alternatively, a chemical analog of E4orf1 could be developed and packaged for delivery to the
bloodstream. Nonetheless, the metabolic effects of E4orf1 are highly promising, and these
caveats present challenges, which need to be overcome.
4.5 Conclusions and Future Directions
The studies presented herein lay the foundation for further elucidation of Ad36 induced
improvements in glycemic control. A three-tiered approach was adapted to identify the role of
Ad36 in improving in glycemic control. First, Ad36 seropositivity was associated with improved
glycemic control in children. Next, in vitro characterization of adipocyte differentiation and
metabolism, and post hoc tissue histological analysis of C57BL/6J mice was conducted. These
studies suggest Ad36 may increase insulin sensitivity through up-regulation of adipogenesis and
hyperplastic adipose tissue expansion, improved lipid accumulation and glucose clearance
through DNL, and hypertrophy in response to a high fat diet. Macrophage infiltration and
adipose tissue vascularization were ruled out as potential contributors to Ad36 induced
improvements in insulin sensitivity. In addition, prevention of hepatic steatosis by Ad36
infection was observed for the first time. Finally, in vitro studies verified that Ad36 E4orf1
protein is sufficient and necessary for Ad36 induced glucose disposal.
Future studies will thus focus on E4orf1 as a potential therapeutic agent. First the
molecular mechanism must be determined more in detail. Although E4orf1 up-regulates the
Ras-PI3K pathway used by the virus for glucose uptake, a H-Ras knockdown experiment is
necessary to demonstrate definitively that E4orf1 depends on this pathway for glucose uptake.
Also, uncoupling of the signaling involved in adipogenic and glucose uptake effects of E4orf1
would add greatly to its therapeutic value. Identification of tissues targeted by E4orf1 to improve
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glycemic control is needed so the development of any drug therapeutic may be targeted to that
particular tissue. Chemical analogs are useful because they can be modified for different
solubility and delivery requirements, and are not as fragile as a protein. And finally, such an
analog will then be tested for safety and efficacy in a T2DM nonhuman primate model. The
studies herein provide the foundation for this future work, and highlight Ad36 viral protein
E4orf1 as a promising anti-diabetic and anti-steatotic agent.
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Table 4. Summary of the Effect of Ad36/E4orf1 on Glycemic Control. Factors related to
glycemic control modulated by Ad36, and/or E4orf1. Factors grouped according to
conventionally “positive” or “negative” modulators of glycemic control.
Insulin sensitizing factors which
Ad36/E4orf1 does not
modulate
Adipose
tissue

Liver

Ad36/E4orf1
modulates positively

-

Macrophage
Infiltration

-

↑ Glucose
uptake

-

Angiogenesis

-

↑ Adipogenesis

-

↑ Lipid uptake

-

↑ DNL

-

↑ Fat Oxidation

-

↑ Adiponectin

-

↓ Leptin

-

↓ Inflammatory
cytokines
(acute
infection)

-

↓ Steatosis

-

↑ Glycogen
stores

-

↓ Glucose
output

-

↑ Lipid Export

-

↓ DNL

-

↑ Complete
oxidation

-

↑AMPK
activation

-

↓ Inflammation

-

↑ AdipoR1 and
AdipoR2

-

Total fat oxidation
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Ad36/E4orf1
modulates negatively
-

↓ Proximal
insulin
signaling

-

↑ Hypoxia

-

↑ TNF-α
(chronic
infection)

-

↑ Large
adipocytes
(HFD)
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